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 1 
ABSTRACT 
 
At present, most cancers are treated with surgery, radiotherapy and 
chemotherapy, used alone or in combination. Surgery and radiotherapy are 
the primary treatment modalities after early detection of cancers and they 
significantly increase the patient survival time. However, the value of 
cytotoxic chemotherapy has recently been questioned (Morgan, Ward and 
Barton 2004. Clinical Oncology 16: 549-560) as it became apparent that 
single cytotoxic chemotherapy barely contributes to the five-year survival 
rate in cancer. However, different chemotherapeutic strategies may be 
combined improving their efficacy dramatically.   
 
In this study, ninety two different compounds having anti-cancer potential 
were tested in various combinations against four human cancer cell lines 
(MCF-7 breast; HepG2 liver; Caco-2 colon and JU77 mesothelioma) in an 
attempt to find compounds that effectively eradicate cancer cell lines within 
a therapeutic range. The cancer cell lines have been chosen to illustrate the 
diversity in cancer cell signaling. The diversity of the signalling patterns in 
different cancer cell lines becomes apparent when monitoring the viability 
of these cell lines during different chemotherapeutic treatments. Several 
potent combinations of narrow and broad-spectrum inhibitors were 
discovered that combined well in killing cell lines. Most of these 
combinations were specific against single cell lines. For example, 
PD98058, LY294002, bromocriptine and 120nM staurosporine promoted 
cell death in JU77 mesothelioma cells, but this combination was not fully 
effective in killing MCF-7 cells. On the other hand, bromocriptine or 
oxytocin and 120nM staurosporine effectively killed MCF-7 cells but not 
JU77 cells. However, some combinations worked effectively to kill 
multiple cell lines. Two such examples include geftinib and 120nM 
staurosporine or selenomethionine and selenite. 
 2 
Broad-spectrum inhibitors alone effectively killed cell populations, but at 
concentrations too high to be applied in vivo, due to their toxicity. 
However, the concentration of the broad-spectrum inhibitors needed in the 
combinations, to ensure eradication of a cell line, could be substantially 
reduced (in some cases by several orders of magnitude) by using 
appropriate combinations of narrow-spectrum inhibitors. For example, 6µM 
staurosporine alone was required to kill JU77 cells. However, 6nM 
staurosporine was effective in killing JU77 cells when combined with 
PD98058, LY294002 and rapamycin. Other successful combinations 
included: 1. vitamin C, suramin and letrozole; 2. flavine adenine nucleotide 
or selenotrisulphides and β-lapachone; 3. a most promising combination, 
because of its potency and bioavailability, was selenite combined with 
selenomethionine and lithium chloride. 
 
Whilst the culture system using banks of cancer cell lines can be a useful 
tool for selecting effective cytotoxic compounds and their combinations, its 
translation to effective in vivo strategies is limited. In most such studies 
fetal calf serum is included as a growth supplement for cells in culture. 
However, this study demonstrates that the inclusion of adult human 
albumin is also important as the adsorption of compounds to it differ 
significantly to fetal albumin (Brodersen and Honore 1989 Acta 
Paediatr.Scand. May, 78(3): 342-6). However, of the combinations 
reported above combination 2. and 3. remained effective in adult human 
albumin within a therapeutic range. 
 
A tumour model was then established by injecting JU77 mesothelioma cells 
into nude balb/c mice. JU77 cells are a “non-tumourigenic” human cell line. 
However, the cells became “tumourigenic” when insulin-like growth factor-
1 was also co-injected on a daily basis. In this manner, a subcutaneous 
tumour of JU77 mesothelioma cells rapidly grew approaching maximum 
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size over nine days. Nude balb/c mice bearing JU77 tumours were treated 
with selenite, selenomethionine and lithium chloride combination while 
supplementing insulin-like growth factor 1 continuously. Tumours rapidly 
decreased in size and became invisible after five days. In contrast, tumours 
treated with carrier and insulin-like growth factor 1 continued to grow. Low 
side effects of the treatment with the selenite combination were observed. 
The most notable observation was a moderate loss in weight of the mice, 
only following the first day of treatment. The inclusion of insulin-like 
growth factor 1 to maintain the tumours altered some of the haematological 
and biochemical parameters but the selenite combination did not further 
change these parameters. The histology of the tumours illustrated thick, 
closely packed layers of malignant cells that surrounded a central necrosis 
and rapidly decreased in thickness as the selenite combination was applied 
leaving behind a few clusters of necrotic cells and an inflammatory 
infiltration. In normal tissues, only a few abnormalities were discovered 
mainly due to the inherited defect of the nude mice. These abnormalities 
were exaggerated by treatment with insulin-like growth factor 1 but did not 
further change with the selenite combination. These results indicated that 
the selenite combination affected the tumour tissues highly selective with 
little side effects to the normal tissues.  
 
 
In future, it will be interesting to know whether this compound combination 
is similar effective for tumours that grow without supplementation of 
insulin-like growth factor-1. In other tumour models, similar high 
concentrations of insulin-like growth factor-1 have been reported without 
supplementation due to existing “autocrine loops” and this might be a 
reason why the immune responses in these models is also disabled against 
aberrant cancerous signalling. This interesting new aspect which focuses on 
the endocrine response due to aberrant cancerous signaling is a promising 
path for inhibiting cancer growth. 
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1.0  LITERATURE REVIEW 
 
In 1971, Richard Nixon declared a “war on cancer”. But despite all good 
intentions, the incidence of cancer continues to rise at an alarming rate. In 
2007, over 7 million people worldwide died from cancer. By the year 2050, 
it is estimated that the human toll will exceed 17 million people worldwide. 
The impact on our lives is staggering, from both a human and financial 
perspective.  
 
The primary modalities for treating cancer include surgery, radiotherapy 
and chemotherapy, used alone or in combination. The value of some of 
these strategies, in particular conventional chemotherapy, has been 
questioned because it has been illustrated repeatedly in large studies that 
chemotherapy contributes very little to the five-year survival rate in cancer.  
 
In 2004 the Australian oncologists Morgan, Ward and Barton published an 
article, “The Contribution of Cytotoxic Chemotherapy to 5-year Survival in 
Adult Malignancies”. The authors conducted an evidence-based analysis of 
cancer treatments. They found an overall 5-year survival rate in adult 
malignancies in Australia of 60%. Cytotoxic chemotherapy increased the 
survival rate by only 2.3% in Australia and 2.1% in USA. The authors 
emphasized that these figures “should be regarded as the upper limit of 
effectiveness” (i.e., they are an optimistic rather than a pessimistic estimate) 
and concluded that the funding and availability of chemotherapeutic drugs 
should undergo rigorous evaluation in terms of cost-effectiveness and 
impact on quality of life.  
 
Interestingly, this is not the first time that efficacy of chemotherapy has 
been reviewed. In 1992, the German epidemiologist Abel reviewed the 
chemotherapeutic success rates of more than 350 medical centres around 
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the world and estimated the success rate as 3%. He concluded that there is 
simply no scientific evidence available that chemotherapy can “extend in 
any appreciable way the lives of patients suffering from the most common 
organic cancers”. Obviously, despite a huge progress in drug development 
over the years the success rate of chemotherapy has stayed the same. 
Scientists and clinicians all over the world are looking for possible reasons. 
 
Analysing the reasons for treatment failures, experiments were undertaken 
to illustrate how cancer cells are able to counteract the lethal effects of 
chemotherapeutics. Insulin-like growth factor-1 receptor was recognised as 
an important survival receptor on mammalian cells and has been the focus 
of intense research. Its pathway interactions in cancer have been reported 
by Navarro and Baserga in 2001. They observed that insulin-like growth 
factor-1 receptor activates three separate signals through insulin-receptor 
substrate 1, Shc and the mitochondrial Raf location. While the activity of 
the receptor did not cease when inhibiting a single pathway, it ceased when 
inactivating any two of the three pathways or all of them. Navarro and 
Baserga described this survival signalling as “limited redundant”. Still, 
inhibiting one pathway alone was not enough to induce cell death which 
explains why some compounds with narrow target structures fail to kill the 
cancer cells. 
  
A second important observation was made by Thimmaiah et.al. in 2003 
who reported that a downstream molecule in the signalling cascade of the 
insulin-like growth factor-1 receptor interacted with molecules of other 
signalling systems. The signalling systems together determined cell death. 
This explains that single receptors inhibited alone rarely promote cell death. 
In most cases, a combined inhibition of different receptor systems is 
necessary to achieve the desired effect. 
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To date, only a few reports of chemotherapeutic combinations targeting 
simultaneously different receptor systems are published. In investigating 
this complex network of receptor systems in terms of cellular function, 
especially in terms of survival, many unknown interactions have yet to be 
examined.  
 
However, compared to the complexity of the signalling network and the 
task to investigate it, most of the metabolic interactions already seem to be 
characterised: The changes in the synthesis and breakdown of glucose, fats 
and proteins as well as energy creation and consumption along membrane 
structures have been well described (Nelson and Cox 2000). It seems as if 
the cellular “hardware” (the structure of molecules and molecular 
interactions) is known quite well while the cellular “software” (how 
molecular reactions are regulated) remains a challenge. Treatment with 
chemotherapeutic agents is described either by a change in signalling 
pathways or by a change in metabolism. Obviously, signalling creates 
metabolic consequences and metabolism induces signalling changes. A 
single metabolic change inside a cancer cell has the potential to create a 
snowball effect and change the total metabolism of these cells as well as 
their signalling structure. 
 
The following review describes some relevant metabolic changes in the 
malignant cells and their hosts. Like a jigsaw puzzle, pieces of information 
will be assembled, describing a mechanism that has the potential to explain 
the initiation and perpetuation of cancer growth. Out of several clinical 
options, chronic renal failure has been chosen as an example to demonstrate 
how the metabolism shifts from the carbon cycle to the nitrogen cycle, and 
the potentially disastrous consequences of this kind of precancerous 
situation. In chronic renal failure (CFR), the incidence of cancer is 
increased (Stopper et.al. 2003). This increase in cancer incidence can be 
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explained by the simultaneous elevation of levels of advanced glycosylated 
end products (AGEs) (for example methylglyoxal-BSA), which are 
genotoxic and change metabolism. Experiments infusing advanced 
glycosylated end products, for example methylglyoxal-BSA, into healthy 
animals leads to increased cancer incidences similar to chronic renal failure 
(Stopper et.al. 2003).  
 
The origin of methylglyoxal synthesis was first described by Freedberg, 
Kistler and Lin in 1971, who discovered that in Escherichia coli the 
conversion from glycerol to triose phosphate had two control mechanisms: 
the rate of synthesis of glycerol kinase and the feedback inhibition of its 
activity by fructose-1,6-bisphosphate. A strain that had lost both control 
mechanisms by double mutation, resulting in excessive synthesis of 
glycerol-3-phosphate, produces a bactericidal factor from glycerol in a two 
step reaction: the excess glycerol-3-phosphate is converted to 
dihydroxyacetone phosphate, which is further metabolized to 
methylglyoxal. In the mammalian cell, glycerol is mainly produced from 
triglycerides. This is illustrated in Fig 1.  
 
Regulation of methylglyoxal-toxicity was discovered by Zhu and Lin in 
1987. They observed that in bacteria like Escherichia coli accumulating 
glyceraldehyde and lactaldehyde attenuate the toxicity of methylglyoxal.  
Glyceraldehyde and dihydroxyacetone phosphate are produced when 
growing Escherichia coli on L-galactose (a structural analogue of L-
fucose); lactaldehyde and dihydroxyacetone phosphate are formed when 
growing E.coli on L-fucose. However, normally the aldehydes are further 
metabolized and loose their attenuating effect. Zhu inhibited the 
metabolising enzymes (aldehyde dehydrogenase or lactaldehyde 
dehydrogenase), enhancing thereby the concentration of these aldehydes 
and observed an attenuating effect.  
 8 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Relationship between the glyoxylate cycle (fatty acid cycle) in 
the peroxisomes and glycolysis in the mitochondria 
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Similar to the situation in bacteria, both metabolites L-glyceraldehyde and  
L-lactaldehyde inhibit the substrate methylglyoxal in mammalian cells and  
exert a protective effect against its toxicity (Ray et.al. 1994; Guerra et.al. 
2006). Inhibiting the dehydrogenases also enhances the aldehydes in 
mammalian cells. Biswas et.al. in 1996 realised that these aldehyde 
metabolising enzymes are totally absent in rapidly growing, highly 
malignant cells. 
 
 
Methylglyoxal is metabolized in two different pathways: normally it is 
broken down by glyoxylase I and II (Brandt and Siegel 1978): glyoxylase I 
(S-lactoyl-glutathione methylglyoxal-lyase) and glyoxylase II (S-2 
hydroxyacylglutathione hydroxylase) transform methylglyoxal to S-D-
lactoylglutathione and to lactate/glutathione (Creighton et.al. 1988). 
Alternatively, methylglyoxal can be metabolized by methylglyoxal 
reductase (Murata et.al. 1985), non-specific aldose reductase (Van der Jagt 
et.al. 1992), aldehyde dehydrogenase and/or alcohol dehydrogenase (Misra 
et.al. 1996), which transform it to acetol/lactaldehyde and later to 1,2-
propanediol/lactate (Van der Jagt et.al. 1992), as shown in Fig 2. 
 
 
Excess methylglyoxal and/or acetol react with albumin in vivo forming 
advanced glycosylated end products (AGEs) (Van der Jagt et.al. 1992). 
However, the direct measurement of AGE`s in blood is problematic (Brandt 
and Siegel 1978). Inhibiting aldose reductase reverses the effects of 
advanced glycosylated end products (Nakamura et.al. 2000) and switches 
glucose toxicity back to hyperglycemia (Sun et.al. 2006). Remarkably, 
AGEs change metabolism in cancer cells: complex I of the electron chain is 
inhibited in malignant cells and no effect is observed on the respiration of 
normal cells (Ray et.al. 1991). AGEs inhibit the glycerol-3-phosphate 
dehydrogenase complex (Ray, Basu and Ray 1997) and the glycolysis 
(Nicolay et.al. 2006) of tumour cells, thereby decreasing their ATP and 
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Figure 2 Glycolysis and methylglyoxal production:  
[1] Methylglyoxal synthetase, [2] Tautomerization, [3a] Glyoxylase I, [3b] 
Glyoxylase II, [4] Aldose reductase, [5a] Acetol reductase, [5b] 
Lactaldehyde dehydrogenase  
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glutathione. They also strongly inhibit alpha-ketoglutarate-, malate- and 
pyruvate-dependent respiration in cancer cells (Ray et.al. 1994). Finally, by 
inhibiting alpha-ketoglutarate dependent respiration in cancer cells, AGEs 
cause nitrosative stress (Obrosava et.al. 2005). This is crucial for the 
development of cancer as explained below.  
 
 
Schreibmayer et.al. in 1980 discovered that the absolute concentration of 
alpha-ketoglutarate is highest in tumours, while the absolute concentrations 
of citrate, succinate, malate and glutamate are highest in host livers. A 
possible explanation of this observation is that AGEs are also formed in 
tumour-bearing diseases, inhibiting alpha-ketoglutarate dehydrogenase. 
However, another option is that tumour bearers synthesize alpha-
ketoglutarate in excess. Schreibmayer stated only that tumours were the 
primary source of increased alpha-ketoglutarate in blood of tumour bearers 
and that alpha-ketoglutarate and glutamate did not correlate in livers or in 
tumours. The regulation of alpha-ketoglutarate metabolism is of great 
interest as a potential target for cancer therapy, in particular because 
methylglyoxal influences it.  
 
Rakhamanova and Popova in 2006 indicated that synthesis of alpha-
ketoglutarate is mainly determined by cytoplasmic NADPH-isocitrate 
dehydrogenase (86%), whereas utilization is dependent on cytoplasmic  
aspartate aminotransferase (78%). Alpha-ketoglutarate links the carbon and 
nitrogen cycles: inhibiting metabolism of alpha-ketoglutarate inside the 
carbon cycle, for example with methylglyoxal promotes its accumulation 
and enhances transamination from amino acids through alpha-ketoglutarate 
to glutamate. The ammonium group of glutamate can either be passed on to 
oxalacetate forming aspartate or can be part of carbamoyl phosphate 
synthesis which is used for the urea cycle (Nelson and Cox 2000, 634).  
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Overall, excess alpha-ketoglutarate will lead to increased catabolism of 
amino acids and nitrogen flux into the urea cycle (see Fig 3).  
 
Consequently, inside the urea cycle arginine will be elevated. It either 
forms ornithine and urea, or it reacts with calcium ion-dependent nitric 
oxide synthetase to produce nitric oxide (NO) (Nelson and Cox 2000, 449) 
and citrulline. While urea excretion will not increase due to renal 
impairment, the metabolic urge to produce nitric oxide increases steadily in 
a vicious circle. Nitric oxide will partially act as a dissolved gas, but it can 
also form instant reactions with albumin, immunoglobulin and sulphydryl-
group containing enzymes, thereby forming S-nitrosothiols. Excess S-
nitrosylation of all kinds of intra- and extracellular enzymes is called 
“nitrosative stress”.   
 
Surprisingly, Christen et.al. in 2007 observed that until birth foetuses 
produce high amounts of S-nitrosylated albumin. Foetal calf serum is a 
mandatory supplement in cancer cell experiments: cancer cells do not grow 
in the absence of S-nitrosylated albumin: for example when supplemented 
with adult (non-nitrosylated) albumin only. However, the amount of 
nitrosylated albumin can vary, so part of the foetal calf serum may be 
replaced by adult albumin. With S-nitrosylated albumin sufficiently 
available, transnitrosylation of other sulphydryl-groups containing 
molecules takes place immediately (Scharfstein et.al. 1994).  
 
Transnitrosylation across the cell membrane is mediated by L-cysteine 
which is taken up into the cell and leads to accumulation of intracellular S- 
nitrothiols of all kinds (Li and Whorton 2007). However, transnitrosylation 
may also happen as a reverse process from other sulphydryl-group 
containing molecules back to albumin (Tsikas et.al. 2001). 
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Figure 3 The regulation of metabolic flux from the carbon cycle (lower 
cycle) to the nitrogen cycle (upper cycle).  
Raising concentrations of α-keto-glutarate influence the synthesis of 
aspartate, purines and pyrimidines.  Enzymes which are involved are: 1 
glutamine synthetase, 2 glutaminase, 3 aspartate transaminase, 4 glutamate 
dehydrogenase, 5 carbamoyl synthetase, 6 trans-amination from amino 
acids  
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The effects of S-nitrothiols are extensive. Some of these effects induce self-
perpetuation of cancer cell growth. The following key observations are 
noteworthy: 
1. Burzynski, Wang and Hnatowitch in 1995 observe that S-nitrosylation 
of albumin decreases palmitate adherence to albumin and that uptake of 
palmitate by hepatocytes increases 27%. More glycerol is synthesized, 
promoting more advanced glycosylated end products.  
2.  Mitsumoto et.al. in 2001 note that S-nitrosoglutathione interacts with 
glyoxylase I and inhibits methylglyoxal metabolism. 
3. Freedman et.al. in 1995 and Naseem et.al. in 1996 describe S-
nitrosoglutathione as inhibiting platelet function. Glutathione peroxidase 
or H2O2 potentiate this effect. 
4. Padgett and Whorton in 1997 state that S-nitrosylation inhibits 
glyceraldehyde-3-phosphate dehydrogenase, thereby increasing     
dihydroxyacetone phosphate. This adds to the formation of advanced 
glycosylated end products induced by methylglyoxal, and starts a 
feedback loop in the metabolic cycles. The reaction is reversed by low-
molecular weight thiols. 
5. Jaiswal, LaRusso and Gores in 2001 illustrate the inactivation of 
mitochondrial aldehyde-dehydrogenase by S-nitrosylation which can act 
as a nitrate reductase.  
6. Dahm, Moore and Murphy in 2006 observe that S-nitrosylation of 
complex I of the mitochondrial electron chain correlates with a 
significant loss of its activity, reversed by thiol reductants. This seems to 
be a similar mode of inhibition to methylglyoxal, regarding the 
mitochondrial complex I.  
 
In addition, it has been noted that S-nitrosylation: 
7. Changes signalling molecules like insulin receptor, insulin receptor 
substrate-1 and AKT (protein kinase B) (Kaneki et.al. 2007).   
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8. Inhibits caspases, the main effectors of apoptosis (Dall`Agnol et.al. 
2006). 
9.  Promotes synthesis of nitrosylcobolamin from cobalamin (vitamin B12) 
inhibiting methylmalonyl-CoA mutase: the formation of succinyl CoA 
from methionine, threonine, isoleucine and/or valine ceases, and causes 
cell death in many cancer cell lines (Tang et.al. 2006; Nelson and Cox 
2000, 650). 
10.  Inhibits ubiquitin-proteasomal degradation of Bcl-2. Bcl-2 is a key 
apoptosis regulatory protein of the mitochondrial death pathway (Azad 
et.al. 2006). 
11.  Targets hypoxia inducible factor-1 alpha, a key regulator sensing   
oxygen partial pressure (Sumbayev et.al. 2003). 
12.  Reversibly inactivates argininosuccinate synthetase (Hao, Xie and 
Gross, 2004). 
13.  Affects thioredoxin inducing apoptosis signal-regulating kinase 1 
(Sumbayev 2003). 
14. Inactivates methionine adenosyltransferase which converts methionine 
into S-adenosyl-methionine (Ruiz et.al. 1998). 
 
This incomplete list demonstrates that S-nitrosylation switches metabolism, 
affecting all kinds of important cellular enzymes. Taken together, these 
findings suggest that S-nitrosylation is involved in onset and perpetuation 
of cancer. However, its specific role in various cancers is yet to be fully 
elucidated.  
However, S-nitrosylation maybe reversed. Five different observations are 
reported: first, Stubauer, Giuffre and Sarti in 1999 emphasize that the redox 
state of copper determines if thiol groups scavenge or release nitric oxide: 
the two-valent copper ion (Cu 2+) promotes S-nitrosylation; the one-valent 
copper ion (Cu +) releases nitric oxide from thiol groups. A compound like 
penicillamine, which reduces the copper ions, releases nitric oxide from 
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thiol groups and reduces S-nitrosylation. Second, simultaneous 
dimerization of glutathione competes with and reverses S-nitrosylation in 
the presence of Cu (2+). Third, serum concentrations of ceruloplasmin 
determine the rate of glutathione nitrosylation (Inoue et.al. 1999). 
Tetrathiomolybdate decreases the transcription rate of this multi-copper-
containing plasma protein with ferroxidase activity, slowing down S-
nitrosylation. Fourth, Vanin, Malenkova and Serezhenkov in 1997 
discovered that a concentration level of more than 10µM ferric iron ion 
concentration (Fe 2+) destabilizes S-nitrosylation. The ratio of oxidized to 
reduced iron (Fe 2+/ Fe 3+) can increase due to chelation or reduction of 
oxidized iron. Coves and Fontecave in 1987 characterised an enzyme called 
NAD(P)H:flavin oxidoreductase (or flavin reductase) catalysing the 
reduction of free flavins, flavin mono-nucleotides, flavin adenosine 
dinucleotides or riboflavins, and rapidly transferring electrons to free iron 
or ferric complexes like ferrisiderophores, ferritin and ferric citrate 
(Sirivech, Frieden and Osaki 1974). Finally, reducing S-nitrosylation is also 
possible by inhibiting the uptake of S-nitrosylated L-cysteine with large 
neutral amino acids (Li and Whorton 2007): this reduces incorporation of 
S-nitrosylated cysteine and the following transnitrosylation from S-
nitrosylated cysteine to other sulphydryl-group containing molecules.  
In summary, a vast increase in protein metabolism and a shift from the 
Krebs cycle to the urea cycle can be observed in situations with enhanced 
intracellular α-ketoglutarate concentrations. Additional ammonium flux 
into the urea cycle results in extensive nitrosylation and nitrosation of 
proteins. This creates a procarcinogenic situation. Strategies to inhibit nitric 
oxide generation during chronic inflammation or to scavenge reactive 
nitrogen species may prove useful in decreasing the risk of cancer (Jaiswal, 
La Rousso and Gores 2001). Another important aspect of excess 
ammonium flux is uncontrolled pyrimidine synthesis, which is an important 
requirement for unlimited cancer cell growth. Usually, pyrimidine synthesis 
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is regulated by the concentration of glutamine. This can be bypassed by 
large amounts of ammonium ions metabolized through the carbamoyl 
phosphate pathway (Monks, Chisena and Cysyk 1985) as illustrated in Fig 
3. Under these circumstances increased pyrimidine synthesis is solely 
dependent on the availability of aspartate (Pausch et.al. 1985).   
Availability of aspartate is dependent upon its origin: inhibition of aspartate 
synthesis from oxalacetate in cancer cells is caused by malate and results in 
the formation of citrate and alanine (Moreadith and Lehninger 1984). 
However, in normal cells malate increases aspartate production. Inhibition 
of synthesis from glutamine is caused by inositol or lactate in either cell 
type and lactate is derived from the ribose moiety of inosine (Kovacevic 
et.al. 1987; Kovacevic, Brkljac and Jerance 1991).   
 
Availability of aspartate is also dependent on its metabolism: aspartate and 
inositol form purines: adenosine monophosphate (AMP) and guanidine 
monophosphate (GMP). Purines inhibit cancer growth (Hugo et.al. 1992). 
However, aspartate and carbamoylphosphate also form the precursors for 
pyrimidine synthesis. Therefore, aspartate which may be consumed in other 
synthetic pathways can be a limiting factor in a situation where excess, 
uncontrolled pyrimidine is synthesised due to elevated ammonium flux.   
This review of the literature dealing with interconnections between the fatty 
acid cycle, the Krebs cycle and the urea cycle is not a complete picture of 
the pathways, but does provide the necessary information to understand the 
inhibiting effects of compound combinations and their effect on the cellular 
metabolism. The literature illustrating interconnections between signalling 
pathways is more complex: Lodish et.al. describe in 2003 a huge diversity 
of receptors on the cell membrane. Some important receptor families are 
receptor tyrosine kinases, G-protein coupled receptors, cytokine receptors, 
TGF-beta receptors, hedgehog receptors, Wnt receptors, and Notch 
receptors. They regulate the transcription of genes, the translation of 
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messenger RNA and most protein interactions. Each family is further 
subdivided. As an example, the first group of receptors mentioned above, 
the receptor tyrosine kinase family, comprise an insulin-like growth factor-
1 and -2 receptor, insulin receptor, epidermal growth factor receptor, 
platelet derived growth factor, vascular endothelial growth factor, fibroblast 
growth factor, nerve growth factor and others. The receptors of each family 
can interconnect with members of other families: the tyrosine-kinase 
receptor family can connect with the G-protein-coupled receptor family but 
it may also connect with any other receptor family. An overview of the 
connections between only two of the families, the tyrosine kinase receptors 
and the G-protein coupled receptors, is illustrated in Fig 4 (Alberts et.al. 
2002). But many interconnections are still unknown: In principle, Fig 4 
illustrates that each receptor has at least one, but usually several, signalling 
pathways. The pathways of different receptors either share signalling 
molecules or interconnect at certain signalling levels. 
 
Additionally, an orchestra of intra-cellular receptors exists, located in either 
the cytosol or the nucleus. Nuclear receptors include hormone receptors 
(oestrogen-, corticoid-, androgen-, parathormone etc.), nuclear factors 
(nuclear factor-kappa B, hepatic nuclear factor) and others (Alberts et.al. 
2002). 
 
 
Complete inhibition of the overlapping receptor signalling pathways 
depends on two factors: first, all the possible diversions and connections of 
the combined receptors have to be taken into account. As a general rule, 
this is most easily achieved by inhibiting targets closest to the receptors. As 
more signalling molecules in a cascade are activated, it becomes more 
difficult to achieve total inhibition of a pathway. Second, the limited 
redundancy of each signalling combination must be considered. Not all 
possible inhibitions have to be in place at the same time, because inhibition  
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Figure 4 Signalling connections between the G-protein-linked receptors 
and the tyrosine kinase receptors.  
(Adapted from Molecular Biology of the cell, B.Alberts et.al. 2002.) 
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of a critical share of them can impair signalling function (Navarro and 
Baserga 2001).  
 
 
As a result, redundancy can be different in cancer cells compared to normal 
cells due to the differences in the signaling pathways. Ahmad et al. in 2004 
observe that insulin-like growth factor-1 in normal cells requires the 
epidermal growth factor receptor tyrosine kinase to exert a mitogenic effect. 
However, in cancer cells it does not. There are many other examples 
illustrating how cancer signalling varies. These crucial cancer-specific 
differences emerge as possible targets for treatment. Usually, treatments 
target only a single cancer-specific structure. However, the simultaneous 
inhibition of several cancer-specific targets could be more effective. 
 
 
This review focuses on compounds that have been chosen primarily 
because, used singularly, they kill cancer cells selectively. The toxic side-
effects of many of these compounds in vivo observed at the doses killing 
complete cell populations in vitro are invariably problematic. However, 
combining these compounds reduces the concentration needed to kill cancer 
cells but does not decrease their selective action between cancer and normal 
cells. Quite often, a therapeutic range can be achieved. It is not intended to 
combine these compounds with commonly used chemotherapeutic agents. 
The aim is to target the limited redundant, constitutively activated 
signalling pathways of cancer cells inducing minimal side effects in normal 
cells. 
 
The broad-spectrum inhibitors that will be investigated are staurosporine, 
genistein, mifepristone, vitamin C, selenite and trisulphides, β-lapachone, 
glycolysis inhibitors, antibiotics, diethylmaleate and hydrogen peroxide. 
These compounds have been chosen as most of them are known to be 
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cancer-selective and/or cancer-preventive. However, the chosen compounds 
are only a small selection in the huge variety of compounds that could have 
been chosen for investigation. Day by day, the number of natural broad-
inhibiting compounds that undergo biochemical investigations expands 
rapidly. Pharmaceutical companies are more and more interested in 
developing some of these compounds for cancer therapy. Examples are 
staurosporine, genistein or β-lapachone. These broad-inhibiting compounds 
have the great advantage that they already target multiple structures in a 
prefixed fashion. When combining them with only a few additional 
compounds, they induce a powerful, cancer-selective treatment response. 
The complexity of their action is under intense investigation as many 
aspects of their broad-inhibiting action are still unknown. When listing their 
action, it sometimes seems as if there is little connection between different 
aspects of their actions. The following part of the literature review intends 
to list and to connect the effects of each of these compounds on cell surface 
receptors and signalling pathways. Where possible their mechanism of 
action is described. Finally, the therapeutic implications of using these 
compounds in vivo are described.   
 
Staurosporine is a cell-permeable, potent compound, isolated from 
Streptomyces staurosporeus. It inhibits multiple cellular protein tyrosine 
kinases. Around a thousand protein tyrosine kinases are known to exist, of 
which only 91 have been identified. There are 59 receptor tyrosine kinases 
and 32 non-receptor tyrosine kinases (Sigma-Aldrich 2007). These enzymes 
catalyse phosphorylation of tyrosine residues of receptor and non-receptor 
types. Receptor protein tyrosine kinases are located in the membrane with 
an extracellular, transmembrane and intracellular domain. Their signalling 
can be aberrant in diseases like diabetes, in inflammatory diseases and 
cancer (Sigma-Aldrich 2007). Non-receptor tyrosine kinases are located in 
the cytoplasm or nucleus, or anchored to the inner leaflet of the plasma 
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membrane. These non-receptor tyrosine kinases are grouped into eight 
families: SRC, JAK, ABL, FAK, FPS, CSK, SYK and BTK. Most families 
are involved in cell growth and some of them are involved in cancer cell 
growth (Sigma-Aldrich 2007).  
 
Staurosporine binds to the adenosine triphosphate binding (ATP) domain of 
tyrosine kinases and thereby inhibits them. It has a broad specificity. The 
concentration of stauropsorine needed to inhibit various kinases differs  
markedly (see Table 1). 
 
At 6µM staurosporine induces apoptosis in all cancer cell lines. Apoptosis 
induced by staurosporine is positively regulated by translocating protein 
kinase C. Simultaneously, the induction of hepatocyte growth factor 
synthesis can be observed without protein kinase inhibition (Yagi et.al. 
2003). This in turn induces angiogenesis independently of any vascular 
endothelial growth factor (Sengupta et.al. 2003). Staurosporine augments  
ornithine decarboxylase and activates Bcl-2 (Stressgen Bioreagents 2006). 
Apoptosis induced by staurosporine is negatively regulated by p38 and 
p44/42 mitogen-activated protein kinases as well as phosphatidyl-inositol-
3- kinase involving the caspase cascade; it is also negatively regulated by 
protein kinase A without caspase involvement (Yamaki et.al. 2002). It 
inhibits topoisomerase II (Lassota, Singh and Kramer 1996), reversibly 
arrests human lung epithelial cells in cell cycle phase G 1, and is used to 
synchronize cell populations (Lin, Chrest and Gabrielson 1992). 
Staurosporine inhibits the insulin-stimulated translocation of GLUT1 and 
GLUT4 glucose transporters in adipose cells (Nishimura and Simpson 
1994).  
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Table 1:   Cellular kinases inhibited by staurosporine 
 
CK1 (100µM)                                 CK = Cyclin kinase 
CK2 (19.5µM) 
IGF-1R (6.2µM)                             IGF-1R = Insulin-like growth factor 
                                                                         receptor 
CSK (2µM)                                     CSK = C-terminal SRC-kinase 
ERK (1.5µM)                                  ERK = Extracellular-regulated kinase 
EGFR (600nM)                               EGFR = Epidermal growth factor 
                                                                        receptor 
IR (60nM)                      IR = Insulin receptor 
PKA (15nM)                                   PKA = Protein kinase A 
PKG (18nM)                                   PKG = Protein kinase G   
PKC a,b,g,d,e                                  PKC = Protein kinase C 
         (58, 65, 49, 325, 160nM)              
MLCK (21nM)                               MLCK = Myosin light chain kinase   
CaMK II (20nM)                            CaMK =Calmodulin kinase 
LYN (20nM)                                   LYN = LYN-kinase 
SYK (16nM)                                   SYK = SYK-kinase  
SRC (6nM)                                     SRC = SRC-kinase 
S6K (5nM)                                      S6K = S6 Kinase 
FGR (2nM)                                     FGR = FGR-kinase  
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In vivo, staurosporine is weakly and reversibly adsorbed to the red blood 
cells of rats. The endothelium of lung and heart acts as a sink for 
staurosporine. The plasma range after bolus injection of staurosporine is in  
the range of 1-10ng/ml for 2.7hr, which indicates that it has to be delivered 
by continuous infusion to stop cell proliferation (Gurley et.al. 1998). Its  
half-life in plasma is 51.6 minutes. In clinical settings, staurosporine and its 
combinations are too toxic for use, and are replaced by 7-hydroxy-
staurosporine (UCN-01) (Fuse et.al. 2005).  
 
Genistein is a soybean-derived protein tyrosine kinase inhibitor. The 
expression of the insulin-like growth factor-1 receptor is inconsistently up- 
or down-regulated depending on the cell line (Kim, Shin and Park 2005; 
Chen and Wong 2004). However, the expression, internalization and 
degradation of the epidermal growth factor receptor and its closely related 
ErbB2/Neu receptor are consistently down-regulated (Yang et.al. 1996) 
independent of the cell line and without any changes in 
autophosphorylation (Peterson and Barnes 1993). The transcription and 
translation of c-erbB-2 and c-raf-1 and their down-stream molecules c-jun 
and c-fos are decreased (Dalu et.al. 1998; Li et.al 2004). Genistein inhibits 
the glycine receptor (Huang and Dillon 2000). It decreases vascular 
endothelial growth factor (Ravindranath et.al. 2004), glutathione reductase  
(Elliot et.al. 1992), aromatase (Whitehead and Lacey 2003), topoisomerase 
I and II (Novogen 2007) and the signal transduction by inositol-3-
phosphate (Shen and Weber 1997). Genistein increases basal cAMP levels 
and potentiates forskolin-induced cAMP accumulation (Burvall, Palmberg 
and Larsson 2002). It alters the cAMP-dependent chloride transport of the 
cystic fibrosis transmembrane conductance regulator, first activating it at 
low concentrations but inhibiting it at higher concentrations (Moran and 
Zegarra-Moran 2005). It also directly affects the transmembrane regulator 
(Illek et.al. 1995). Together with its metabolites equol and p-ethyl phenol, it 
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up-regulates prostaglandin F2 alpha (PGF2 alpha) (Woclawek-Potocka 
et.al. 2005). It up-regulates lipopolysaccharide-sensitive inducible nitric 
oxide synthetase through estrogen receptors (Nakaya, Tachibana and 
Yamada 2005). It increases metallothionine expression (Kuo and Leavitt 
1999). 
 
Genistein renders volume-sensitive chloride channels inactive (Shi et.al. 
2002), disables the regulation of active Na+/K+-transport by dopaminergic 
agonists (Nakai et.al. 1999) and acts with insulin on the Na+/K+/2Cl-
cotransporter (Ueda-Nishimura et.al. 2005). It binds to thromboxane A2 
receptors and inhibits platelets (Guerrero et.al. 2005). It retards hepatic 
growth factors promoting wound healing (Watanabe et.al. 1994) as well as 
myoblast proliferation, fusion and myotube protein synthesis (Ji et.al. 
1999). Below 60µM, genistein induces cellular differentiation 
(Constantinou, Krygier and Mehta 1998), dendrite-like structures and 
tyrosinase activity (Kiguchi, Constantinou and Hubermann 1990). Above 
60µM , cell viability changes independently of topoisomerase II inhibition 
(Salti et.al. 2000). Genistein arrests the cell cycle in phase G2/M (Novogen 
2007) and combines with quercetin to arrest the cell cycle in phase (G1/S) 
(Shen and Weber 1997) or with vitamin D to arrest the cycle in phase 
(G1/0) (Rao et.al. 2002).  
 
In vivo, genistein adheres to subdomain IIa of human serum albumin and is 
displaced by other compounds fitting into this pocket, like warfarin, 
diazepam or similar isoflavonoids (Mahesha et.al. 2006). This changes the 
distribution, elimination and potency of the compound. Genistein is rapidly 
absorbed, glucuronidated in the gut wall with a significant entero-hepatic 
circulation (Sfakianos et.al. 1997). Not all humans metabolize genistein 
well, and are classified as high or low metabolizers. The half-live of 
genistein in plasma is estimated as eight hours (Watanabe et.al. 1998), but 
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in renal insufficiency it accumulates and may not return to the baseline for 
more than seven days (Walker et.al. 2001). Administered intravenously into 
the forearm, genistein produces a nitric oxide-dependent dilatation of the 
vasculature (Fanti et.al. 1999). In young, healthy females it changes the 
length of menstruation due to hormonal effects (Watanabe et.al. 2000). 
 
Mifepristone (RU486) inhibits progestin-induced cell growth. However, in 
the absence of progestins RU486 exerts intrinsic activity and stimulates cell 
growth (Bowden, Hissom and Moore 1989). Mifepristone self-oxidizes 
with nitroso species catalysed by cytochrome P450 (CYP) 3A4 thereby 
complexing the heme of the enzyme and inactivating it (Jang and Benet 
1998). It inhibits 17-hydroxylase activity in human testicular, ovarian and 
adrenal steroidgenesis (Sanchey et.al. 1989). In pregnant women, it 
sensitizes the myometrium to the contraction-inducing activity of 
prostaglandins. With increasing doses, mifepristone progressively inhibits 
the progesterone-, the glukokortikoid- and finally the androgen-receptor 
(RxList 2006). It competes with cyproterone acetate at the androgen-
receptor binding site, forming an overlapping steroid scaffold in the binding 
pocket (Honer et.al. 2003). Mifepristone also inhibits the alpha folate 
receptor (Tran et.al. 2005).  
 
Mifepristone decreases progestin-induced phosphorylation of insulin 
receptor substrate 2, phosphadityl inositol 3 kinase and protein kinase B 
(AKT) (Cui et.al. 2003). It suppresses transcription of the vascular 
endothelial growth factor and messenger molecule bcl-2 (Zhang et.al. 
2006). However, it enhances signalling through phosphorylation of p38, 
p42/p44, and cyclin D1 and enables S-phase progression (Skildum, Faivre 
and Lange 2005). It stimulates the binding activity of nuclear factor-kappa 
B (Han and Sidell 2003), and the expression of cyclooxygenase 2 (Hardy 
et.al. 2006), and the phosphorylation of signalling molecule bax (Zhang 
 27 
et.al. 2006). Mifepristone up-regulates nitric oxide production (Martin, 
Alalami and van den Berg 1999) and induces apoptosis in a dose- and time-
dependent manner (Li et.al. 2003). It arrests cells in G0/G1 phase after 
completing the cell cycle (Li et.al. 2003).  
 
In vivo, 70% of mifepristone is absorbed with 40% bioavailability after the 
first pass effect in the liver (Sarkar 2002). It is bound to albumin and alpha 
1-acid glycoprotein, the latter being quickly saturated. After a single 
administration, mifepristone is eliminated non-linearly and can be detected 
in serum up to 11 days later. Mifepristone is metabolized by N-
demethylation and terminal hydroxylation of the 17-propynyl chain, and 
finally excreted into the faeces (RxList 2006). Treatment with mifepristone 
enlarges the pituitary and the ovaries which can be explained as prolactin-
induced estrogen effects that are not opposed by progesterone (Di Mattina 
et.al. 1987). The clinical picture is very similar to the polycystic ovary 
syndrome (Ruiz et.al. 1995). During a combined treatment with 
mifepristone and bromocriptin (a prolactin inhibitor), growth of the 
pituitary and the ovaries is significantly suppressed (van der Schoot, 
Uilenbroek and Slappendel 1990). These hormonal changes are beneficial 
in treatment of benign unresectable and/or recurrent meningiomas. Anti-
neoplastic activity has been noticed in tamoxifen-resistant breast cancer and 
hormone- insensitive prostate cancer (Sartor and Figg 1996), and long-term 
treatment is well tolerated (Grunberg et.al. 2006). 
 
Vitamin C and ascorbate exert antineoplastic activity and are used in 
combination with arsenic trioxide for the treatment of lymphoid 
malignancies such as multiple myeloma and some lymphomas (Campbell 
et.al. 2007). As antioxidants they prevent lipid peroxidation and protein 
oxidation in the presence of iron ions, copper ions and hydrogen peroxide 
(Suh, Zhu and Frei 2003). Vitamin C is oxidized to semidehydro-ascorbate 
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and dehydro-ascorbate (Linster and Schaftingen 2007), enters the 
mitochondria via the glucose transporter (Glut 1), accumulates there as 
mitochondrial ascorbic acid (mtAA) and protects mitochondrial DNA (KC, 
Carcamo and Golde 2005). It activates the p38 mitogen-activated protein 
kinase (Bowie and O`Neill 2000), induces circulating insulin-like growth 
factor binding proteins 1 and 2 (Peterkofsky et.al. 1994), expresses collagen 
IV and promotes retinoblastoma (Rb) phosphorylation. (Saeed, Peng and 
Mety 2003). It enhances concentration-dependent glucose synthesis (Braun 
et.al. 1996) and generates hydrogen peroxide, depending on the glutathione 
levels (Han et.al. 2004). Vitamin C increases synthesis of high density 
lipoproteins, decreases low density lipoproteins (Mehl-Madrona 2004) and 
inhibits enzymes that degrade the extracellular matrix. Vitamin C inhibits 
interleukin 1 and 8 (Bowie and O`Neill 2000), cyclo-oxygenase 2 (Han 
et.al. 2004), nuclear factor kappa B (Carcamo et.al. 2004), lactate 
dehydrogenase (Russel et.al. 2004) and steroid hydroxylation (Pintauro and 
Bergan 1982). 
 
Alone or in combination with selenite, vitamin C causes growth inhibition, 
redifferentiation of cancer cells (Zheng, Sun and Wang 2002) and caspase 
independent apoptosis (Verrax et.al. 2004). In combination with vitamin 
K3 (menadione) it decreases the formation of lactate, adenosine 
triphosphate and nicotinamide adenine dinucleotide by up to 80% (Verrax 
et.al. 2007) and promotes “autoschizis”, a special form of cell death 
(Verrax et.al. 2003).  
 
Therapeutic plasma concentrations above 400mg/dL are needed in vivo to 
treat cancer (CIHF 2007). However, 3g of vitamin C given four-hourly as a 
maximum tolerated oral dose, results only in plasma levels of 4.3mg/dL and 
a single intravenous dose of 50g vitamin C results only in plasma levels of 
265mg/dL. Vitamin C is, therefore, used in combination with radiotherapy 
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or chemotherapy (Dettman 2003).    
 
Selenium has been used to treat cancer in physiological and supra-
physiological doses, as inorganic and organic compounds and in its four 
different states of oxidation, elemental selenium, selenide, selenite and 
selenate with oxidation states of 0, -2, +4 and +6.  
  
Selenium uptake and insertion is unique. It has its own codon in mRNA 
that specifies its insertion into selenoproteins as selenocysteine (SeCys) 
(Rayman, 2005). Selenocysteine, the 21st amino acid, is then incorporated 
into selenoproteins. The mode of incorporation is significantly different 
from other amino acids (Hatfield and Gladyshev, 2002). Selenoproteins that 
may be particularly relevant to cancer risk include the glutathione 
peroxidases, 15kDa selenoprotein, selenoprotein P and the thioredoxin 
reductases (Rayman, 2005).  
  
Selenium is a nutritional essential trace element with anti-carcinogenic 
properties (Nomura et al. 2000) and it has been reported that daily selenium 
supplementation in the diet reduces the overall development of cancers. In 
1996, Clark et al. published a study in which he stated that a 10 year 
supplementation with a moderate daily dose of 200µg day-1 selenium-
enriched yeast significantly reduced total cancer incidence, total cancer 
deaths and incidence of carcinomas at sites other than the skin. However, it 
was later pointed out by Coombs Jr. (2004) that the chemical specification 
of selenium in food is important to achieve this reduction in cancer risk. A 
number of mechanisms have been suggested to explain the anti-cancer 
effects of selenium. This list can only be incomplete. However, the main 
effects are listed by Rayman in 2005. The effects describe the differences 
between a low versus a normal selenium concentration in serum: a 
reduction of DNA damage; a reduction of oxidative stress; a reduction of 
 30 
inflammation; an induction of phase II conjugating enzymes so that 
carcinogens can be detoxified and DNA adduct formation can be reduced; 
an enhancement of the immune response; a stimulation of DNA repair; an 
inactivation of protein kinase C; an alteration in DNA methylation; a 
blockage of the cell cycle to enhance DNA repair; an induction of apoptosis 
due to sequential activation of caspases; an inhibition of angiogenesis and 
other mechanisms. In most of these chemopreventive investigations, 
selenomethionine or high selenium-enriched yeast was used as the 
chemopreventive supplement.  
 
However, as outlined by Coombs Jr. (2004) it seems to be important to 
specify the chemical form of selenium that has been applied. Anti-cancer 
properties are published for several selenium-containing compounds e.g. 
for metabolites of selenoproteins, for selenodiglutathione, for hydrogen 
selenide and for methylated selenides. However, their modes of action 
differ. Coombs Jr. (2004) illustrates the metabolic relationship between 
these compounds and specifies their generally accepted effects on 
mammalian cells. 
 
Another important aspect of supplementing selenium compounds is the 
nutritional requirement for them. A dietary intake of 70µg/day selenium for 
men and 60µg selenium for women is recommended by the Medical 
Research Council in Australia (Position Statement Aug. 2005). An upper 
intake limit of 400µg/day selenium intake seems to be accepted as a safe 
measure. However, in supra-nutritional doses selenium intake in its 
different chemical specification can also be toxic. The speed of selenium 
accumulation which ultimately culminates in the appearance of a disease 
called selenosis appears to be different for inorganic or organic compounds 
with organic selenium agents accumulating faster than their inorganic 
counterparts. In contrast, it also has been reported that sub-nutritional 
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uptake leading to selenium deficiency causes the so-called Keeshan disease 
(Liu et al. 2002). 
It is of note that cell cycle-related effects of selenium compounds are 
concentration-dependent. Zeng (2002) illustrates that low concentrations of 
selenite and selenomethionine up-regulate multiple key cell-cycle-related 
mRNA- and total phosphorylated protein-levels. In contrast, high 
concentrations of these compounds inhibit cell growth and induce 
apoptosis. The different sensitivity of cancer versus normal cells to some 
selenium-containing chemotherapeutics is quite remarkable and warrants 
further investigations in particular of the following observations: selenium-
containing compounds with different chemical specification have been 
combined to increase the overall cytotoxicity to cancer cells (e.g. selenite 
and selenomethionine); selenium compounds have also been combined with 
cytotoxic chemotherapy increasing cytotoxicity to cancer cells whilst 
minimising toxicity of cytotoxic chemotherapeutics to normal tissues in a 
compound-dependent manner (Zhang 2007).  
 
The following paragraphs further details the plethora of biochemical effects 
attributed to various selenium-based inorganic and organic compounds. 
These two groups differ significantly in their in vitro and in vivo properties. 
Research has been reported on the cancer-selectivity of elemental grey and 
nano red selenium, selenide, selenite, selenate, selenic- and methylselenic 
acid, selenomethionine, selenocysteine and synthesized (organic) 
compounds. The list of newly developed or discovered compounds is 
continuously growing and not all of them are described here.  
 
Selenite is a potent inorganic anti-cancer selective agent (Birringer, Pilawa 
and Flohe 2002). It induces synthesis of glutathione peroxidase (GPX-1) 
and membrane-bound phospholipid hydroperoxide glutathione peroxidase 
(GPX-4) (Miller et.al. 2001) and protects cellular membranes from 
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oxidative attack (Hawkes and Tappel 1983). Usually, fatty acid 
hydroperoxide, a substrate of the above-mentioned phospholipid 
hydroperoxide glutathione peroxidase (GPX-4), induces interleukin 1 
(Brigelius-Flohe et.al. 1997) and activates the binding of nuclear factor 
kappa B. Alternatively, interleukin 6 can induce binding as well (Renard 
et.al. 1997). Nuclear factor kappa B controls the expression of membrane 
type 1 matrix metalloproteinase (but not the tissue type), of matrix 
metalloproteinases 2 and 9 (Park et.al. 2007), of cytokines, of cell adhesion 
molecules and of inducible nitric oxide synthetase (Kim and Stadtman 
1997). Selenite inhibits the binding of two nuclear factors, the activating 
protein 1 and the nuclear factor kappa B (Handel et.al. 1995; Kim and 
Stadtman 1997). Selenite oxidizes insoluble protease-resistant, fibrin-like 
polymers of cell membranes and changes their polythiols to disulphides 
(Lipinski 2005).  
 
Selenite affects signalling pathways: It binds to Sp-1 in the androgen 
receptor promoter region and downregulates androgen receptor expression 
(Husbeck et.al. 2006). Selenite reduces the serum levels of growth hormone 
and somatomedin C (Thorlacius-Usiing, Flyvbjerg and Orskov 1988), 
decreasing the amount of circulating insulin-like growth factor-1 (Gronback 
et.al. 1995). It irreversibly inhibits glucocorticoid binding (Tashima et.al. 
1989). It inhibits cJUN N-terminal kinase, stress-activated protein kinase 
and p38 mitogen-activated protein kinase (Park et.al. 2000). It inhibits 
caspase-9 and caspase-3 through a redox mechanism (Park et.al. 2000; 
Yoon et.al. 2002) and sensitises cells resistant to tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL) to undergo caspase-mediated 
apoptosis (Hu et.al. 2006; Yamaguchi et.al. 2005). It decreases the ratio 
between type I and type II isozymes of cyclo-adenosine mono phosphate 
kinase (cAMP), which explains that selenite is cancer-selective (Liu et.al. 
1986).  
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Selenite exerts metabolic changes: Intracellularly, it increases oxygen 
consumption and oxidizes glutathione as well as nicotinamide adenine 
dinucleotide phosphate (NADPH) (Anundi, Stahl and Hoegberg 1984; 
Bahmre et.al. 2000); it non-competitively, dose-dependently inhibits liver-
DNA-methylase (the DNA-methylating protein) (Cox 1985): generally, 
inhibiting DNA-methylase promotes apoptosis in all cells (Vanyushin 
2006). However, due to the differences in DNA-methylation patterns 
between malignant and normal cells, selenite exhibits selectivity for cancer 
cells (Vanyushin 2006). Selenite decreases serum glucose and the 
precursors for gluconeogenesis including lactate, alanine and glycerol 
(Iizuka et.al. 1993), and inhibits activity of gluconeogenic enzymes 
including pyruvate carboxylase and glucose-6-phosphatase. It promotes the 
activity of glycolytic enzymes, in particular glycokinase and phospho-
fructokinase (Iizuka et.al. 1993). Lactate dehydrogenase and NADP 
isocitric dehydrogenase are enhanced; succinic dehydrogenase is decreased 
(Nebbia, Gremmels and Soffietti 1990). Selenite promotes the opening of 
the mitochondrial permeability transition pore, releases cytochrome c from 
the membrane and enhances mitochondrial aspartate transaminase activity 
(Yhu, Woo and Huang 2002). It promotes calcium ion release from the 
mitochondrial matrix and uncouples respiration (Shilo et.al. 2003).  
 
In microorganisms, selenite is incorporated into several compounds that 
depend on the selenium for their activity: selenocysteine, selenophosphate, 
formate dehydrogenase H, seleno tRNA and deoxyribose-phosphate 
aldolase (Larcouciere, Levine and Stadtman 2002). As part of protein 
synthesis, the incorporation of selenium into selenocysteine is encoded by a 
stop codon UGA in the mRNA and involves a unique tRNA (Daniels 
1996). Selenocysteine is the precursor of a minimum of thirteen different 
selenoproteins (Daniels 1996).  
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In vivo, selenite is mainly bound to haemoglobin, and in approximately the 
following proportions to three binding-proteins in plasma: selenoprotein P 
52%, glutathione peroxidase 39%, albumin 9% (Sheehan and Halls 1999). 
Selenium is rapidly internalised and incorporated into erythrocytes (Mas, 
Jiang and Sarkar 1988). Its uptake, metabolism to selenide and release as 
selenium depends on the amount of intracellular reduced glutathione. The 
gamma glutamyl transferase inhibitor serine-borate and the glutathione 
depleter diethylmaleate both reduce the cellular uptake of selenite 
(Anunadi, Hogberg and Stahl 1984). Inhibiting intracellular glutathione 
reductase, for example with chromate, decreases the release of selenium 
from cells (Gasiewicz and Smith 1978). 
 
Selenite is efficiently absorbed when taken by mouth (Janghorbani et.al 
1990), with a steady state in blood achieved after 12-17 days (Hansen and 
Kristensen 1979). However, this has been rejected by Patterson et.al. 
(1989) who illustrates this to happen after several months. After injection, 
88% selenite is taken up by the anion exchange carrier into red blood cells 
(Styblo, Kalouskova and Pavlik 1988; Suzuki et al. 1998). With the uptake 
of 66µg selenite, full expression of glutathione peroxidase is achieved (Xia 
et.al. 2005). Stopping selenite supplementation results in a half-life of 
decay of glutathione peroxidase of 4.2 days (Ip and Hayes 1989). Most of 
the selenite consumed is excreted as selenium in the faeces or urine. 
However, about one third of the ingested selenium is volatilised forming 
dimethylselenide (Janghorbani et.al. 1990). Volatilisation of selenite is 
delayed with cumene hydroperoxide and completely stopped with tert-
butylbenzoic acid (Stahl, Anundi and Hogberg 1984).  
 
There are other clinical observations regarding exposure to selenium: 
selenium deficiency, for example in Keeshan disease, leads to a decrease in 
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hepatic 5`deiodinase- and thyroxin-3 syntheses (Jianhua, Ohtsuka and 
Hayashi 2000). Applying selenite alone causes cataracts as it induces 
oxidative stress (Gupta et.al. 2002) which can be prevented by 
simultaneous administration of green tea or vitamin C (Gupta et.al. 2002; 
Devamanoharan et.al. 1991). Selenite inhibits complement activation 
through the alternative pathway at the level of complement factor C3 (Hou, 
Jiang and He 1993) and induces an antithrombotic effect by stimulation of 
glutathione peroxidase (Ricetti et.al. 2000). Without a certain blood 
concentration of selenoprotein P, selenite administered intravenously will 
lead to nervous system disorders (Hill et.al. 2004): the striatum in the brain 
is affected by raising levels of dihydroxyphenylacetic acid and 
homovanillic acid (Tsunoda, Johnson and Sharma 2000). Selenite reduces 
lymphoedema after oral surgery (Zimmermann et.al. 2005) and attenuates 
arginine-induced pancreatitis (Hardman et.al. 2005). As selenite induces 
glutathione peroxidase, an inverse correlation between the severity of 
lymphoedema or pancreatitis and glutathione peroxidase-activity has been 
observed. Selenite inhibits progression of hormone refractory prostate 
carcinoma (Corcoran, Najdovska and Costello 2004) and slows growth of 
crocidolite-induced mesothelioma (Yang, Luo and Liu 1994). This has been 
explained by a decrease in angiogenesis. For cancer treatment “normal” 
selenium concentrations (usually below 2µM) have to be greatly exceeded 
(Husbeck et.al. 2006); serum levels of over 7µM are required to achieve 
complete inhibition of the nuclear factor kappa B in vivo (Kim and 
Stadtman 1997). Resistance to selenite treatment has been observed in 
different settings (Pinson, Sagot and Daignan-Fornier 2000). 
 
Selenite and sulphydryl group-containing compounds form cancer-selective 
selenotrisulphides (Abdullaev, MacVicar and Frenkel 1992). Selenite 
reacts with the following sulphydryl group-containing compounds: 
cysteine, cysteamine, methionine, reduced glutathione, mercaptoethanol, 
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oxidized and reduced alpha lipoic acid and penicillamine. Selective 
reactivity to cancer cells seems to be due to the formation of 
selenotrisulphides, not to selenite itself (Ip and Hayes 1989).  
 
The sequence of compound application is crucial: when intracellular 
sulphydryl groups are elevated or reduced prior to the application of 
selenite, a loss in cell-killing efficacy can be observed. As an example, 
selenite does not inhibit growth or induce apoptosis if reduced glutathione 
has been applied twenty-four hours prior to its administration. However, the 
simultaneous administration of reduced glutathione with selenite has a 
dramatic effect (Kuchan and Milner 1991). Withholding reduced 
glutathione and other sulphydryl group-containing compounds with 
diethylmaleate twenty-four hours prior to applying selenite inhibits growth 
and apoptosis; that can be reversed with trisulphides (Frenkel and Falvey 
1988). 
 
There are multiple mechanisms of trisulphide action: trisulphides inhibit 
amino acid incorporation into proteins including the branched chain amino 
acid leucine (Vernie et.al 1979), reduce elongation factor 2 (Vernie et.al. 
1975) and inhibit DNA/RNA-polymerases (Frenkel, Walcott and Middleton 
1987). Trisulfides target RNA polymerase II; they do not affect the 
initiation-stage of forming an enzyme binary complex, but do affect the 
elongation stage (Frenkel and Falvey 1989). They generate five to twenty-
five-fold more active oxygen species in tumour cells than in normal cells 
(Terada et.al. 1999; Yan and Spallholz 1993) and they inhibit colony 
formation by cancer cells (Caffrey and Frenkel 1991).  
 
In contrast to selenite, organic selenomethionine dose-dependently 
increases plasma selenium levels and accumulates intracellularly (Burk 
et.al. 2006). It affects normal cells but requires a 100-fold higher 
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concentration than cancer cells do (Redman et.al. 1998). Selenomethionine 
synergises with selenite, topoisomerase I inhibitors (Rustum et.al. 2005), 
taxanes, platinum, 5-FU and anthracyclines (Fakih et.al. 2005).  
Selenomethionine is well absorbed orally (Shen et.al. 1997) and further 
catalysed to methylselenol (CH3SeH) by cystathionine-gamma-lyase 
(Okuno et.al. 2005). More recent literature is pointing out that 
methylselenol has anti-carcinogenic function.   
 
Differences between Methylselenic acid and selenite have been observed: 
Methylselenic acid does not affect the androgen receptor promoter Sp-1 
(Husbeck et.al. 2006) and induces no measurable superoxide radical levels 
(Shen, Ding and Ong 2002). Differences in the phosphorylation status of 
protein kinase B, extracellular regulated kinases 1 and 2, JNK 1 and 2 and 
p38 mitogen activated protein kinase have been observed (Jiang et.al. 
2002). Methylselenic acid is taken up into the liver, reduced to 
methylselenol, and transformed into selenide, selenosugar A and 
selenosugar B. 
 
Red elemental selenium or red nanoselenium has only 10% of the 
potency of selenite in synergy with glutathione and is seven times less toxic 
(Gao, Zhang and Zhang 2000).  
 
Other well-known synthetic organic selenium compounds are Ebselen and 
pXSC. Ebselen inhibits electron transfer from reduced nicotinamide 
adenine dinucleotide phosphate cytochrome P450 to flavin adenine mono- 
and dinucleotide by flavin reductase (Nagi et.al. 1989). It also inhibits fatty 
acid chain elongation, beta-ketoacyl CoA reductase and dehydrase/enoyl 
CoA reductase (Laguna et.al. 1989). It depletes intracellular sulphydryl-
group containing compounds and induces apoptosis (Yang, Shen and Ong 
2000). pXSC decreases COX-2 specific activity without affecting protein 
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levels (Rao et.al. 2001).  
 
β-Lapachone is an antineoplastic compound discovered in the bark of the 
Amazonian tree bignoniaceae tabebuja avellanedae (Choi, Cheong and 
Choi 2003). At concentration of 5-10µM in vitro it competitively inhibits 
glucocorticoid binding to the cell membrane, targeting antigenic 
determinants which seem to be shared between the cytoplasmatic gluco-
corticoid receptor and DNA polymerase. However, it does not affect the 
mineralocorticoid-, estrogen-, androgen- or progesterone-binding site 
(Schmidt, Miller-Diener and Litwack 1984). It abrogates reverse 
transcriptase (Schmidt, Bollum and Litwack 1982), interleukin 6, vascular 
endothelial growth factor, nuclear factor kappa B and intracellular adhesion 
molecule 1(Gupta et.al. 2002; Choi, Cheong and Choi 2003). It inhibits 
NADPH-dependent cytochrome P450 destruction and NADPH-dependent 
iron-catalysed microsomal lipid peroxidation (Dubin, Fernandez Villamil 
and Stoppani 1990). However, β-lapachone increases caspase-9 and 
caspase-3 activity without affecting caspase-8 (Choi, Cheong and Choi 
2003), and interacts with topoisomerase 1 (Oliveira-Brett, Goulart and 
Abreu 2002). It induces an elongation factor E2F1 and a Ca-ion-dependent 
cysteine protease (Pink et.al. 2000), promotes synthesis of hydrogen 
peroxide (Cruz, Docampo and Boveris 1978) and activates the S-phase 
checkpoint (Li et.al. 2003). Its mechanism is thought to be a two-step 
oxidation: it reduces NAD(P)H:quinone oxidoreductase 1 (NQO1) to an 
unstable hydroquinone which then reforms back into the parent compound, 
reducing FE(III)ADP and diverting reducing equivalents from NADPH to 
dioxygen (Reinicke et.al. 2005). The first early apoptotic events are 
cytochrome c release with mandatory caspase-3 activation (Li et.al. 1999). 
However, β-lapachone also induces necrosis and is inhibited by dicoumarol 
(Pink et.al. 2000). β-lapachone synergises with vitamin C (Dubin, 
Fernandez Villamil and Stoppani 1990) and genistein (Kumi-Diaka et.al. 
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2004). 
 
In vivo, β-lapachone is applied as an equimolar complex with α- or  
β-cyclodextrins to increase the solubility of the compound (Nasongkla et.al. 
2003). Administration of β-lapachone is strongly abortive (Guerra et.al. 
2001) and combines well with taxol and radiation (Li et.al. 1999; Park et.al. 
2005).  
 
The following section of this review focuses on the use of glycolysis 
inhibition, antibiotic administration, diethylmaleate- and H2O2-addition in 
cancer treatment: Disturbing the lactate-to-pyruvate ratio of glycolysis, the 
three metabolites fructose-1,6-biphosphate, glyceraldehyde-3-phosphate 
and dihydroxyacetonephosphate accumulate (Tilton et.al. 1991), forming 
advanced glycosylation end products and additional lactate. T-lymphocytes 
are suppressed at high lactic acid levels: a 95% reduction of their cytokine 
synthesis and proliferative activity and 50% reduction of their cytotoxic 
activity can be observed (Fischer et.al. 2007). Inhibiting glycolysis under 
aerobic conditions is cancer-selective and enhances the efficacy of any 
chemotherapy (Kim et.al. 2002). 
 
Oxamate competes with pyruvate and inhibits the rate of reduction to 
lactate. The effects of oxamate are concentration-dependent: below 0.4mM 
it inhibits gluconeogenesis, but above 0.4mM has no apparent influence it 
(de Arriba et.al. 2003). Another glycolysis inhibitor, iodoacetate, targets 
nonspecific sulphydryl group-containing enzymes like glyceraldehyde-3-
phophate dehydrogenase and glucose-6-phosphate dehydrogenase. 
Synthesis of glutamate decreases in the presence of iodoacetate. This can be 
reversed by administration of citrate (Birnbaum and Demain 1969). 
Combined with dimethylsulphoxide, iodoacetate inhibits tumour 
progression (Fahim et.al. 2003). Finally, iodoacetate influences tumour 
 40 
immunity (Apffel, Arnason and Peters 1966).  
 
The rationale for using antibiotics in tumour treatment is twofold: First, 
some antibiotics like tetracyclines or sulphonamides inhibit isozymes of 
glutathione-S-transferases (GST M3-3 and GST P1-1) in some 
circumstances inducing apoptosis (Mukanganyama et.al. 2002). 
Tetracyclines inhibit the cleavage of matrixmetalloproteinases (Saikali and 
Singh 2003), sulphonamides reduce the synthesis of uric acid (Chertow 
et.al. 1996). Second and equally importantly, they affect the multiplication 
and cellular interference of mycoplasma, chlamydia, streptococci, 
heliobacter and other intracellular parasites: there is a high correlation 
between mycoplasma infection and human carcinomas (Huang et.al. 2001). 
Mycoplasma-mediated malignant transformation is associated with high H-
ras and c-myc levels which induce the nuclear factor kappa B (Zhang et.al. 
1997) and enhance inducible nitric oxide synthetase independently of 
cytokines (Kagemann et.al. 2005). In the presence of the urokinase-type 
plasminogen activator, mycoplasma adheres to plasminogen receptors 
promoting intracellular invasion and potently reducing cellular antioxidant 
activity (Yavlovich et.al. 2004 and 2006, Yavlovich, Tarshis and Rottem 
2004). Trypsin treatment of cells detaches mycoplasma from human cells 
(Razin et.al. 1981).  
 
Diethylmaleate is a glutathione depleting agent binding to glutathione-S-
transferase. It enhances blood lactate levels similar to advanced 
glycosylation end products (Jimenez et.al. 1986). Diethylmaleate increases 
L-cysteine transport across the cell membrane (Ruiz et.al. 2003). At high 
concentrations it causes the immediate and sustained loss of intracellular 
glutathione (Casey et.al. 2002); however, in low concentrations (0.025-
0.1mM) it increases intracellular glutathione levels (Bannai 1984). It is 
excreted into the bile. 
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H2O2 is an important mediator of cellular signalling and induces dose-
dependent apoptosis. A remarkable inhibition in the phosphorylation of 
insulin-like growth factor-1 can be observed. However, it increases 
phosphorylation of insulin- and epidermal growth factor receptors (Schmitt, 
Klein and Droge 2006; Zhung and Schnellmann 2004). It stimulates 
glucose transport across the membrane, up-regulates the insulin-induced 
vascular endothelial growth factor and the hypoxia-induced factor 1 alpha 
through p70S6K1-kinase (Zhou et.al. 2007) and mediates cell adhesion 
(Chiarugi et.al. 2003). It promotes phosphorylation of stress-activated 
protein kinase and JNK-kinase, extracellular regulated kinase 1 and 2, 
proteinkinase B (AKT) and src-kinase (Inanami et.al. 1999; Zhung and 
Schnellmann 2004), releasing mitochondrial Ca-ions and arachidonate. 
H2O2 up-regulates polyADP-ribosylation activity and pyruvate 
dehydrogenase and decreases adenosine triphophate synthesis (Ramasarma 
1990). Finally, it is inactivated by NAD(P)H-dependent catalases  
(Calderon et.al. 2006) and antioxidants.  
 
In vivo treatment with H2O2 inhibits tumour cell attachment to  
extracellular matrix proteins and enhances metastasis (Kundu, Zhang and 
Fulton 1995).  
 
This review of the literature details the mechanisms of how the metabolic 
flux in many cancer cells is shifted from the carbon cycle to the nitrogen 
cycle resulting in excessive nitrosylation of proteins. The effects of 
excessive nitrosylation of proteins are deleterious and impact on cell 
growth, survival, migration and angiogenesis. Indeed, the role of nitric 
oxide in cancer development is a highly active area of current research 
worldwide. Preventing excessive nitrosylation of proteins may be a 
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mandatory requirement to combat cancer. In addition, the actions of several 
broad-spectrum inhibitors that show promise for cancer therapy by 
targeting various metabolic signaling pathways in cancer cells are 
reviewed. Some of these inhibitors target nitric oxide production and/or 
nitrosylation. Others impact on the cellular synthesis of hydrogen peroxide. 
The mode of action of each compound has been described in detail. 
However, this review of the literature also highlights the need of 
improvement for most current chemotherapeutic approaches. More 
effective strategies require that combined chemotherapeutic approaches are 
used to overcome the redundant nature of signaling processes in cancer 
cells. 
1.1    The Present Study 
 
Cancer cell biology is extremely complex and invariably involves multiple 
constitutively activated steps in overlapping networks of intracellular 
signaling pathways. Thus, it is perhaps not surprising that individual 
narrow-spectrum inhibitors often have limited efficacy in the treatment of 
cancer. Unfortunately, clinical trials using individual, broad-spectrum 
inhibitors also have yielded disappointing results. Consequently, there has 
been a plethora of studies evaluating combinations of chemotherapeutic 
agents.  
 
The aim of this study was to evaluate a selection of combinations of 
chemotherapy agents. Many of the individual compounds chosen in this 
study were selected as they either are currently in various stages of 
development within various pharmaceutical companies (eg staurosporine 
developed as its derivates UCN-01 or CGP41251 by Pharmaceutical 
Research Institute, Kyowa Hakko Kogyo Co, Ltd Shizuoka-ken, Japan; or 
genistein developed as GCP by Pharmaceutical Company Amin Up 
Chemicals Sappiro Japan) or are being trialed under the special access 
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scheme (SAS) provisions. These SAS provisions allow developmental 
therapies to be tested in end-stage cancer patients for whom conventional 
cancer therapies have failed. 
The hypothesis to be tested in this study was that some combinations of 
broad-spectrum inhibitors together with narrow-spectrum inhibitors would 
be more effective in killing cancer cells than either the broad- or the 
narrow-spectrum inhibitors used alone. This approach was based on the 
rational that inhibition of multiple aberrant signalling pathways was 
essential to eradicate cancer cell populations. Broad-inhibiting compounds 
target multiple aberrant signaling steps. However, within a therapeutic 
range, most of these compounds are only partially effective. Narrow 
spectrum inhibitors were then added to the combination in an attempt to 
completely eradicate cancer cell populations.  
The first objective of this study was to establish continual and optimal 
growth of a series of cancerous cell lines including: a) JU-77, a human 
mesothelioma cell line b) MCF-7, a human breast cancer cell line; 
c) Caeco-2, a human colon cancer cell line; d) HepG2, a human 
hepatoblastoma cell line. This thesis reports predominantly on the results 
from the JU77 and MCF-7 cell lines. Human albumin was included in many 
of the cell culture tests because it is known that it can change the potency of 
chemotherapeutic agents. High levels of IGF-1 were also included in many 
of the cell culture tests to simulate the autocrine loops of tumours in vivo, 
which also attenuates the action of many chemotherapeutic agents.  
The second objective was to identify specific and generalized inhibitors 
against various receptor tyrosine kinases, which are involved in signalling 
pathways of the: a) insulin receptor; b) insulin like growth factor receptor 1 
(IGF-1R); c) epidermal growth factor receptor (EGFR); d) growth hormone 
(GH)/ prolactin receptor (PRL); e) oestrogen receptor (ER) and f) 
progesterone receptor (PR). The third objective was to determine the 
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minimum dose of agents required to effectively kill cancer cell populations.  
 
The final objective of this study was to establish an animal model (nude 
mice growing human xenografts of cancer cells) of cancer to enable the 
most promising candidate combination(s) to be tested in vivo. This entailed 
histopathology reporting on the xenograft tumours to enable the efficacy of 
the control and treated animals to be more fully assessed and clinical 
biochemistry blood reports to enable animal well-being to be more fully 
monitored. 
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2. 0 MATERIALS AND METHODS 
2.1 Materials 
Various inhibitors were obtained from three companies (Sigma, NSW, 
Australia; Merck, UK; Biaffin, Germany) listed in Appendix 1, general 
pharmacies or Dr.W.Barnes, General Practitioner and Nutritional Specialist 
in 246 South Terrace/Fremantle. The four cancer cell lines (JU77, MCF-7, 
Caco-2 and HepG2) were a kind gift of Dr.Simon Fox, Curtin University of 
Technology who obtained the JU77 cell line from the team of Manning 
et.al.1991 and the other three cell lines from American Tissue Cell 
Cultures, USA. Materials and medium for cell cultures were ordered from 
Invitrogen, Victoria, Australia. Foetal calf serum was ordered from SAFC 
Biosciences, Victoria, Australia. Growth factors were ordered from 
GroPep, South Australia. Nude balb/c mice were ordered from the Animal 
Resources Centre, Murdoch University, Western Australia. 
2.2 Methods 
2.2.1 Establishing cell cultures of human cancer cell lines 
2.2.1.1 Description of the four cell lines 
 
Mesothelioma cell line JU77 (ATCC No. none): 
Establishment and characterization of the mesothelioma cell line JU77 was 
performed by Manning et.al. in 1991. The cells were derived from the 
serosal cavities of untreated male patients with known crocidolite asbestos 
exposure. Diagnosis was made by cytology, histology and electron 
microscopy. The cells appear in spindle form and have a minimum 
doubling time of 18 hours. They carry the epithelial membrane antigen 
(EMA) and cytokeratin. They lack carcinoembryonic antigen (CEA) and 
epithelial mucin. Cell junctions, glycogen and numerous long, thin 
branching microvilli are typical. An abnormal karyotype exists, with 
between 40 and 80 chromosomes. The mesothelioma cell line JU77 was 
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initially established in RPMI supplemented with 5% foetal calf serum 
(FBS), 2mM L-glutamine, penicillin (100IU/ml), streptomycin (100ug/ml) 
and neomycin (100ug/ml) in a humidified atmosphere of 95% air and 5% 
CO2. 
Breast cancer cell line MCF-7 (ATCC No. HTB-22): 
The cells were derived from the pleural effusion of a 69 year old Caucasian 
female with adenocarcinoma and were characterised by Soule et.al. in 
1973. The cells have a minimal doubling time of 29 hours and are able to 
process estradiol via cytoplasmatic estrogen receptors; the secretion of 
insulin-like growth factor binding proteins 2, 4 and 5 can be modulated by 
treatment with antiestrogens. Growth is inhibited by tumour necrosis factor 
alpha. The cells express the WNT7B oncogene and contain the Tx-4 
oncogene. Stem line chromosome numbers ranges from hypertriploid to 
hypotetra-ploid, with the chromosomes numbering between 66 and 87. The 
cells are tumourigenic in mice. The breast cancer cell line MCF-7 was 
initially grown in RPMI supplemented with 5% foetal calf serum (FBS), 
2mM L-glutamine, penicillin (100IU/ml), streptomycin (100ug/ml) and 
neomycin (100ug/ml) in a humidified atmosphere of 95% air and 5% CO2. 
Colon cancer cell line Caco-2 (ATCC No. HTB-37): 
This cell line was derived from a 72 year old Caucasian male with 
moderately well differentiated adenocarcinoma consistent with colonic 
primary (grade II) (Rousset 1986). Cells are epithelial-like, and upon 
confluence they express characteristics of enterocytic differentiation. The 
cells have a minimal doubling time of 62 hours. They express heat stable 
enterotoxin and epidermal growth factor. They produce keratin, retinoic 
acid binding protein 1 and retinol binding protein 2. The stemline modal 
chromosome number is 96, occurring at 16%, with polyploidy at 3.2%. The 
cells are tumourigenic in mice. Caco-2 was initially grown in DMEM 
supplemented with 10% foetal calf serum (FBS), L-glutamine, penicillin 
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(100IU/ml), streptomycin (100ug/ml) and neomycin (100ug/ml) in a 
humidified atmosphere of 95% air and 5% CO2. 
Hepatocellular liver carcinoma cancer cell HepG2 (ATCC No. HB-8065):  
This cell line was derived from the liver tissue of a 15 year old Caucasian 
male and was characterised by Darlington, Kelly and Buffone in 1987. 
These cells are epithelial in morphology and have a minimal doubling time 
of 59 hours. They express receptors for insulin and insulin-like growth 
factor-2. In addition, they express 3-hydroxy-3-methylglutaryl-CoA 
reductase and hepatic triglyceride lipase activity. Under oxidative stress 
(gramoxon) they decrease the expression of apoA-1 mRNA and increase 
the expression of catalase mRNA. They secrete alpha fetoprotein, albumin, 
alpha2 macroglobulin, alpha1 antitrypsin, transferrin, alpha1 
antichymotrypsin, haptoglobin, ceruloplasmin, plasminogen, complement 
(C4), C3 activator, fibrinogen, alpha1 acid glycoprotein, alpha2 HS 
glycoprotein, beta lipoprotein and retinol binding protein. There is no 
evidence of a Hepatitis B virus genome in this cell line. The chromosomal 
modal number is 55, ranging between 50 and 60. Chromosome 1 is 
rearranged. The cells are not tumourigenic in mice. The hepatocellular cell 
line HepG2 was first established in DMEM and 1mM sodium pyruvate, 
supplemented with 10% foetal calf serum (FBS), 2mM L-glutamine, 
penicillin (100IU/ml), streptomycin (100ug/ml) and neomycin (100ug/ml) 
in a humidified atmosphere of 95% air and 5%CO2.  
2.2.1.2 Medium conditions for optimal cancer growth                                                      
Once cells were established as described above in section 2.2.1.1 they were 
grown in various media in an attempt to find a common medium that could 
support exponential growth for each cell line. As detailed in the results 
section of this thesis, the medium of choice, supporting exponential growth 
of each cell line, was DMEM supplemented with 10% foetal calf serum 
(FBS), 110 mg/L (=1mmol) of sodium pyruvate, 2mM L-glutamine and 
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100nM IGF-1. The inclusion of L-glutamine is crucial to the growth of 
most cancer cell lines. 
2.2.1.3 Selection of antibiotics 
Antibiotics are added to cell cultures to reduce the risk of contamination, 
but some antibiotics, especially when used in combination with other 
agents, may inhibit growth or induce cell death. An example is neomycin, 
which is often used in cell cultures and heavily influences the effect of 
other compounds. In this research, several antibiotics were tested in 
cultures with other inhibiting agents; details are given in section 3.1.9. In 
this study a mixture of penicillin 100IU/ml and streptomycin 100ug/ml was 
chosen as this antibiotic mixture did not appear to influence cell growth or 
cell death when combined with various other agents.  
2.2.1.4 Creating a tumour-like environment in vivo 
It is well documented that the effects of compounds on cell inhibition or 
cell death can be attenuated by treatment with high insulin-like growth 
factor-1 (Tao et.al. 2007). So-called “autocrine loops” inside tumours often 
create an environment high in these growth factors. In an attempt to mimic 
a tumour-like environment in cancer cell cultures, insulin-like growth 
factor-1 was included in the media at 100nM. At this concentration, all cells 
grew at their maximum doubling rates.      
2.2.1.5 Treatment with trypsin  
All four cancer cell lines grew as monolayers and adhered to the flat 
bottoms of standard 25cm2 culture flasks. The medium was changed every 
third day. After cell lines reached 90% confluency, they were detached by  
treatment with 0.016% trypsin for 5 minutes. Great care was taken in using 
trypsin to detach cells because it has been shown that concentration and 
time of exposure of cells to trypsin influences the rates of cell death: 
Furthermore it has been shown that exposing cells to trypsin activates the 
insulin receptor and other cell surface receptors (Internal communication 
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and Clark et.al. 1991). 
 
No additional compound combination was applied for 24 hours following 
trypsin treatments, to minimize the influence of trypsin on treatment. In 
addition, the lowest possible trypsin concentration was used to detach the 
cells (0.016%) at the shortest possible exposure time (5 min). After 
removing the cells from the flasks, cells were centrifuged with a force of 
100g for 5min, resuspended in medium, counted and fourfould diluted. A 
quarter was reseeded into the flasks. The rest was used for experiments in 
24 well plates at a density of 104 cells/ml.   
2.2.1.6 Centralising cells towards the middle of 24 wells  
Seeding cancer cells in suspension led to an even spread of cells across a 
well. This made it very difficult to judge cell morphology and cell staining 
along the walls of the wells, because the outer area of a well reflects light 
irregularly and cells in this area appeared only as silhouettes. To focus the 
cells in the middle of wells, they were pipetted into wells already 
containing some medium. Cancer cells in 125µl were added to wells 
containing 375µl medium: in the next 15 minutes, the cells assembled and 
adhered in the middle of the well. Assembling the cells in the middle of the 
well was necessary to ensure that the cells were actually in contact with 
each other.  
2.2.1.7 Determining cell density 
The usual procedure to determine cell density is to remove the cells from 
their flasks and count them in a “Neugebauer” chamber. This chamber 
contains a determined volume of fluid between a bottom glass cover slip 
and slide. The chamber has engraved lines that define a highly accurate 
area. Counting the cells in this area determines the cell density in a given 
volume.  
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2.2.2 Methylene blue-staining of cell lines  
 
After cells had been treated with compound combinations most of the 
methylene blue-stained cells literally disintegrated if treated with trypsin. 
This made it impossible to count them in a “Neugebauer” chamber. False 
low readings were recorded. The same observation was made treating cells 
first with trypsin and then staining them with methylene blue. To avoid this 
problem, the cells were stained in situ in the wells. However, the lack of a 
precisely engraved area on the bottom of the wells, made it impossible to 
determine the absolute number of stained cells per volume in the wells. 
Nevertheless, it was still possible to count the relative number of stained to 
non-stained cells in a given area which was the approach taken in this 
study. For this purpose, a hole was created by puncturing thin aluminium 
foil with a 23-gauge needle. The size of the hole was equivalent to four 
large squares in the “Neugebauer” chamber, determined by putting the 
punched aluminium over the chamber to check that the hole was equivalent 
to the size of the four large squares of the Neugebauer chamber. The foil 
was then fixed to the underside of the well so that the hole was centred.  
2.2.3 Regrowth of compound treated cell lines 
To verify the viability of cancer cells after treatment with compound 
combinations, the cells were split into two populations which were treated 
identically. After 24 hours, the number of methylene blue-stained cells was 
counted in the first population, whilst the medium was changed in an 
attempt to regrow the second population. After 24 hours the regrown 
population was stained and the differences in the two ratios of stained to 
non-stained cells was determined.          
2.2.4 Preparation of compounds for in vitro treatments 
2.2.4.1 Dissolving compounds 
Most of the compounds were dissolved in medium as stock solutions at 
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concentrations tenfold higher than the concentrations reported to inhibit 
50% of their target structure (IC50). However, due to a wide range in 
solubility some of the compounds had to be dissolved in medium on lower 
stock concentration. Some drugs could not even be dissolved on 
concentrations needed for 50% inhibition of their target structure (IC50). 
Compounds that were not directly soluble in medium were first dissolved in 
DMSO or ethanol prior to dilution into medium. Dissolving a compound in 
dimethyl sulphoxide or ethanol before dissolving it in water is a standard 
procedure in the management and combination of drugs. 
 
Compounds which are insoluble in both, polar protic and aprotic solvents 
cannot be handled using standard laboratory protocols. These substances 
are not bioavailable, and treatment of cell cultures or animals with these 
compounds is extremely difficult. A drug that dissolves transiently in 
dimethyl sulphoxide or ethanol and can then be mixed with medium 
successfully retains a certain end concentration of dimethyl sulphoxide and 
ethanol, together with the drug compounds, all of which will be applied to 
the cell culture. As both solvents, dimethyl sulphoxide and ethanol, 
themselves have an effect on cancer cells, the final concentration of these 
solvents was kept below 0.1% if they were used. This concentration does 
not affect the growth of cancer cells and has no known effect in 
combination with other compounds.  
Appendix 2 illustrates the molecular weights, the solubility and the applied 
range of the used compounds. 
2.2.4.2 Preparing compounds at their IC50 concentrations 
All compounds were tested at concentrations based on their known IC50 for 
their target molecules. Compound with demonstrated effectiveness at their 
IC50 were further tested over a range of concentrations prepared by serial 
dilutions of the drug solution. The effect of the inclusion of heat-treated 
human albumin (56 degrees for 25min) was also determined with 
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compounds as it is known that albumin binds many drug molecules and in 
doing so, may alter their properties. To predict if this level of combined 
compounds could be achieved in vivo the maximum tolerated dose of each 
drug was compared with the levels needed in culture.  
2.2.5 Compound preparation for in vivo studies  
2.2.5.1 Minimal compound concentrations       
When trialling compounds in vivo, the speed of uptake, metabolism and 
excretion of each compound fluctuates. In addition, the uptake, metabolism 
and excretion of a compound vary depending on the administration route. 
Furthermore, some compounds are “recycled” in the entero-hepatic 
circulation, which makes it very hard to determine how much is available in 
the blood stream at any point of time. In an attempt to take these issues into 
account when selecting compound concentrations for in vivo trials, the 
pharmacodynamic profile of compounds in serum were firstly evaluated by 
plotting concentrations of drugs in serum against time. The area below the 
plot demonstrates the absolute amount of drug available at each time in the 
serum, as long as the starting concentration is known. By overlapping the 
areas of the pharmacodynamic plots of the compounds, so that after 
peaking each drug just exceeded the minimal amount of drug needed to 
induce cell death, a “window” was created which guaranteed a minimal 
level for each compound in blood similar to that found in culture. It has to 
be kept in mind, however, that overlapping the minimal levels of the 
compounds after peaking, may create toxic levels during the phase of 
peaking.  
2.2.5.2 The maximum tolerated dose of combinations 
When determining the maximum tolerated dose of a compound 
combination, accumulation of some compounds has to be considered. The 
pharmacodynamic parameters of accumulating compounds change with 
every repeated administration. The tissue concentration and, eventually, the 
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serum concentration increase with each administration. There are two main 
scenarios of accumulation: intra- and extracellular accumulation of 
compounds. Extracellular accumulation or re-entry of compounds is caused 
by the excretion of compounds through the bile into the gut and their 
reabsorption into the blood stream: this entero-hepatic circulation is a 
mechanism that leads to accumulation of compounds administered 
repeatedly. Any compound excreted through the bile can be part of this 
process. Intracellular accumulation is a result of a compound`s ability to 
pass membranes and incorporate into cellular structures. Intracellular 
accumulation can take place after repeated administration. Organic 
compounds usually accumulate better than inorganic compounds. 
 
A combination of accumulating and non-accumulating compounds was 
chosen to be trialled. For a period of nine days a fixed concentration of 
75µg lithium chloride once daily with 70µg selenite and 70µg 
selenomethionine twice daily was chosen to be applied in vivo. This 
treatment was not toxic to normal tissues due to the slow intracellular 
accumulation of selenomethionine but had great impact on cancer cells. 
Administration longer than nine days requires a reduction in concentration 
of selenomethionine. 
2.2.6 Creating tumours in nude mice 
2.2.6.1 Animal Handling and Ethics 
Approval of this study (N58-06) was provided by the Animal 
Experimentation and Ethics Committee of Curtin University of 
Technology. Animal well-being was carefully monitored daily and tumour 
growth determined using micro callipers. Treatments with chemo-
therapeutic commenced as soon as the tumour diameter reached 3mm in 
diameter. This generally took between 10 – 15 days of tumour cell growth. 
A small tumour size (3mm) was chosen for this study to avoid advanced 
tumour pathology and to avoid spreading of the tumour. This approach 
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avoided the animals feeling sickness or pain or loss in body weight, which 
can occur when very large tumours (>50mm) are grown in these animals. 
 
All the chemotherapeutic compounds that were administered to mice in this 
study have been previously characterised in biochemical, pharmaceutical 
and drug metabolism studies. Indeed, most of the compounds used in this 
study are presently in use in humans. The doses of compounds to be given 
to mice in this study were well within these guidelines and in most 
instances were delivered at much lower levels.   
 
Test animals (n=2) for each treatment were sacrificed daily by i.p. injection 
of 170mg/kg pentobarbitone (Nembutal, Merial, Australia). The tumour in 
each mouse as well as other tissues (gut, liver, lung, spleen etc.) was 
collected into 10% formalin. Control animals (for each route of delivery), 
were treated only with the compound carrier. Tumour growth in control 
animals was never allowed to exceed 10mm in diameter and as noted 
above, great care was taken to ensure that the animals were not unwell.  
 
2.2.6.2 Dietary regime of the mice 
 
The rats in this study were fed ad libitum with a fixed formulation diet for 
laboratory rats and mice fortified with vitamins and minerals to meet the 
requirements of breeding animals (Specialty Feeds, Glen Forrest, Western 
Australia [www.specialtyfeeds.com]).  The total fat content was 
deliberately kept low at around 5%, to maximise the long term breeding 
performance of most strains.  All nutritional parameters of this diet met or 
exceeded the National Research Council (NRC) guidelines for rats and mice. 
Mammalian meals were excluded from the diet, however the diet did 
contain fish meal. The diet included wheat, barley, lupins, soya meal, fish 
meal, mixed vegetable oils, canola oil, salt, calcium carbonate, dicalcium 
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phosphate, magnesium oxide, and a vitamin and trace mineral premix. The 
diet comprised 20% protein, 4.8% total fat, 4.8% crude fibre, 7.6% acid 
detergent fibre, 16.4% neutral detergent fibre and 59.4% total 
carbohydrates. 
 
 
2.2.6.3 Marking the mice and randomizing 
Six week-old male nude balb/c mice were individually identified by making 
cuts to their ears. First, the mice were exposed to a 100% CO2 atmosphere 
in a small container with a glass top until they lost consciousness. The ears 
of the mice were then cut. A generator for random numbers on the 
following internet website created the order of treated animals:  
www.cognitive-tools.de/Easy-Mapping/Wissensmanagement/Mapping_Software/ 
Zufallszahlen_erzeugen/zufallszahlen-erzeugen.html.  
The numbers and how often they were used was typed into the generator 
and a random list of numbers was presented. The first three numbers chosen 
by the generator determined the animals to be used as controls (9 days 
without treatment but with 9 days of insulin-like growth factor-1 
application). The next three numbers determined the animals of day 4 
(before start of treatment but with 4 days of insulin-like growth factor-1 
application), followed by the animals of day 6.5 (2.5days of treatment and 
6.5 days of insulin-like growth factor-1 application), finally followed by the 
animals of day 9 (5 days of treatment and 9 days of insulin-like growth 
factor-1 application). The order of the numbers created by the generator 
was 3,7,9,1,10,12,2,6,11,5,4 and 8. Mice regained consciousness within 30-
40 seconds by breathing normal air.    
2.2.6.4 Preparation of cells grown in vitro for injection in vivo                                
The mesothelioma cell line JU77 was chosen to create a xenograft in nude 
mice. Cells were grown exponentially in a 25cm2 flask, then passaged into 
three 75cm2 flasks and thereafter cultivated in six 225cm2 flasks. The cells 
were detached from the flasks with trypsin 0.016%, washed twice in 0.9% 
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NaCl solution, counted in the Neugebauer chamber and resuspended in 
PBS. The JU77 cells were kept on ice and 107 cells were injected into the 
left groin of the mice. The timespan between detaching the cells and 
injecting them into the groin of the mice did not exceed fifteen minutes. 
There was no need to anaesthetise the mice for the subcutaneous injection 
of cells.    
2.2.6.5 Maintaining tumour growth with growth factors in vivo 
The non-transformed cancer cell line JU77 alone did not immediately 
create xenografts in nude balb/c mice when injected into the groin. This cell 
line JU77 is one of several human cancer cell lines which do not grow as a 
xenograft in nude mice. Human cancer cell lines which do not grow in nude 
mice are generally labelled “non-tumourigenic” in mice. However, injected 
tumour cells of the “non-tumourigenic” cell line JU77 did grow under the 
skin of the mice, if 10nM insulin-like growth factor-1 was injected 
subcutaneously into the opposite groin of the nude mice. The injections of 
insulin-like growth factor-1 into the opposite side ensured that the fluid 
injected with it did not influence measurement of tumour size on the side of 
cell injection and these injections had to be continued daily to maintain 
tumour growth. A volume of 100µl was applied for this purpose. 
2.2.6.6 Measuring tumour size  
Tumour size was measured with a digital caliper in two orthogonal 
dimensions. The smallest reliably measured span with this digital caliper 
was 0.01mm. Repeated measurement of the same tumours showed that 
there was a risk that tumours were compressed from the sides with the 
instrument, changing their diameters; to avoid this, no direct contact with 
the skin was made with the caliper. When tumours were very small, the 
transparency of the skin was determined by diaphany. The cells of these 
very small subcutaneous tumours reflected the light differently to normal 
skin. If these white “spots” under the pink could not be seen any more, the 
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remaining tumour-free skin was excised for histology. 
2.2.6.7 Observation of tumour size, weight and side-effects 
First, tumour cells were injected subcutaneously into the groin and tumours 
were grown for 4 days with administration of insulin-like growth factor-1 
subcutaneously into the opposite groin. At the start of treatment mice were 
injected twice a day into the peritoneum with 100µl compound mixture; this 
continued for 5 days. Tumour diameters, weight of each mouse and side-
effects were recorded on a daily basis. No anaesthetic was needed for the 
injection of insulin-like growth factor-1 below the skin or injection of 
compound combinations into the peritoneum.  
2.2.6.8 Haematology and Biochemistry 
The following list shows the day and the animal when haematological and 
biochemical parameters were taken:    
                            day                                   animal 
                              4                                    1, 10, 12                                      
                        6.5                                  2,   6, 11 
                         9                                    4,   5,   8 
                         9(controls)                     3,   7,   9    
To determine the haematological and biochemical parameters, mice were 
anaesthetised with ether and exsanguinated by cardiac puncture using a 
23G needle and a 5ml syringe. Every care was taken that cardiac puncture 
did not cause haemolysis by creating too much negative pressure on the 
syringe. The blood was separated into two commercial pediatric 0.5ml 
sample containers: One was mixed with EDTA powder for blood count 
(lilac), the other one was mixed with Lithium/Heparin (green) to measure 
electrolytes, liver enzymes, creatinine and albumin. Anaesthetised animals 
were euthanised with 4.5mg (170mg/kg) pentobarbital intraperitoneally.  
All these experiments were performed according to the Australian Code of 
Practice for the care and use of animals for scientific purpose. 
 58 
2.2.6.9 Histology 
After euthanasing the mice, a skin sample at the tumor location was taken 
from each mouse. In addition, a sample of gut, liver, spleen and lung of 
each animal was kept in 10% formalin for 24 hours. All samples were 
processed automatically in a Hypercenter Tissue Processor (Shendon), 
inserted into wax-blocks and cut to 4µm thick histoslides according to 
standard pathological procedures. They were stained in hematoxylin and 
eosin.  
Tumour samples of animals as well as the samples of their normal tissues 
(gut, liver, spleen and lung) were collected at day 4, day 6.5 and day 9. 
Great care was taken to evaluate whether the tumours had spread locally or 
from the injection site to other tissues. Several hundred serial sections of 
the tumours and the surrounding tissues were taken every 4µm to search for 
local and systemic metastasis. Particular attention was directed towards 
finding some remaining dead cells following treatment.  
Serial sections of tumours were evaluated by Emeritus Professor John 
Papadimitriou (OSJ BA MBBS MD PhD FRC Path FRCPA) (University of 
Western Australia). Prof. Papadimitrou evaluated each tissue section and 
provided guidance and advice regarding tumour morphology.  
2.2.7 Statistical calculations  
2.2.7.1 Estimating LD100 values 
Probit analysis is the preferred method for giving the most closely fitting 
results when biological responses are plotted against their causal stimuli (or 
logarithms thereof) (Finney, 1971, 1978).  The SPSS version 16.0.2 for 
Macintosh was used to undertake the Probit analyses in this study. This 
procedure provides an estimate of the strength of a stimulus required to 
induce a certain proportion of responses and was used in this study to 
provide estimates of the lethal dose of compounds inducing the death of 
100% of cells in culture (LD100). Regression coefficients, intercept and 
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standard error, Pearson goodness-of-fit chi-square, observed and expected 
frequencies, and confidence intervals were evaluated as part of the Probit 
analysis.   
2.2.7.2 Comparing LD100 values   
The t test was used to compare two means from independent samples.  The 
ordinary one-way analysis of variance (ANOVA) was used to compare 
values when more than two independent samples were compared. These 
statistical tests assume that the data is sampled from populations following 
a Gaussian bell-shaped distribution but, generally, are reliable even if the 
distribution is only approximately Gaussian. ANOVA and t tests were 
performed using the GraphPad InStat  for Macintosh (Version 3.0b). 
 
“Post” tests were also used when comparing three or more groups (as it is 
not appropriate to repeatedly use a t test to compare various pairs of 
columns). The Bonferroni test was used to compare selected pairs of 
columns whereas the Tukey-Kramer Multiple Comparison tests was used 
when comparing all pairs of columns.  The Dunnett test was used when 
comparing means relative to the control treatment.  These tests apply 
"corrections" that are designed to offset the advantage of post hoc selection 
of the most extreme comparisons. 
2.2.7.3 Selecting the number of mice 
It is unethical to use too many or too few animals in research protocols. 
Therefore, the number of animals used in the study were selected to ensure 
they were sufficient to ensure that the objectives and endpoints of this study 
could be appropriately realised. Reduction of tumour size was the key 
measure of success in this study. Treatments were commenced on tumours 
that reached 3 mm in diameter. Given that only treatments achieving a 
minimum reduction of 80% in tumour size (to less than 0.6 mm in 
diameter) were of interest in this study, and that a minimum 5% change in 
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tumour size (0.15 mm) could be microscopically detected, it was estimated 
that one animal per treatment and day were needed to achieve 95% 
confidence of prediction. Four animals were used for each treatement group 
and the experiment repeated to ensure a high level of confidence in the 
results. 
2.2.7.4 Comparing tumour size and weight trends in animals following 
various treatments. 
Animals were treated as described in section 2.2.6.  The slope of each data 
set was used to evaluate whether tumour size or weight altered as a function 
of time following the initiation of a treatment on day 4.  Slopes of lines 
were first calculated and compared using the Prism software package 
(GraphPad Software, Inc, La Jolla, CA 92037 USA).  Prism was then 
utilized to test the null hypothesis that the overall slope of a line is zero.  In 
essence, if there were no linear relationship between X and Y overall, Prism 
calculated the probability that randomly selected points would differ from a 
horizontal regression line. The P values were calculated from an F test and 
its degrees of freedom. You would get exactly the same P value from the t 
ratio computed by dividing the slope by its standard error. 
A P value (two-tailed) testing the null hypothesis that the slopes are all 
identical (the lines are parallel) was calculated to determine the chance that 
randomly selected data points would have slopes different to that observed. 
For P values less than 0.05, it was concluded that the lines were 
significantly different.  For P values greater than 0.05, it was concluded that 
the slopes were not significantly different. This method is equivalent to an 
Analysis of Covariance (ANCOVA), although ANCOVA can be extended 
to more complicated situations. It also is equivalent to using Prism's 
nonlinear regression analysis with a straight-line model, and using an F test 
to compare a global model where slope is shared among the data sets with a 
model where each dataset gets its own slope. 
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3.0   RESULTS 
 
3.1 Compound combinations in cell culture 
The viability of cancer cell lines was tested in the presence of a wide range 
of inhibitors selected because they either targeted the key receptors of 
intracellular signalling pathways or other factors important for cell survival. 
Over 99 compounds were evaluated in various combinations against JU77, 
MCF-7, Caco-2 and HepG2 human cancer cell lines (Table 2). In general, 
inhibitors used singularly within their known therapeutic human 
concentration range failed to kill the entire cell population of a cancer cell 
line. When used in combination they increased the cell killing potency to a 
varying extent.  
3.1.1 Combinations with staurosporine 
Staurosporine is a broad range tyrosine kinase inhibitor binding to the 
adenosine triphosphate binding (ATP) domain of tyrosine kinases. Used 
alone, it affects cell viability dose-dependently, and in micromolar 
concentrations kills cell populations. However, in combination with 
narrow-spectrum inhibitors, far less staurosporine exerts the same potent 
effects. Fig 5 highlights the differences in the viability of two cancer cell 
lines, JU77 and MCF-7, in the presence of narrow-spectrum inhibitors 
(geftinib, PD98058, LY294002, bromocriptine and oxytocin), alone or in 
combination with staurosporine. Narrow-spectrum inhibitors themselves 
had little effect in changing cellular viability. This changed substantially in 
the presence of staurosporine (Table 3, p<0.001). The choice of narrow-
spectrum inhibitors in combination with staurosporine determined if only a 
proportion of cells were killed or if the cell line was eradicated. Most of the 
combinations that eradicated a cell line were only effective in one cell line: 
Fig 5 illustrates that JU77 cells were killed by PD98058, LY294002 (two  
pathway inhibitors of the insulin-like growth factor-1 receptor) and 
bromocriptine (a dopamine receptor agonist). MCF-7 cells were eradicated  
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Table 2 Summary of combinations of compounds tested in JU77 cells.  
Over 30,000 compounds and combinations were tested for their ability to 
cause death in JU77 cells.  
 
(i) Single Compounds A B 
Compounds 1-99 
 
  
(ii) Double combinations   
Each of compounds 1-99 with each compound 
in column A  
 
12, 13, 25, 27, 39,46, 50, 
51, 62, 66, 72, 82, 88 or 97 
 
 
(iii) Triple combinations   
Each of compounds 1-99 with each compound 
in column A, and each compound in column B  
 
3, 6, 9, 17, 35, 36, 37, 38, 
48, 53, 55, 58, 68, 71, 89 
or 96 
12, 13, 25, 27, 39, 46, 50, 
51, 62, 66, 72, 82/83*, 
88 or 97 
(iv) Quadruple combinations   
Each of compounds 1-99 with each 
combination in column A and each compound 
in column B  
 
9 and 37, 9 and 55, 9 and 
71, 17 and 89, 35 and 48 
or 55 and 71 
12, 13, 25, 27, 39, 46, 50, 
51, 62, 66, 72, 82/83*, 
88 or 97 
(v) Quintuple combinations   
Each of compounds 1-99 with each 
combination in column A and each compound 
in column B  
 
9, 55 and 71 or 
37, 55 and 71 
 
12, 13, 25, 27, 39, 46, 50, 
51, 62, 66, 72, 82/83*, 
88 or 97 
(vi) Sextuple combinations   
Each of compounds 1-99 with the 
combination in column A and each compound 
in column B  
 
9, 37, 55 and 71 
 
12, 13, 25, 27, 39, 46, 50, 
51, 62, 66, 72, 82/83*, 
88 or 97 
• Compounds 82 and 83 pre-incubated together 
 
1. 17-Aageldanamycin 26. Digoxin 51. β-Lapachone 76. Quercetin 
2. Adrenaline 27. Doxycyclin 52. Letrozole 77. Rapamycin 
3. 8Cl-cAMP 28. DMSO 53. Lithium chloride 78. Red Clover 
4. Ascorbate 29. EGCG 54. α-Lipoic acid 79. Salbutamol  
5. Aspirin 30. Emodin 55. LY294002 80. Salicylic acid 
6. ATP 31. Epichlorohydrin 56. Magnesium chloride 81. Selenate 
7. Avandia 32. Equol 57. Menadione 82. Selenite 
8. Bromelin 33. Estradiol 58. Mercaptoethanol 83. Selenomethionine 
9. Bromocriptin 34. p-Ethylphenol 59. Metformin 84. Se-piccolinate 
10. t-Butyl benzoic acid 35. Forskolin 60. Methylene blue 85. Suphamethoxazole 
11. Caesium chloride 36. Gadolinium chloride 61. Metoprolol 86. Sulphosalazine 
12. Chloramphenicol 37. Geftinib 62. Mifepristone 87. Suramin 
13. Ciprobay 38. Geldanamycin 63. NADH 88. Staurosporine 
14. Citrate 39. Genistein 64. NADPH 89. Tamoxifen 
15. Clindamycin 40. Glibenclamide 65. Naphtalene 90. Tautomycin 
16. Curcumin 41. Glutathione red. 66. Oxamate 91. Tetrathiomolybdate 
17. Cyproterone acetate 42. Glycerol 67. Oxythiamine 92. Theophylline 
18. 2-Deoxyglucose 43. Glyceryltrinitrate 68. Oxytocin 93. Thiosulphate 
19. Dexamethasone 44. Haloperidol 69. Parthenolide 94. Trimethoprime 
20. DHEA 45. Hesperidin/Hesperitin 70. PD153035 95. Trypsin 
21. DHLA(Trisulphide) 46. H2O2 71. PD98058 96. Verapamil 
22. Dichloroacetate 47. 1,6Hexabromocriptin 72. Penicillin/Streptomycin 97. Vitamin C 
23. Dicumarol 48. IBMX 73. Picropodophyllin 98. Warfarin 
24. Diphenyleneiodonium 49. Ibuprufen 74. PP2 Src kinase inhibitor 99. Wortmannin 
25. Diethylmaleate 50. Iodoacetate 75. Progesterone   
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Figure 5 The viability of JU77 and MCF-7 cells in the presence of 
various narrow-spectrum compounds alone or in combination with stauro-
sporine.  
The viability of JU77 cells (     ) and MCF-7 cells (     ) was measured in the 
presence of 120 nM staurosporine, 1mM geftinib, 20mM PD98058, 20mM 
LY294002, 0.75nM bromocriptin, 100nM oxytocin, either singularly or in 
various combinations. Viability of cells was determined as described in the 
Methods section 3.2. The bars represent the mean + SD of three 
determinations.  
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Table 3 A statistical analysis of the lethal effects of various narrow-spectrum 
compounds alone or in combination with staurosporine in JU77 and MCF-7 cells.  
Description LE 
%CD 
SEM 
 
Ref. 
Fig  
Level of Significance  
Comparison to [Fig x] 
Stauro Geft 100 
 
0 5o [5p] P > 0.05 (NS) 
Stauro Geft PD LY Br 
 
100 0 5q [5r] P < 0.001*** 
Stauro Bromo 
 
20 2.88 5s [5t] P < 0.001*** 
 
Stauro Oxytocin 
 
40 3.22 5u [5v] P < 0.001*** 
Geft 8 
6 
0.57 
0.57 
 
5c 
5d 
 
[5o] P < 0.001*** 
[5p] P < 0.001*** 
 
PD 8 
4 
1.16 
2.31 
5e 
5f 
 
[5q] P < 0.001*** 
[5r] P < 0.001*** 
LY 4 
4 
 
1.16 
0 
5g 
5h 
 
[5q] P < 0.001*** 
[5r] P < 0.001*** 
Bromo 4 
 
8 
 
0 
 
1.73 
5i 
 
5j 
 
 
[5q] P < 0.001*** 
[5s] P < 0.001*** 
[5r] P < 0.05 * 
[5t] P < 0.001*** 
 
Oxytocin 5 
11 
1.16 
1.73 
 
5k 
5l 
 
[5u] P < 0.001*** 
[5v] P< 0.001*** 
Stauro 14 
 
11 
5.77 
 
3.05 
5m 
 
5n 
 
 
[5o],[5q],[5u] P<0.001 
[5s] P > 0.05 (NS) 
[5p],[5t],[5v] P<0.001 
[5r] P > 0.05 (NS) 
 
Lethal effects of compounds and their combinations were compared by 
ANOVA, Benferroni and Tukey-Kramer Multiple Comparison Tests as 
detailed in the Methods. By conventional criteria the data is considered to 
be not statistically significant (NS), statistically significant (*), very 
statistically significant (**), or extremely statistically significant (***). 
Abbreviations: [Stauro, Staurosporine]; [Geft, Geftinib]; [PD, PD98058]; 
[LY, LY294002]; [Br, Bromocriptin]; [Oxy, Oxytocin], [LE %CD, Lethal 
effect in % cell death]; [Ref. Fig , Reference Figure]. 
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in the presence of bromocriptine and staurosporine, or oxytocin and 
staurosporine. Table 3 illustrates that these differences between the cell 
lines are extremely significant (all p<0.001). Remarkably, one combination 
containing geftinib (an inhibitor of the epidermal growth factor receptor) 
and staurosporine killed both cell lines. Eradication of cell lines was 
confirmed by lack of success in regrowing the cell lines.  
 
The minimal concentration of staurosporine required to eradicate a cell 
population was dependent on the choice of narrow-spectrum inhibitor. The 
minimal concentration decreased when staurosporine was combined with 
narrow-spectrum inhibitors in the following order (illustrated in Fig 6): 
epidermal growth factor receptor inhibitor (geftinib), insulin-like growth 
factor-1 receptor pathway inhibitors (PD98058, LY294002), dopamine 
receptor agonist (bromocriptine). A combined treatment using an inhibitor 
of the mammalian target of rapamycin (rapamycin) was equally effective 
than using bromocriptin (Table 4, p>0.05 (NS)).   
 
Following the removal of the epidermal growth factor receptor inhibitor 
from the combinations it became apparent that geftinib had no influence on 
the percentage of cell death induced by a combination containing 
staurosporine and the rest of the narrow-spectrum inhibitors (Table 5,  
p>0.05 (NS)). The narrow-spectrum inhibitors themselves and 
staurosporine reduced the final concentration of staurosporine into a 
therapeutic range of estimated 11nM. Again, the optimal combination was 
PD98058, LY249002, staurosporine either  including bromocriptine or 
including rapamycin, as illustrated in Fig 7, with no statistic difference 
between the two of them (Table 5, p>0.05 (NS)). 
 
In an attempt to replace staurosporine completely, many other combinations  
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Figure 6 The minimal concentration of staurosporine promoting 
complete death of JU77 cells in the presence of narrow-spectrum inhibitors 
including the epidermal growth factor receptor inhibitor.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of staurosporine in the presence of: 1mM geftinib (..O..), 
1mM geftinib, 20mM PD98058, 20mM LY294002 (-- x --), 1mM geftinib, 
20mM PD98058, 20mM LY294002, 0.75nM bromocriptin  (  __ _ ),  
1mM geftinib, 20mM PD98058, 20mM LY294002, 20nM rapamycin  
(____). The therapeutic range (TR) in which staurosporine can be used in 
vivo is illustrated at the top left of the figure. Data points are the mean + 
SD of three determinations.  
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Table 4 A statistical analysis of the lethal dose estimates of various 
narrow-spectrum compounds alone or in combination with staurosporine in 
JU77 and MCF-7 cells.  
 
Description LD100 
(nM) 
SEM 
(nM) 
Ref. 
Fig  
Level of Significance  
Comparison to [Fig x] 
 
Stauro 
 
 
>500 
 
 
 
5 
 
  
 
Stauro Geft 
 
 
131 
 
13 
 
6a 
 
 
Stauro Geft PD LY 
 
 
51 
 
5 
 
6b 
 
[6a] P < 0.001 *** 
 
 
Stauro Geft PD LY Br 
 
 
11 
 
1 
 
6c 
 
[6b] P < 0.001 *** 
 
 
Stauro Geft PD LY Ra 
 
 
11 
 
1 
 
6d 
 
[6b] P <0.001  *** 
[6c] P =1 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 6 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Stauro, Staurosporine]; [Geft, Geftinib]; [PD, PD98058]; [LY, 
LY294002]; [Br, Bromocriptin]; [Ra, Rapamycin]; [Ref. Fig , Reference 
Figure]. 
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Figure 7 The minimal concentration of staurosporine promoting 
complete death of JU77 cells in the presence of narrow-spectrum inhibitors 
excluding the epidermal growth factor receptor.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of staurosporine in the presence of: 20mM PD98058, 
20mM LY294002 (--x--), 20mM PD98058, 20mM LY294002, 0.75nM 
bromocriptin (__ _), 20mM PD98058, 20mM LY294002, 20mM  
rapamycin (____). The therapeutic range (TR) in which staurosporine can 
be used in vivo is illustrated at the top left of the figure. Data points are the 
mean + SD of three determinations.  
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Table 5 A statistical analysis of the lethal dose estimates of 
staurosporine combinations excluding geftinib but including other narrow 
spectrum inhibitors in JU77 cells. 
 
Description LD100 
(nM) 
SEM 
(nM) 
Ref. 
Fig  
Level of Significance  
Comparison to  
[Fig x] 
 
Stauro PD LY 
 
 
68 
 
6 
 
7a 
 
 
[6b] P > 0.05 (NS) 
 
 
Stauro PD LY Br 
 
 
20 
 
2 
 
7b 
 
 
[7a] P < 0.001***   
[6c] P > 0.05 (NS) 
 
 
Stauro PD LY Ra 
 
 
15 
 
2 
 
7c 
 
 
[7a] P < 0.001***   
[7b] P > 0.05 (NS) 
[6d] P > 0.05 (NS)  
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 7 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Stauro, Staurosporine]; [PD, PD98058]; [LY, LY294002]; [Br, 
Bromocriptin]; [Ra, Rapamycin]; [Ref. Fig , Reference Figure]. 
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were trialled. One combination comprised the two inhibitors of insulin-like 
growth factor-1 receptor, an agonist for the dopamine receptor, 
geldanamycin and 6nM staurosporine; this is illustrated in Fig 8.  However, 
including geldanamycin did not significantly decrease the concentration of 
staurosporine (Table 6, p>0.05 (NS)). Geldanamycin is a benzoquinone 
ansamycin antibiotic that binds to heat shock protein 90 and alters its 
function. It induces the degradation of proteins that are mutated in tumour 
cells preferentially over their normal counterparts (Bedin et.al. 2004). In 
contrast, the combination of geldanamycin and 6nM staurosporine killed 
only a proportion of the JU77 cells.     
 
In MCF-7 cells, the minimal concentration of staurosporine required to 
eradicate this cell line was estimated as 42nM or greater, irrespective of the 
narrow-spectrum inhibitors combined with it (Table 7, all p>0.05 (NS)). 
The concentration of staurosporine needed in the presence of geftinib 
(inhibitor of epidermal growth factor receptor) or a combination of 
PD98058, LY294002 (inhibitors of insulin-like growth factor-1 receptor 
pathways) and rapamycin (inhibitor of mammalian target of rapamycin) 
was equally high in the JU77 cell line than in the MCF-7 cell line (Table 7, 
both p>0.05 (NS)). This is illustrated in Figure 6, 7 and 9, respectively. 
However, a combined treatment of geldanamycin and staurosporine 
exerted an extreme significant difference (Table 7, p<0.001), as illustrated 
in Figure 8 and 9.  
3.1.2 Combinations with genistein 
The flavonoid genistein is derived from the plant family leguminosae, 
which includes the soyabean. Genistein possesses a wide spectrum of 
physiological and pharmacological functions due to its protein tyrosine 
kinase inhibition. The binding of genistein to human serum albumin in a 
cell-free system has been studied by Mahesha et.al. in 2005 who reported  
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Figure 8 The minimal concentration of staurosporine promoting 
complete death of JU77 cells in the presence of narrow-spectrum inhibitors 
and geldanamycin. 
 JU77 cells in their exponential growth phase were treated with varying 
concentrations of staurosporine in the presence of: 20µM PD98058, 
20mM LY294002, 0.75nM bromocriptin, 20nM geldanamycin (__o__) and 
20nM geldanamycin (-- x --). The therapeutic range (TR) in which 
staurosporine can be used in vivo is illustrated at the top left of the 
Figureure.  Data points are the mean + SD of three determinations.  
 
 
  
  
 72 
 
Table 6 A statistical analysis of the lethal dose estimates of 
staurosporine combinations including geldanamycin and narrow spectrum 
inhibitors in JU77 cells. 
 
Description LD100 
(nM) 
SEM 
(nM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x]] 
 
Stauro Geld 
 
 
863 
 
222 
 
8b 
 
[8a] P < 0.001 *** 
 
 
Stauro Geld PD LY Br 
 
2 
 
1 
 
8a 
 
[7b] P > 0.05 (NS)  
[7a] P > 0.05 (NS)  
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 8 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods.  By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***).   Abbreviations: 
[Stauro, Staurosporine]; [PD, PD98058]; [LY, LY294002]; [Br, 
Bromocriptin]; [Geld, Geldanamycin]; [Ref. Fig , Reference Figure]. 
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Figure 9 The minimal concentration of staurosporine promoting 
complete death of MCF-7 cells in the presence of narrow-spectrum 
inhibitors, mifepristone and geldanamycin.  
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of staurosporine in the presence of: 1µΜ geftinib ( ….. x …..),  
20µΜ PD98058, 20µΜ LY294002, 20nΜ rapamycin (__o__), 100nM 
oxytocin, 20µΜ mifepristone (__ _), 20nΜ geldanamycin (____ ). The 
therapeutic range (TR) in which staurosporine can be used in vivo is 
illustrated at the top left of the figure. Data points are the mean + SD of 
three determinations.  
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Table 7 A statistical analysis of the lethal dose estimates of 
staurosporine combinations including mifepristone, geldanamycin and 
narrow spectrum inhibitors in MCF-7 cells. 
 
Description LD100 
(nM) 
SEM 
(nM) 
Ref. 
Fig  
Level of Significance  
Comparison to  
[Fig x] 
 
Stauro Mif Oxy 
 
 
59 
 
 
6 
  
9c 
 
 
 
Stauro Geld 
 
82 
 
11 
 
9b 
 
[9c] P > 0.05 (NS) 
[8a] P < 0.001 *** 
 
 
Stauro Geft 
 
51 
 
5 
 
9a 
 
[9b] P > 0.05 (NS) 
[9c] P > 0.05 (NS) 
[9d] P > 0.05 (NS) 
[6a] P > 0.05 (NS) 
 
 
Stauro PD LY Ra 
 
42 
 
2 
 
9d 
 
[9b] P > 0.05 (NS) 
[9c] P > 0.05 (NS) 
[7c] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 9 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Stauro, Staurosporine]; [Mif, Mifepristone]; [Oxy, Oxytocin]; [Geld, 
Geldanamycin]; [Geft, Geftinib]; [PD, PD98058]; [LY, LY294002]; [Ra, 
Rapamycin]; [Ref. Fig , Reference Figure]. 
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that the activity of genistein in a cell culture changes after contact with 
human serum albumin. Figure 10 illustrates the influence of human serum 
albumin on the cell killing potency of genistein. Supplementing JU77 cell 
cultures with human serum albumin significantly increased the 
concentration of genistein needed to eradicate the JU77 cell line (Table 8, 
p<0.05). Genistein presumably engaged into the subdomain IIa of human 
serum albumin as detailed in Mahesha`s study, altering its availability. 
Figure 10 illustrates that genistein recovered its full potency when 
displaced from this pocket by an equimolar concentration of warfarin 
(Table 8, p<0.001). 
 
Genistein was hydrolysed to genistein chalcone to change its 
bioavailability. This enhanced the solubility enormously. Both compounds 
displayed a marked cell death in the presence of letrozole (an inhibitor of 
aromatase) and suramin (a broad-range inhibitor of growth factor 
receptors). However, equimolar genistein was twice as potent as genistein 
chalcone in killing JU77 cells, as illustrated in Figure 11 and Table 9, 
p<0.05).   
 
The potency of genistein was substantially increased in JU77 cells treated 
with a combination of letrozole and inhibitors of insulin-like growth factor-
1 receptor (Figure 12 and Table 10, p<0.001). A combination of PD98058, 
LY294002, letrozole and genistein was equipotent in JU77 cells, compared 
to suramin, letrozole and genistein (Table 10, p>0.05 (NS)).  
 
The effectiveness of all these compound combinations was cell line- 
dependent. Similar to their effects on JU77 cells, the combination of 
genistein with suramin and letrozole used on MCF-7 cells was no more 
potent than genistein with letrozole (Table 11, p>0.05 (NS) and Table 9, 
p>0.05 (NS)). However, the potency of genistein with PD98058,  
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Figure 10 The effect of genistein on the death of JU77 cells in the 
presence of human serum albumin and warfarin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of genistein on its own and in the presence of albumin and 
warfarin: No additives (__o _), 40g/L albumin (….….), 40g/L albumin, 
100µM warfarin (__x __). The therapeutic range (TR) in which genistein can 
be used in vivo is illustrated at the top left of the figure. Data points are the 
mean + SD of three determinations.  
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Table 8 A statistical analysis of the lethal dose estimates of genistein 
including human serum albumin and warfarin in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to  
[Fig x]] 
 
Gen 
 
 
444 
 
26 
 
 
10a 
 
 
Gen Alb 
 
 
542 
 
25 
 
10b 
 
[10a] P < 0.05 * 
 
 
Gen Alb Warf 
 
 
382 
 
29 
 
10c 
 
[10a] P < 0.001*** 
[10b] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 10 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Gen, Genistein]; [Alb, Albumin]; [Warf, Warfarin]; [Ref. Fig , Reference 
Figure]. 
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Figure 11 The effect of genistein and genistein chalcone on the death of 
JU77 cells in the presence of letrozole and suramin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of either genistein or genistein chalcone in the presence of 
letrozole and suramin: genistein with 1µΜ letrozole and 180mM suramin 
(__o _), genistein chalcone with 1µΜ letrozole and 180mM suramin (__x __). 
Data points are the mean + SD of three determinations.  
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Table 9 A statistical analysis of the lethal dose estimates of genistein 
and genistein chalcone including letrozole and suramin in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x]] 
 
Gen/L/Sur 
 
 
195 
 
35 
 
 
11b 
 
 
GenCh/L/Sur 
 
 
390 
 
93 
 
11a 
 
[11b] P < 0.05 * 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 11 as described in the Methods. Data were compared the students t-
test as detailed in the Methods. By conventional criteria the data is 
considered to be not statistically significant (NS), statistically significant 
(*), very statistically significant (**), or extremely statistically significant 
(***). Abbreviations: [Gen, Genistein]; [GenCh, Genistein Chalcone];  [L, 
Letrozole]; [Sur, Suramin]; [Ref. Fig , Reference Figure]. 
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Figure 12 The minimal concentration of genistein promoting complete 
death of JU77 cells in the presence of PD98058, LY294002, letrozole and 
suramin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of genistein singularly or in the presence of: 
20µΜ PD98058, 20µM LY294002, 1µΜ letrozole (….o….), 180mM 
suramin, 1µΜ letrozole (__x __), 1µΜ letrozole (__ _), no additives (____). 
The therapeutic range (TR) in which genistein can be used in vivo is 
illustrated at the top left of the figure. Data points are the mean + SD of 
three determinations.  
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Table 10 A statistical analysis of the lethal dose estimates of genistein 
including letrozole, suramin, PD98058 and LY294002 in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
 
Gen 
 
 
481 
 
38 
 
 
12a 
 
 
Gen/L 
 
 
283 
 
11 
 
12b 
 
[12a] P < 0.001*** 
 
 
Gen/L/Sur 
 
 
260 
 
45 
 
12c 
 
[12a] P < 0.001*** 
[12b] P > 0.05 (NS) 
 
 
Gen/L/PD/LY 
 
 
202 
 
30 
 
12d 
 
[12a] P < 0.001*** 
[12b] P > 0.05 (NS) 
[12c] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 12 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***).  Abbreviations: 
[Gen, Genistein]; [L, Letrozole]; [Sur, Suramin]; [PD, PD98058]; [LY, 
LY294002]; [Ref. Fig , Reference Figure].   
 
 
 82 
LY294002 and letrozole did change in MCF-7 cells and presented as the 
most effective (Figure 13, table 11, p<0.001). Supplementing MCF-7 cell 
cultures with human serum albumin changed the situation again: now 
suramin was the most potent compound in the presence of genistein (Figure 
14, table 12, p<0.001). However, as illustrated in Figure 13 and 14, none of 
the combinations reduced the concentration of genistein to within a 
therapeutic range of 100µM. 
 
Combinations with gadolinium chloride, a lanthanide, were investigated, as 
they are known to suppress nitric oxide overproduction and to recover 
glutathione-synthesis during carcinogenic challenge (Abdel-Zaher et.al. 
2007). Gadolinium chloride combined with letrozole increased cell death in 
the presence of genistein (or genistein chalcone) (Figure 15, table 12, 
p<0.001). However, a therapeutic range of gadolinium chloride was only 
achieved in the absence of human serum albumin.  
 
Another pair of compounds also combined well in the presence of 
genistein. The combination of forskolin (an inhibitor of protein kinase C) 
and 3-isobutyl-1-methylxanthine (IBMX) (a broad phosphodiesterase 
inhibitor) decreased phosphorylation of elongation factor 2, an essential 
factor for cell replication (Feschenko et.al. 2002). The observed increase in 
cell killing potency of forkolin/IBMX in the presence of genistein 
correlated with concentrations of IBMX, as illustrated in Figure 16. 
However, this was statistically not significant (table 14, p>0.05 (NS)).      
3.1.3 Combinations with mifepristone 
The anti-progesterone mifepristone or RU486 was originally developed as 
an abortion drug. Later, the compound was also recognized as having a 
significant anti-neoplastic activity due to its effect on cytochrome P450 and 
the steroidgenesis. The description of the overlapping steroid scaffold in the 
binding pocket of the receptor by C.Honer in 2003 is crucial in  
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Figure 13 The minimum concentration of genestein promoting the death 
of MCF-7 cells in the presence of geftinib, PD980580, LY294002, letrozole 
and suramin.  
 
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of genistein in the presence: 1µΜ geftinib (__x _), 
20µΜ PD98058, 20µΜ LY294002, 1µΜ letrozole (__o__), 180mM suramin, 
1µΜ letrozole (-  -), 1µΜ letrozole (____), no additives (_ _ _ _). The 
therapeutic range (TR) in which genistein can be used in vivo is illustrated 
at the top left of the figure. Data points are the mean + SD of three 
determinations.  
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Table 11 A statistical analysis of the lethal dose estimates of genistein 
including geftinib, letrozole, suramin, PD98058 and LY194002 in MCF-7 
cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to  
[Fig x] 
 
Gen 
 
 
455 
 
31 
 
13a 
 
 
 
Gen L 
 
 
345 
 
32 
 
13c 
 
 
[13b] P > 0.05 (NS) 
 
Gen Geft 
 
 
218 
 
0 
 
13d 
 
 
[13a] P < 0.001*** 
[13b] P > 0.05 (NS) 
[13c] P < 0.05 * 
 
 
Gen Sur L 
 
 
293 
 
10 
 
13b 
 
 
[13a] P < 0.001*** 
[13c] P > 0.05 (NS) 
[12c] P > 0.05 (NS) 
 
 
Gen PD LY L 
 
 
 
177 
 
6 
 
13e 
 
[12d] P > 0.05 (NS) 
[13a] P < 0.001*** 
[13b] P < 0.05 * 
[13c] P < 0.001*** 
[13d] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 13 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Gen, Genistein]; [L, Letrozole], [Geft, Geftinib], [Sur, Suramin]; [PD, 
PD98058], [LY, LY294008]; [Ref.Fig , Reference Figure].   
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Figure 14 The minimal concentration of genistein promoting complete 
death of MCF-7 cells grown in the presence of human serum albumin, 
suramin and PD98058.  
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of genistein in the presence of: 40g/L albumin, 180mM 
suramin (__o__), 40g/L albumin, 20µM PD98058 (__x _), 40g/L  
albumin (…..  …..), no additives (_  _). The therapeutic range (TR) in which 
genistein can be used in vivo is illustrated at the top left of the figure. The 
results are representative of two experiments.  
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Table 12 A statistical analysis of the lethal dose estimates of genistein 
including suramin and PD98058 in the presence of human serum albumin 
in MCF-7 cells 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to [Fig x] 
 
Gen 
 
 
447 
 
33 
 
14b 
 
[14c] P < 0.01** 
[14d] P < 0.01** 
 
 
Gen Alb 
 
 
583  
 
44 
 
14a 
 
[14b] P >0.05 (NS) 
[14c] P >0.05 (NS) 
[14d] P >0.05 (NS) 
 
 
Gen Alb Sur 
 
 
319 
 
71 
 
14d 
 
[14c] P >0.05 (NS) 
 
 
Gen Alb PD 
 
 
356 
 
20 
 
14c 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 14 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Gen, Genistein]; [L, Letrozole]; [Sur, Suramin]; [PD, PD98058]; [Ref. Fig 
, Reference Figure]. 
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Figure 15 The minimal concentration of gadolinium chloride promoting 
complete death of JU77 cells in the presence of genistein or genistein 
chalcone with letrozole.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of gadolinium chloride in the presence of: 135µM genistein, 
1µΜ letrozole (__x __), 270µΜ genistein chalcone, 1µΜ letrozole (__o _). 
Data points are the mean + SD of three determinations.  
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Table 13 A statistical analysis of the lethal dose estimates of gadolinium 
chloride including letrozole and genistein or genistein chalcone in JU77 
cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
 
Gd/Gen/L 
 
 
121 
 
16 
 
15a 
 
 
[15b] P > 0.05 (NS) 
[11b] P < 0.01 ** 
[12b] P <0.001***  
 
 
Gd/GenCh/L 
 
 
135 
 
23 
 
15b 
 
 
[11a] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 15 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Gen, Genistein]; [GenCh, Genistein chalcone], [L, Letrozole], [Gd, 
Gadolinium chloride]; [Ref.Fig , Reference Figure].   
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Figure 16 The effect of genistein on the death of JU77 cells in the 
presence of forskolin and 3-isobutyl-1-methylxanthine (IBMX).  
 
JU77 cells in their exponential growth phase were treated with varying 
concentrations of genistein in the presence of: 100µM/500µM forskolin/IBMX 
(….o….), 100µΜ/750µΜ forskolin/IBMX (__x _   ), 100 µM/1000 µM 
forskolin/IBMX (____). The therapeutic range (TR) in which genistein can be 
used in vivo is illustrated at the top left of the figure. The results are 
representative of two experiments. 
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Table 14  A statistical analysis of the lethal dose estimates of genistein 
including forskolin and varying concentrations of 3-isobutyl-1-methyl-
xanthine (IBMX) 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to [Fig x] 
 
Gen Forsk IBMX500 
 
391 
 
132 
 
14a 
 
[14b] P > 0.05 (NS) 
[14c] P > 0.05 (NS) 
 
 
Gen Forsk IBMX750 
 
 
302 
 
31 
 
14b 
 
[14c] P > 0.05 (NS) 
 
Gen Forsk IBMX1000 
 
 
171 
 
8 
 
14c 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 16 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Gen, Genistein]; [Forsk, Forskolin]; [IBMX, 3-isobutyl-1-methyl-
xanthine]; [Ref. Fig , Reference Figure]. 
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understanding the interactions of mifepristone with other anti-steroids.    
 
The combination of mifepristone with cyproterone acetate (an inhibitor of 
the androgen receptor) promoted cell death in JU77 as illustrated in Figure 
17. The cell killing potency of mifepristone correlated with the 
concentration of cyproterone acetate (table 15, p<0.001). As an example, 
100µM cyproterone acetate increased the eradicating potency of 
mifepristone by a third. However, a therapeutic level could not be achieved 
using this dual combination. 
 
In comparison to the JU77 cell line, the MCF-7 cell line did not seem to be 
homogenous. MCF-7 cells could not be eradicated with mifepristone only. 
Interestingly, 75% of cells died in the presence of more than 30µM 
mifepristone. However, further increases in mifepristone concentration did 
not further enhance cell death. This could be explained by the presence of 
two subpopulations of cells, one resistant to the action of mifepristone. 
Nevertheless, all cells died in the presence of mifepristone and just 12nM 
staurosporine (Figure 18 and table 16).  
 
To understand the kinases potentially involved in the survival of the 
“mifepristone-resistant” MCF-7 cell population, staurosporine was replaced 
with several compounds (illustrated in Figure 19 and table 17) which 
targeted the following molecular structures: the epidermal growth factor 
receptor (geftinib), the dopamine receptor (bromocriptine), the insulin-like 
growth factor-1 receptor (PD98058, LY294002), the oxytocin receptor 
(oxytocin), heat shock protein 90 (geldanamycin), elongation factor 2 
(forskolin, IBMX), growth factor receptors (suramin) and estrogen receptor  
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Figure 17 The effect of mifepristone on the death of JU77 cells in the 
presence of cyproterone acetate.    
JU77 cells in their exponential growth phase were treated with varying 
concentrations of mifepristone in the presence of: 100mM cyproterone 
acetate (__o__), 50mM cyproterone acetate (__x _ ), 20mM cyproterone 
acetate  (….….).  The therapeutic range (TR) in which mifepristone can be 
used in vivo is illustrated at the top left of the figure. Data points are the 
mean + SD of three determinations.  
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Table 15 A statistical analysis of the lethal dose estimates of 
mifepristone including varying concentrations of cyproterone acetate in 
JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to  
[Fig x] 
Mif/CA 20 40 3 17a [17c] P < 0.001*** 
Mif/CA 50 28 1 17b [17a] P < 0.001*** 
Mif/CA 100 16 0 17c [17b] P < 0.001*** 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 17 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Mif, Mifepristone]; [CA, Cyproterone acetate]; [Ref.Fig , Reference 
Figure].   
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Figure 18 The effect of mifepristone on the death of MCF-7 cells in the 
presence or absence of staurosporine.  
 
MCF-7 cells in their exponential growth phase were treated with 
mifepristone singularly or in the presence of staurosporine: No additive  
(__x _), 12nM staurosporine (__o__). The therapeutic range (TR) in which 
mifepristone can be used in vivo is illustrated at the top left of the figure. 
Data points are the mean + SD of three determinations.  
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Table 16 A statistical analysis of the lethal dose estimates of 
mifepristone including staurosporine in MCF-7 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Mif 87 8 18a [18b] P is N/A  
Mif / Stauro 21 0 18b Standarddeviation=0 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 18 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Mif, Mifepristone]; [Stauro, Staurosporine]; [Ref.Fig , Reference Figure].   
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Figure 19 The effect of mifepristone on the death of MCF-7 cells in the 
presence of narrow and broad-spectrum inhibitors.  
 
MCF-7 cells in their exponential growth phase were treated with no additive, 
1µΜ geftinib, 0.75nM bromocriptin, 20µM/20µM PD98058/LY294002, 
100nM oxytocin, 20nM geldanamycin, 75µM/750µM forskolin/IBMX, 
180mM suramin or 5µM nolvadex in the absence (     ) or in the presence (     ) 
of 40µM mifepristone (Mif.). Τhe results are representative of two 
experiments. 
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Table 17 A statistical analysis of the lethal effects of mifepristone 
including narrow- and broad-spectrum inhibitors in MCF-7 cells. 
Description LE 
%CD 
Ref. 
Fig  
Level of Significance  
Comparison to [Fig x] 
Geft Mif 
 
78 17j [17a] P < 0.001*** 
[17o] P < 0.001*** 
[17p] P < 0.001*** 
Bromo Mif  
 
82 17k [17b] P < 0.001*** 
[17o] P < 0.001*** 
[17p] P < 0.001*** 
PD LY Mif 81 17l [17c] P < 0.001*** 
[17o] P < 0.001*** 
[17p] P < 0.001*** 
Oxy Mif 79 17m [17d] P < 0.001*** 
[17o] P < 0.001*** 
[17p] P < 0.001*** 
Geld Mif 80 17n [17e] P < 0.001*** 
[17o] P < 0.001*** 
[17p] P < 0.001*** 
Forsk IBMX Mif 98 17o [17f],[17i] 2P<0.001*** 
[17p] P < 0.001*** 
Sur Mif 97 17p [17g],[17i]2P<0.001*** 
Nolv Mif 79 17q [17h] P < 0.001*** 
[17o] P < 0.001*** 
[17p] P < 0.001*** 
Geft 
Bromo 
PD LY 
Oxy 
Geld 
Forsk IBMX 
Sur 
Nolv 
Mif 
6 
8 
24 
11 
10 
28 
16 
14 
78 
17a 
17b 
17c 
17d 
17e 
17f 
17g 
17h 
17i 
 
Lethal effects of compounds and their combinations were compared by 
ANOVA, Benferroni and Tukey-Kramer Multiple Comparison Tests as 
detailed in the Methods. By conventional criteria the data is considered to 
be not statistically significant (NS), statistically significant (*), very 
statistically significant (**), or extremely statistically significant (***). 
Abbreviations: [Geft, Geftinib]; [Bromo, Bromocriptin]; [PD, PD98058]; 
[LY, LY294002]; [Oxy, Oxytocin]; [Geld, Geldanamycin]; [Forsk/IBMX, 
Forskolin/3-isobutyl-methylxanthine]; [Sur, Suramin]; [Nolv, Nolvadex]; 
[Mif, Mifepristone]; [LE %CD, Lethal effect in % cell death]; [Ref. Fig , 
Reference Figure]. 
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(nolvadex). Forskolin and IBMX or suramin displayed a strong effect on all 
MCF-7 cells in the presence of 30µM mifepristone, but none of the 
compounds eradicated the cell line as staurosporine did. Applying 
mifepristone singularly at concentrations less than 30µM, staurosporine 
affected neither MCF-7 nor JU77 cells. However, at these low 
concentrations mifepristone combined well with cyproterone acetate in both 
cell lines: increasing concentrations of cyproterone acetate enhanced the 
percentage of cell death, as illustrated in Figure 20 and table 18  
3.1.4 Combinations with vitamin C 
Vitamin C is an antineoplastic compound regulating the synthesis of 
insulin-like growth factor binding proteins 1 and 2, thereby affecting 
collagen gene expression and proteoglycan synthesis (Peterkofsky et.al. 
1994). It prevents the degradation of the extracellular matrix. In JU77 cells, 
cell viability and vitamin C (ascorbic acid) concentrations were inversely 
correlated. In the absence of human serum albumin JU77 cells died with 
increasing concentrations of vitamin C and were eradicated with 2mM 
vitamin C. However, in the presence of human serum albumin, a “lag-
phase” was observed with no change in viability up to 3.5mM vitamin C 
(Figure 21). Above a 3.5mM concentration of vitamin C, cell viability in 
the presence of human serum albumin correlated with increasing 
concentrations of vitamin C. Vitamin C concentrations above an estimated 
concentration of 11mM eradicated the JU77 cell population. However, this 
concentration exceeded a therapeutic level. In comparison, vitamin C 
significantly lost its cell killing potency when added to JU77 cells in the 
presence of human serum albumin , as illustrated in table 19, p<0.001. 
 
In MCF-7 cells, human serum albumin also changed the cell killing potency 
of vitamin C, as illustrated in Figure 22 and table 20, p<0.001. However,  
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Figure 20 The effect of mifepristone on the death of MCF-7 cells in the 
presence of cyproterone acetate.  
 
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of mifepristone in the presence of cyproterone acetate: 
0µΜ cyproterone acetate (….◊….),  5µΜ cyproterone acetate (-  - ), 
10µΜ cyproterone acetate (_ _ _ _), 20µΜ cyproterone acetate (_  _), 
50µΜ cyproterone acetate (__x _), 100µΜ cyproterone acetate (__o__). The 
therapeutic range (TR) in which mifepristone can be used in vivo is 
illustrated at the top left of the figure. The results are representative of two 
experiments.  
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Table 18 A statistical analysis of the lethal dose estimates of 
mifepristone including varying concentrations of cyproterone acetate in 
MCF- cells 
 
Description LD100 
(µM) 
SEM 
  (µM) 
Ref. 
Fig  
Level of Significance  
Comparison to [Fig x] 
Mif CA 0 N/A N/A 20a Couldn`t be determined  
Slope of data is zero 
Mif CA 5 43 8 20b [20c] P > 0.05 (NS) 
[20d] P > 0.05 (NS) 
[20e] P > 0.05 (NS) 
[20f]  P < 0.001*** 
 
Mif CA 10 40 2 20c [20d] P > 0.05 (NS) 
[20e] P > 0.05 (NS) 
[20f]  P < 0.01** 
 
Mif CA 20 39 1 20d [20e] P > 0.05 (NS) 
[20f]  P < 0.01** 
 
Mif CA 50 39  1 20e [20f]  P < 0.01** 
 
Mif CA 100 19 1 20f  
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 20 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Mif, Mifepristone]; [CA, Cyproterone acetate]; [Ref. Fig , Reference 
Figure]. 
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Figure 21 The effect of vitamin C on the death of JU77 cells in the 
presence or absence of human serum albumin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of vitamin C singularly and in the presence of albumin: No 
additives (….o….), 40g/L albumin (__x _). The therapeutic range (TR) in 
which vitamin C can be used in vivo is illustrated at the top left of the 
figure. Data points are the mean + SD of three determinations.  
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Table 19 A statistical analysis of the lethal dose estimates of vitamin C 
including human serum albumin in JU77 cells. 
 
Description LD100 
(mM) 
SEM 
(mM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Vit.C 2 0 21b [21a] P <0.001*** 
Vit.C /Alb 11 1 21a  
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 21 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Vit.C, Vitamin C]; [Alb, Albumin]; [Ref.Fig , Reference Figure].   
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Figure 22 The effect of vitamin C on the death of MCF-7 cells in the 
presence or absence of human serum albumin.  
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of vitamin C on its own and in the presence of albumin: No 
additives (__o__), 40g/L albumin  (__x _). The therapeutic range (TR) in 
which vitamin C can be used in vivo is illustrated at the top left of the 
figure. Data points are the mean + SD of three determinations.  
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Table 20 A statistical analysis of the lethal dose estimates of vitamin C 
including human serum albumin in MCF-7 cells. 
 
Description LD100 
(mM) 
SEM 
(mM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Vit.C 2 0 22b 
 
 [21b] P > 0.05 (NS) 
 [22a] P < 0.001*** 
 
Vit.C /Alb 11 1 22a [21a] P <0.001***  
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 22 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Vit.C, Vitamin C]; [Alb, Albumin]; [Ref.Fig , Reference Figure].   
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there was also a significant difference comparing the two treatments with 
vitamin C and albumin in JU77 or MCF-7 cells (table 20, p<0.001).  
 
A very effective combination with vitamin C was observed in the absence 
of human serum albumin: A mitogen-activated protein kinase inhibitor 
(PD98058), genistein and vitamin C promoted cell death in JU77 cells 
(Figure 23). However, the presence of human serum albumin attenuated the 
effects of all this combination on cell death of JU77 cells (table 21, 
p<0.001).  Other effective combinations were letrozole (an inhibitor of 
aromatase), suramin (a broad inhibitor of receptor tyrosine kinases) and 
vitamin C or mifepristone (an inhibitor of the progesterone receptor), 
suramin and vitamin C inducing complete cell death in JU77 cells (Figure 
24) in the absence of human serum albumin. The addition of letrozole and 
suramin or mifepristone and suramin to JU77 cells treated with vitamin C 
significantly changed the cell killing potency (table 22, p< 0.001).  
However, the presence of human serum albumin attenuated the effects of 
both combinations on cell death of JU77 cells.  
3.1.5 Combinations with selenite 
Selenite is an inorganic selenium compound that oxidizes fibrin-polymers 
of cell membranes (Lipinski 2005) and induces the expression of 
membrane-anchored peroxidases (GPX-4) and serum peroxidases (GPX-1) 
protecting cell membranes against the lipid peroxidizing effects of fatty 
acid hydroperoxides and hydrogen peroxide (Brigelius-Flohe, R., 1997). 
Other compounds containing selenium are inorganic selenate and organic 
selenomethionine. Their activity is distinct from selenite`s effects. 
 
Increasing selenite concentrations decreased the viability of JU77 cells as 
illustrated in Figure 25. Adding human serum albumin changed the 
threshold of selenite-dependent cell death from an estimated concentration  
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Figure 23 The effect of genistein on the death of JU77 cells in the 
presence vitamin C and PD98058 with or without human serum albumin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of genistein in the presence of: 1mM vitamin C, 
20µΜ PD98058 (__o__), 1mM vitamin C (__x _), 1mM vitamin C, 
20µΜ PD98058, 40g/L albumin (_   _), 1mM vitamin C, 40g/L albumin 
(…..   …..). The therapeutic range (TR) in which genistein can be used in vivo 
is illustrated at the top left corner of the figure. Data points are the mean + 
SD of three determinations.  
 
 
 107 
 
Table 21 A statistical analysis of the lethal dose estimates of genistein 
including vitamin C and PD98058 in the presence or absence of human 
serum albumin in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Gen/Vit.C 29 2 23c 
 
[10b] P < 0.001*** 
[21b] P > 0.05 (NS) 
[23a] P < 0.001*** 
[23d] P > 0.05 (NS) 
 
Gen/PD/Vit.C 4 4 23d 
 
[23b] P > 0.05 (NS) 
  
Gen/PD/Vit.C/Alb 62 9 23b 
 
[23a] P < 0.001*** 
[23d] P < 0.001*** 
 
Gen/Vit.C/Alb 188 45 23a 
 
[10a] P < 0.001*** 
[21a] P < 0.001*** 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 23 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Gen, Genistein]; [PD, PD98058]; [Vit.C, Vitamin C]; [Alb, Albumin]; 
[Ref.Fig , Reference Figure].   
 
 
 
 
 
 108 
 
 
 
Figure 24 The effect of suramin, letrozole and mifepristone combinations 
with vitamin C on the death of JU77 cells.  
JU77 cells growing exponentially were treated with 1mM vitamin C, 1µΜ 
letrozole and 180mM suramin or 1mM vitamin C, 20µΜ mifepristone and 
180mM suramin. Data points are the mean + SD of three determinations.  
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Table 22 A statistical analysis of the lethal effects of vitamin C 
including letrozole, mifepristone and suramin in JU77 cells.  
 
Description LE 
%CD 
SEM 
 
Ref. 
Fig  
Level of Significance  
Comparison to [Fig x] 
L Sur Vit.C  
 
100 0 22j [22h] P > 0.05 (NS) 
[22g] P < 0.001*** 
[22d] P < 0.001*** 
[22b] P < 0.001*** 
 
Mif Sur Vit.C 
 
100 0 22k [22i] P < 0.05 * 
[22g] P < 0.001*** 
[22d] P < 0.001*** 
[22c] P < 0.001*** 
 
L Vit.C 89 4.04 22h [22g] P > 0.05 (NS) 
 
Mif Vit.C 86 2.39 22i [22g] P > 0.05 (NS) 
 
Vit.C 80 3.05 22g  
L Sur 20 2.98 22e  
Mif Sur 20 4.16 22f  
L 4 1.15 22b  
Mif 9 1.73 22c  
Sur 11 2.88 22d  
 
Lethal effects of compounds and their combinations were compared by 
ANOVA, Benferroni and Tukey-Kramer Multiple Comparison Tests as 
detailed in the Methods. By conventional criteria the data is considered to 
be not statistically significant (NS), statistically significant (*), very 
statistically significant (**), or extremely statistically significant (***). 
Abbreviations: [L, Letrozole]; [Sur, Suramin]; [Mif, Mifepristone]; [Vit.C, 
Vitamin C]; [LE  %CD, Lethal effect in % cell death]; [Ref. Fig , Reference 
Figure]. 
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Figure 25 The effect of selenite on the death of JU77 cells in the 
presence or absence of human serum albumin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of selenite singularly or in the presence of albumin: No 
additives (__o__), 40g/L albumin (….. x …..). The therapeutic range (TR) in 
which selenite can be used in vivo is illustrated at the top left corner of the 
figure. Data points are the mean + SD of three determinations.  
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Table 23 A statistical analysis of the lethal dose estimates of selenite 
including human serum albumin in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to  
[Fig x] 
Sele 32 1 25b [25a] P <0.001*** 
Sele/Alb 128 7 25a  
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 25 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Sele, Selenite]; [Alb, Albumin]; [Ref.Fig , Reference Figure].   
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of 7µM to 28µM (table 23, p<0.001) and increased the concentration-
dependent cell death for eradication of JU77 cells from an estimated 
concentration of 32µM to 128µM. Other selenium containing compounds 
like selenate and selenomethionine used singularly did not influence the 
viability of JU77 cells as illustrated in Figure 26. Lithium chloride and 
geldanamycin seemed to increase the cell-killing potency of selenite in 
JU77 cells in the absence of albumin (Figure 26 and 27, respectively). 
However, this was not statistically significant (table 24 and 25, p>0.05 
(NS)). Both compounds seemed equally potent in combination with selenite 
(table 27, p>0.05 (NS)), and only a very small increase could be observed 
with either selenate or selenomethionine (table 24, p<0.001 and table 25, 
p<0.001). 17-Allyl-amino-geldanamycin (17-AAG), a derivate replacing 
geldanamycin in clinical settings, had to be applied at a tenfold higher 
concentration relative to geldanamycin to induce a similar cell killing effect 
(Figure 28 and table 26, p>0.05).  
 
Of other compounds tested on JU77 cells, gadolinium chloride strongly 
increased cell death induced by selenite. The combination was only a third 
as potent when tested in the presence of human serum albumin (table 27, 
p<0.001). However, this was still within a therapeutic concentration range 
(Figure 29).  
 
As in JU77 cells, the viability of MCF-7 cells decreased with increasing 
selenite concentrations. The inclusion of albumin in the culture medium had 
the same effect on selenite action in both cell lines (Figure 25 and 30, table 
28, p>0.05 (NS)), and lithium chloride increased the potency of selenite in 
MCF-7 cells (table 29, p<0.01). Two additional compounds (metformin and 
8Cl-cAMP) combined well with selenite in MCF-7 cells (Figure 31 and  
table 29, p<0.05 and p<0.001), but thiosulfate did not (Figure 31 and table 
29, p>0.05 (NS)).  
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Figure 26 The effect of three selenium compounds - selenite, selenate 
and selenomethionine - on the death of JU77 cells in the presence or 
absence of lithium chloride.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of: selenite and 0.5mM lithium chloride (__o__), selenite only 
(__x _), selenate and 0.5mM lithium chloride (____), selenate only (_ _ _ _), 
selenomethionine and 0.5mM lithium chloride (____), selenomethionine 
only (-   -). Lithium chloride (0.5mM) used alone causes 14% cell death 
and is marked on the X-axis as  (◊). Data points are the mean + SD of three 
determinations.  
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Table 24 A statistical analysis of the lethal dose estimates of three 
selenium compounds – selenite, selenate and selenomethionine – including 
lithium chloride in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Senite/Li 26 2 26f  
Senate/Li 4779 0 26c  
Seme/Li -1609 0 26d  
Senite 32 1 26e 
 
[26a] P < 0.001*** 
[26b] P < 0.01 ** 
[26c] P < 0.01 ** 
[26d] P < 0.001*** 
[26f]  P > 0.05 (NS) 
 
Senate 1489 0 26a 
 
[26b] P < 0.001***  
[26c] P < 0.001*** 
[26d] P < 0.001*** 
[26f]  P < 0.001*** 
 
Seme 324 122 26b 
 
[26c] P < 0.001*** 
[26d] P < 0.001*** 
[26f]  P < 0.001***  
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 26 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [Senate, Selenate]; [Seme, Selenomethionine]; [Li, 
Lithium chloride]; [Ref.Fig , Reference Figure].   
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Figure 27 The effect of three selenium compounds - selenite, selenate 
and selenomethionine - on the death of JU77 cells in the presence or 
absence of geldanamycin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of: selenite and 20nM geldanamycin (__o__), selenite only 
(__x _), selenate and 20nM geldanamycin (____), selenate only (_ _ _ _), 
selenomethionine and 20nM geldanamycin (___), selenomethionine only 
(-  -).  Geldanamycin sy 20nM used singularly caused 20% cell death and 
is marked on the X-axis as (◊). Data points are the mean + SD of three 
determinations.  
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Table 25 A statistical analysis of the lethal dose estimates of three 
selenium compounds – selenite, selenate and selenomethionine – including 
geldanamycin in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to  
[Fig x] 
Senite/Geld 23 3 27f 
 
[26f] P > 0.05 (NS) 
 
Senate/Geld 489 372 27c [26c] P < 0.001*** 
Seme/Geld 838 0 27d [26d] P < 0.001*** 
Senite 32 1 27e 
 
[27a] P < 0.001*** 
[27b] P > 0.05 (NS) 
[27c] P > 0.05 (NS) 
[27d] P < 0.001*** 
[27f]  P > 0.05 (NS) 
 
Senate 1489 0 27a 
 
[27b] P < 0.001*** 
[27c] P < 0.001*** 
[27d] P < 0.05 * 
[27f]  P < 0.001*** 
 
Seme 324 122 27b 
 
[27c] P > 0.05 (NS) 
[27d] P > 0.05 (NS) 
[27f]  P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 27 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [Senate, Selenate]; [Seme, Selenomethionine]; [Geld, 
Geldanamycin]; [Ref.Fig , Reference Figure].   
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Figure 28 The effect of selenite on the death of JU77 cells in the 
presence of human serum albumin and geldanamycin or 17-allylamino-
geldanamycin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of selenite in the presence of: 20nM geldanamycin and 
40g/L albumin (__o__), 200nM 17-allylamino-geldanamycin and 40g/L 
albumin (__x _). The therapeutic range (TR) in which selenite can be used in 
vivo is illustrated at the top left corner of the figure. Data points are the 
mean + SD of three determinations.  
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Table 26 A statistical analysis of the lethal dose estimates of selenite 
including human serum albumin and geldanamycin or 17-allylamino-
geldanamycin in JU77 cells.  
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
Senite/Geld/Alb 23 3 28b  
Senite/17-AAG/Alb 25 3 28a [28b] P > 0.05 (NS) 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 28 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [Geld, Geldanamycin]; [17-AAG, 17-Allylamino-
geldanamycin]; [Alb, Albumin]; [Ref. Fig , Reference Figure].   
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Figure 29 The effect of selenite on the death of JU77 cells in the 
presence of gadolinium chloride with or without human serum albumin.  
 
JU77 cell in their exponential growth phase were treated with varying 
concentrations of selenite in the presence of: 200µΜ gadolinium chloride 
(__o__), 200µΜ gadolinium chloride, 40g/L albumin (__x _). The therapeutic 
range (TR) in which selenite can be used in vivo is illustrated at the top left 
corner of the figure. Data points are the mean + SD of three determinations.  
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Table 27 A statistical analysis of the lethal dose estimates of selenite 
and gadolinium chloride including human serum albumin in JU77 cells.  
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Senite/Gd 13 1 29b  
Senite/Gd/Alb 36 3 29a 
 
[29b] P < 0.001*** 
[25a] P < 0.001*** 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 29 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [Gd, Gadolinium chloride]; [Alb, Albumin]; [Ref.Fig , 
Reference Figure].   
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Figure 30 The effect of selenite on the death of MCF-7 cells in the 
presence or absence of human serum albumin.  
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of selenite in the presence or absence of albumin: No 
additives (__o__), 40g/L albumin (__x _). The therapeutic range (TR) in 
which selenite can be used in vivo is illustrated at the top left corner of the 
figure. Data points are the mean + SD of three determinations.  
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Table 28 A statistical analysis of the lethal dose estimates of selenite 
including human serum albumin in MCF-7 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Senite 30 2 30b [25b] P > 0.05 (NS) 
Senite/Alb 128 7 30a 
 
[25a] P > 0.05 (NS) 
[30b] P < 0.001*** 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 30 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [Alb, Albumin]; [Ref.Fig , Reference Figure].   
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Figure 31 The effect of selenite on the death of MCF-7 cells in the 
presence of metformin or lithium chloride or thiosulfate or 8Cl-cAMP.  
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of selenite in the presence of: No additive (__◊ _), 
50µΜ metformin (….….), 0.5mM lithium chloride (__x __), 0.5mM 
thiosulfate (_ _ _ _), 20µΜ 8Cl-cAMP (__o__).  The therapeutic range (TR) 
in which selenite can be used in vivo is illustrated at the top left corner of 
the figure. Data points are the mean + SD of three determinations.  
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Table 29 A statistical analysis of the lethal dose estimates of selenite 
including metformin, 8Cl-cAMP, thiosulfate or lithium chloride in MCF-7 
cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Senite 31 1 31a  
Senite/Metf 25 2 31c 
 
[31a] P < 0.05 * 
[31b] P > 0.05 (NS) 
[31d] P > 0.05 (NS) 
[31e] P > 0.05 (NS) 
 
Senite/8Cl-cAMP 22 0 31e [31a] P < 0.001*** 
Senite/Thio 28 2 31b 
 
[31a] P > 0.05 (NS) 
[31e] P < 0.05 * 
 
Senite/Li 24 1 31d 
 
[31a] P < 0.01 ** 
[31b] P > 0.05 (NS) 
[31e] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 31 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [Metf, Metformin]; [8Cl-cAMP, 8Chloro-cyclic 
Adenosinmonophosphate]; [Thio, Thiosulfate]; [Li, Lithium chloride] [Ref. 
Fig , Reference Figure].   
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3.1.6 Combinations with trisulphides 
Selenite and sulphydryl group-containing compounds form cancer-selective 
selenotrisulphides (Abdullaev, Mac Vicar and Frenkel 1992) that target the 
elongation stage of RNA-polymerase 2 (Frenkel, Walcott and Middleton 
1987). Many trisulphides were synthesised with different non sulphydryl 
group-containing compounds. 
  
Figure 32 illustrates how increasing concentrations of trisulphides directly 
correlated with a loss in viability of JU77 cells in the presence of human 
serum albumin. Four different sulphydryl group-containing compounds 
were compared: selenomethionine, dihydrolipoic acid, cysteine and 
glutathione. An equimolar concentration of each sulphydryl group- 
containing compound was combined with selenite. The potency of all the 
trisulphides appeared to be identical (table 30, p>0.05 (NS)). The minimal 
trisulphide-forming selenite concentration that eradicated JU77 cells 
decreased to an estimated 48µM in the presence of human serum albumin. 
None of the sulphydryl group- containing compounds alone completely 
killed the JU77 cell population in the presence of human serum albumin 
(Figure 33 and table 31).   
 
Selenodimethionine is the trisulphide synthesised with inorganic selenite 
and organic selenomethionine. In JU77 cells, selenodimethionine 
substantially increased cell death in combination with lithium chloride or 
geldanamycin in the presence of human serum albumin (table 32, p<0.05 
and p<0.01) reducing the concentration of both selenite and seleno-
methionine to an estimated 35µM and 38µM, respectively, which is well in 
the therapeutic range (Figure 34). In MCF-7 cells, no statistic significant 
increase in cell death was observed using selenodimethionine and lithium 
chloride in the presence of albumin (Figure 35 and table 33, p>0.05 (NS)). 
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Figure 32 The effect of simultaneous application of selenite and 
sulphydryl group-containing compounds (RSH) on the death of JU77 cells 
in the presence of human serum albumin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of selenite and the following sulphydryl group-containing 
compounds in 40g/L albumin: selenite/dihydrolipoic acid in 40g/L albumin 
(____), selenite/cysteine in 40g/L albumin (__x _), 
selenite/selenomethionine in 40g/L albumin (-- o--), selenite/glutathione in 
40g/L albumin (--   --). Data points are the mean + SD of three 
determinations.  
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Table 30 A statistical analysis of the lethal dose estimates of selenite 
and sulphydryl group-containing compounds (RSH) in the presence of 
human serum albumin in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Senite/Glut/Alb 48 3 32d  
Senite/Seme/Alb 48 3 32a 
 
[32d] P > 0.05 (NS) 
[25a] P < 0.001*** 
 
Senite/Cyst/Alb 51 3 32b 
 
[32a] P > 0.05 (NS) 
[32d] P > 0.05 (NS) 
 
Senite/DHLA/Alb 51 3 32c 
 
[32a] P > 0.05 (NS) 
[32b] P > 0.05 (NS) 
[32d] P > 0.05 (NS)  
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 32 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [DHLA, Dihydrolipoic acid]; [Cyst, Cysteine]; [Seme, 
Selenomethionine]; [Alb, Albumin]; [Ref. Fig , Reference Figure].   
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Figure 33 The effect of sulphydryl group-containing compounds on the 
death of JU77 cells in the presence of human serum albumin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations 
of dihydrolipoic acid (__o__), lipoic acid (__x _), cysteine (____), 
selenomethionine (-- o--  ), glutathione (____) and mercaptoethanol 
(_ _ _ _ ) in the presence of 40g/L albumin. Data points are the mean + SD 
of three determinations.  
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Table 31 A statistical analysis of the lethal dose estimates of sulphydryl 
group-containing compounds in the presence of human serum albumin in 
JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Seme/Alb 427 349 33a 
 
[33b] P > 0.05 (NS) 
[33c] P > 0.05 (NS) 
[33d] P > 0.05 (NS) 
[32a] P > 0.05 (NS) 
Cyst/Alb 237 46 33d 
 
[32b] P < 0.01 ** 
 
Lipoic/Alb 110 7 33f 
[33a] P > 0.05 (NS) 
[33b] P > 0.05 (NS) 
[33c] P > 0.05 (NS) 
[33d] P > 0.05 (NS) 
DHLA/Alb 135 11 33e 
 
[33a] P > 0.05 (NS) 
[33b] P > 0.05 (NS) 
[33c] P > 0.05 (NS) 
[33d] P > 0.05 (NS) 
[33f]  P > 0.05 (NS) 
[32c] P < 0.001*** 
Merc/Alb 316 104 33c [33d] P > 0.05 (NS) 
Glut/Alb 296 88 33b 
[33c] P > 0.05 (NS) 
[33d] P > 0.05 (NS) 
[32d] P < 0.01 ** 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 33 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Seme, Selenomethionine]; [Cyst, Cysteine]; [Lipoic, Lipoic acid]; [DHLA, 
Dihydrolipoic acid]; [Merc, Mercaptoethanol]; [Glut, Glutathione]; 
[Ref.Fig , Reference Figure].   
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Figure 34 The effect of a combination of selenite and selenomethionine 
on the death of JU77 cells in the presence of human serum albumin, lithium 
chloride or geldanamycin.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of selenite and selenomethionine in the presence of: 40g/L 
albumin (-- o--), 40g/L albumin, 0.5mM lithium chloride (__x __), 40g/L 
albumin, 20nM geldanamycin (__ _). Data points are the mean + SD of 
three determinations.  
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Table 32 A statistical analysis of the lethal dose estimates of selenite 
and selenomethionine in the presence of human serum albumin including 
lithium chloride or geldanamycin in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
Senite/Seme/Alb 48 3 34a  
Senite/Seme/Li/Alb 38 3 34b [34a] P < 0.05 * 
Senite/Seme/Geld/Alb 35 2 34c 
 
[34a] P < 0.01 ** 
[34b] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 34 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [Seme, Selenomethionine]; [Li, Lithium chloride]; [Geld, 
Geldanamycin]; [Alb, Albumin]; [Ref.Fig , Reference Figure].   
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Figure 35 The effect of a combination of selenite and selenomethionine 
on the death of MCF-7 cells in the presence of human serum albumin and 
lithium chloride.  
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of selenite and selenomethionine in the presence of: 40g/L 
albumin, 0.5mM lithium chloride (__o _ ) 40g/L albumin (__x __). Data points 
are the mean + SD of three determinations.              
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Table 33 A statistical analysis of the lethal dose estimates of selenite 
and selenomethionine in the presence of human serum albumin including 
lithium chloride in MCF-7 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
Senite/Seme/Alb 46 2 35a [34a] P > 0.05 (NS) 
Senite/Seme/Li/Alb 40 3 35b 
 
[34b] P > 0.05 (NS) 
[35a] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 35 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [Seme, Selenomethionine]; [Li, Lithium chloride]; 
[Alb,Albumin]; [Ref.Fig , Reference Figure].   
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In JU77 cells, selenodimethionine also increased cell death in combination 
with mercaptoethanol. Mercaptoethanol reduced the minimal concentration 
of selenodimethionine that promoted complete death of JU77 cells from an 
estimated 49µM to 14µM (Figure 36 and table 34, p<0.001). However, 
other RSH-group containing compounds like cysteine and glutathione did 
not change the activity of selenodimethionine significantly (table 34, both 
 p>0.05 (NS)).  
 
A combination of selenite and dihydrolipoic acid (DHLA-trisulphide) was 
prepared in an attempt to reduce the total concentration of selenium needed 
to promote death of MCF-7 and JU77 cells. The DHLA-trisulphide was 
then combined with a low concentration of selenomethionine, 
mercaptoethanol and gadolinium chloride. Figure 37 illustrates that in the 
presence of gadolinium chloride the total concentration of selenite needed 
to promote complete death of a JU77 cell population decreased to an 
estimated concentration of 8µM (table 35, p<0.001). This was the lowest 
concentration of trisulphide (and total selenium) observed to be effective in 
the presence of human serum albumin. 
 
The four cell lines were equally susceptible to a combination of selenite and 
dihydrolipoic acid with low concentrations of selenomethionine and 
mercaptoethanol in the presence of human serum albumin, as highlighted in 
Figure 38. The mesothelioma cell line JU77, the breast cancer cell line 
MCF-7, the colon cancer cell line Caco-2 and the hepatocellular carcinoma 
cell line HepG2 were all killed with the same concentration using this 
combination (table 36, p>0.05 (NS)). 
3.1.7 Combinations with β-lapachone 
β-lapachone inhibits antigenic determinants that seem to be shared between  
 
 
 135 
 
 
 
 
Figure 36 The effect of a combination of selenite and selenomethionine 
on the death of JU77 cells in the presence of human serum albumin and 
various other sulphydryl group-containing compounds.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of selenite and selenomethionine in the presence of: 40g/L 
albumin (_ _ _ _), 40g/L albumin and 40µΜ cysteine (__x _), 40g/L albumin 
and 40µM glutathione (_  _), 40g/L albumin and 40µΜ mercaptoethanol 
(__o__). Data points are the mean + SD of three determinations.  
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Table 34 A statistical analysis of the lethal dose estimates of selenite 
and selenomethionine in the presence of human serum albumin including 
various other sulphydryl group-containing compounds in JU77 cells.  
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
Senite/Seme/Alb 49 4 36b 
 
[36a] P > 0.05 (NS) 
[36c] P > 0.05 (NS) 
 
Senite/Seme/Merc/Alb 14 1 36d [36b] P < 0.001*** 
Senite/Seme/Cyst/Alb 54 4 36a 
 
[36c] P > 0.05 (NS) 
[36d] P < 0.001*** 
[32b] P > 0.05 (NS) 
 
Senite/Seme/Glut/Alb 50 4 36c 
 
[36d] P < 0.001*** 
[32d] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 36 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Senite, Selenite]; [Seme, Selenomethionine]; [Cyst, Cysteine]; [Merc, 
Mercaptoethanol]; [Glut, Glutathione]; [Alb, Albumin]; [Ref.Fig , 
Reference Figure].   
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Figure 37 The effect of a combination of selenite and dihydrolipoic acid 
on the death of JU77 cells in the presence of human serum albumin, 
selenomethionine and mercaptoethanol with or without gadolinium 
chloride.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of selenite and dihydrolipoic acid in the presence of 40g/L 
albumin, 3µΜ selenomethionine and 40µΜ mercaptoethanol (-- x --) or 
40g/L albumin, 3µΜ selenomethionine, 40µΜ mercaptoethanol and 
100µΜ gadolinium chloride (__o__). Data points are the mean + SD of three 
determinations.  
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Table 35 A statistical analysis of the lethal dose estimates of selenite, 
dihydrolipoic acid, selenomethionine and mercaptoethanol in the presence 
of human serum albumin including gadolinium chloride in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
 
Merc Seme DHLA 
Senite Alb 
 
20 2 37a [37b] P < 0.001*** 
 
Gd Merc Seme DHLA 
Senite Alb 
 
8 4 37b [32c] P < 0.001*** 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 37 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Gd, Gadolinium chloride]; [Merc, Mercaptoethanol]; [Seme, Seleno-
methionine]; [DHLA, Dihydrolipoic acid]; [Senite, Selenite]; [Alb, 
Albumin]; [Ref.Fig , Reference Figure].   
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Figure 38 The effect of a combination of selenite and dihydrolipoic acid 
on the death of four different cell lines in the presence of human serum 
albumin, selenomethionine and mercaptoethanol.  
JU77 cells (-- x --), MCF-7 cells (__o__), Caco-2 cells (____) and HepG2 
cells (_ _ _ _) in their exponential growth phases were treated with varying 
concentrations of selenite and dihydrolipoic acid (DHLA) in the presence 
of 40g/L albumin, 3µM selenomethionine and 40µΜ mercaptoethanol. Data 
points are the mean + SD of three determinations.  
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Table 36 A statistical analysis of the lethal dose estimates of selenite, 
dihydrolipoic acid selenomethionine and mercaptoethanol in the presence 
of human serum albumin in fourdifferent cell lines. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of 
Significance  
Comparison to 
 [Fig x] 
 
Merc Seme DHLA 
Senite Alb (HepG) 
 
20 2 38d  
 
Merc Seme DHLA 
Senite Alb (JU77) 
 
20 3 38a 
[38b] P > 0.05 (NS) 
[38c] P > 0.05 (NS) 
[38d] P > 0.05 (NS) 
 
Merc Seme DHLA 
Senite Alb (MCF-7) 
 
19 2 38b [38c] P > 0.05 (NS) [38d] P > 0.05 (NS) 
 
Merc Seme DHLA 
Senite Alb (Caco-2) 
 
19 2 38c [38d] P > 0.05 (NS) 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 38 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Merc, Mercaptoethanol]; [Seme, Selenomethionine]; [DHLA, 
Dihydrolipoic acid]; [Senite, Selenite]; [Alb, Albumin]; [Ref. Fig , 
Reference Figure].   
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the cytoplasmatic glucocorticoid receptor and DNA polymerase alpha 
(Schmidt, Miller-Diener and Litwack 1984). There is some evidence that its 
cell death-inducing potency is increased with compounds that reduce 
NADPH-dependent lipid peroxidation and/or inhibit DNA or RNA-
polymerases.    
 
β-lapachone alone eradicated JU77 cell populations between an estimated 
31µM to 40µM in the presence of human serum albumin, a concentration 
that exceeds a therapeutic range (Figure 39). Combinations with 
trisulphides or flavin adenine dinucleotide (FAD), as well as with 
menadione, geftinib and thiosulfate did not significantly increase the 
potency of β-lapachone (table 37, all p>0.05 (NS)). 
 
In MCF-7 cells, β-lapachone exerted its maximal cell killing potency 
between an estimated 29µM to 33µM in the presence of human serum 
albumin. As occurred in the JU77 cells, combinations with trisulphides or 
flavin adenine dinucleotide did not significantly reduced the concentration 
of β-lapachone in MCF-7 cells, as highlighted in Figure 40 and table 38, 
p>0.05.   
3.1.8 Combinations with glycolysis inhibitors 
A fundamental difference between normal and cancerous cells was reported 
in 1924 by Warburg, Posener and Negelein, who discovered that the ratio 
between glycolysis and respiration differs in normal and cancerous cells. 
He demonstrated that glycolytic flux under aerobic conditions is greater in 
cancer cells than in their normal counterparts. In general, the potency of 
chemotherapeutic combinations increases with the simultaneous inhibition 
of glycolysis (Kim et.al. 2002). 
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Figure 39 The effect of β-lapachone on the death of JU77 cells in the 
presence of human serum albumin and menadione or geftinib or thiosulfate 
or a combination of selenite and dihydrolipoic acid or flavin adenine 
dinucleotide.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of β-lapachone in the presence of 40g/L albumin (____), 
40g/L albumin and 25µM menadione (_ _ _ _), 40g/L albumin and 
1µΜ geftinib (_  _), 40g/L albumin and 0.5mM thiosulfate  
(…..  …..), 40g/L albumin and 16µM/32µM selenite/dihydrolipoic acid 
(__o__) or 40g/L albumin and 100µΜ flavin adenine dinucleotide (__x __). 
The therapeutic range (TR) in which β-lapachone can be used in vivo is 
illustrated at the top left corner of the figure. Data points are the mean + SD 
of three determinations.  
 
 143 
Table 37 A statistical analysis of the lethal dose estimates of β-
lapachone in the presence of human serum albumin including menadione or 
geftinib or thiosulfate or a combination of selenite and dihydrolipoic acid or 
flavin adenine dinucleotide in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
Lap Alb 39 0 39a  
Lap Menad Alb 40 12 39c 
 
[39a] P > 0.05 (NS) 
[39b] P > 0.05 (NS) 
[39d] P > 0.05 (NS) 
Lap Thio Alb 38 14 39b 
 
[39a] P > 0.05 (NS) 
 
Lap Geft Alb 36 9 39d 
 
[39a] P > 0.05 (NS) 
[39b] P > 0.05 (NS) 
 
Lap FAD Alb 31 5 39e 
 
[39a] P > 0.05 (NS) 
[39b] P > 0.05 (NS) 
[39c] P > 0.05 (NS) 
[39d] P > 0.05 (NS) 
 
Lap DHLA Senite Alb 31 5 39f 
 
[39a] P > 0.05 (NS) 
[39b] P > 0.05 (NS) 
[39c] P > 0.05 (NS) 
[39d] P > 0.05 (NS) 
[39e] P > 0.05 (NS) 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 39 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Lap, β-Lapachone]; [Alb, Albumin]; [Menad, Menadione]; [Thio, 
Thiosulfate]; [Geft, Geftinib]; [FAD, Flavine adenine dinucleotide]; 
[DHLA, Dihydrolipoic acid]; [Senite, Selenite]; [Ref.Fig , Reference 
Figure]. 
 144 
 
Figure 40 The effect of β-lapachone on the death of MCF-7 cells in the 
presence of human serum albumin and a combination of selenite and 
dihydrolipoic acid or flavin adenine dinucleotide. 
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of β-lapachone in the presence of 40g/L albumin (_  _), 
40g/L albumin and 16µM/32µM selenite/dihydrolipoic acid (__o__) or 40g/L 
albumin and 100µM flavin adenine dinucleotide (__x _). The therapeutic 
range (TR) in which β-lapachone can be used in vivo is illustrated at the top 
left corner of the figure. Data points are the mean + SD of three 
determinations.  
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Table 38 A statistical analysis of the lethal dose estimates of β-
lapachone in the presence of human serum albumin including a 
combination of selenite and dihydrolipoic acid or flavin adenine 
dinucleotide in MCF-7 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
Lap Alb 33 8 40a  
Lap FAD Alb 31 5 40b 
 
[40a] P > 0.05 (NS) 
[39e] P > 0.05 (NS) 
 
Lap DHLA Senite Alb 29 4 40c 
 
[40a] P > 0.05 (NS) 
[40b] P > 0.05 (NS) 
[39f]  P > 0.05 (NS)  
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 40 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Lap, β-Lapachone]; [Alb, Albumin]; [FAD, Flavin adenine dinucleotide]; 
[DHLA, Dihydrolipoic acid]; [Senite, Selenite]; [Ref.Fig , Reference 
Figure].   
 
 
 
 
 
 
 
 146 
In JU77 cells, oxamate or iodoacetate (inhibitors of glycolysis) were 
combined with a trisulphide combination comprising selenite, 
selenomethionine and mercaptoethanol in the presence of human serum 
albumin. Under these conditions both compounds increased cell death with 
the trisulphide combination reducing the total concentration of trisulphide 
substantially (Figure 41 and table 39, all p<0.001). Increasing glycolysis 
inhibition enhanced the percentage of cell death (table 39, p<0.001). 
 
3.1.9 Combinations with antibiotics 
Cytostatic and cytotoxic activity of antibiotics against various tumour cell 
lines has been reported. Tetracyclines such as doxycycline seem to inhibit 
the activity of glutathione S-transferase isozymes (Mukanganyama et.al. 
2002) as well as the cleavage of matrix metalloproteinases (Saikali and 
Singh 2003). The combination of trimethoprime-sulphamethoxazole is 
reported to correlate strongly with the reduction of uric acid (Chertow et.al. 
1996). Both compounds increase cell death of trisulphides. 
 
As illustrated in Figure 42, the three cell lines JU77, MCF-7 and Caco-2 
displayed different sensitivities to the combination of cotrim (a two step 
tetrahydrofolic acid inhibitor) and selenodimethionine in the presence of 
human serum albumin (table 40). All JU77 cells were killed with this 
combination in human serum albumin, but the viability of MCF-7 cells and 
Caco-2 cells was only partially reduced. In contrast, Figure 43 illustrates 
that combining doxycycline (an inhibitor of the prokaryotic 30S ribosome) 
with selenodimethionine promoted cell death in all MCF-7 cells in human 
serum albumin, but JU77 cells and Caco-2 cells were only partially affected 
(table 41). 
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Figure 41 The effect of a combination of selenite and selenomethionine 
on the death of JU77 cells in the presence of human serum albumin, 
mercaptoethanol and iodoacetate or oxamate.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of selenite and selenomethionine in the presence of 40g/L 
albumin, 40µΜ mercaptoethanol and 100µM iodoacetate (__o__), 40g/L 
albumin, 40µΜ mercaptoethanol and 20µM iodoacetate (-- x --), 40g/L 
albumin, 40µΜ mercaptoethanol and 2mM oxamate (____) and 40g/L 
albumin (40g/L), 40µΜ mercaptoethanol and 1mM oxamate (__ _ ). Data 
points are the mean + SD of three determinations.  
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Table 39 A statistical analysis of the lethal dose estimates of selenite, 
selenomethionine and mercaptoethanol in the presence of human serum 
albumin including  iodoacetate or oxamate in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
IAA100 Merc Seme 
Senite Alb 0 0 41d 
 
[41a] P < 0.001*** 
[41b] P > 0.05 (NS) 
[41c] P < 0.001*** 
[36b] P < 0.001*** 
 
IAA20 Merc Seme 
Senite Alb 16 1 41c 
 
[41a] P < 0.001*** 
[41b] P < 0.001*** 
[36b] P < 0.001*** 
 
Ox2 Merc Seme 
Senite Alb 8 1 41b 
 
[41a] P < 0.001*** 
[36b] P < 0.001*** 
  
 
Ox1 Merc Seme 
Senite Alb 
 
16 2 41a [36b] P < 0.001*** 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 41 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[IAA, Iodoacetate]; [Ox, Oxamate]; [Merc, Mercaptoethanol]; [Seme, 
Selenomethionine]; [Senite, Selenite]; [Alb, Albumin]; [Ref.Fig , Reference 
Figure].   
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Figure 42 The effect of cotrim (trimethoprime/sulfamethoxazole) and a 
combination of selenite and selenomethionine on the death of JU77 cells, 
MCF-7 cells and Caco-2 cells in the presence of human serum albumin.  
JU77 cells (     ), MCF-7 cells (     ) and Caco-2 cells (     ) in their 
exponential growth phase were treated with 20µΜ/20µM 
selenite/selenomethionine and 10µM cotrim in 40g/L albumin or 10µM 
cotrim in 40g/L albumin. Data points are the mean + SD of three 
determinations.  
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Table 40 A statistical analysis of the lethal effects of selenite and 
selenomethionine in the presence of human serum albumin including cotrim 
or a combination of trisulfide and cotrim in JU77, MCF-7 and Caco-2 cells.  
 
Description LE 
%CD 
SEM 
 
Ref. 
Fig  
Level of Significance  
Comparison to [Fig x] 
Tris Cotr Alb (JU77) 
 
100 0 40g [40a] P < 0.001*** 
[40d] P < 0.001*** 
[40h] P > 0.05 (NS) 
[40i] P < 0.05 * 
 
Tris Cotr Alb (MCF-7) 
 
76 10.69 40h [40b] P < 0.001*** 
[40e] P < 0.001*** 
[40i] P > 0.05 (NS) 
 
 
Tris Cotr Alb (Caco-2) 69 3.51 40i [40c] P < 0.001*** 
[40f] P > 0.05 (NS) 
 
Cotr Alb (JU77) 
 
55 4.00 40d [40a] P < 0.001*** 
[40e] P > 0.05 (NS) 
[40f] P > 0.05 (NS) 
 
Cotr Alb (MCF-7) 35 2.08 40e [40b] P < 0.05 * 
[40f] P < 0.05 * 
 
Cotr Alb (Caco-2) 63 9.10 40f [40c] P < 0.001*** 
Alb (JU77) 2 0.58 40a [40b] P > 0.05 (NS) 
[40c] P > 0.05 (NS) 
 
Alb (MCF-7) 4 1.15 40b [40c] P > 0.05 (NS) 
 
Alb (Caco-2) 3 1.73 40c   
 
Lethal effects of compounds and their combinations were compared by 
ANOVA, Benferroni and Tukey-Kramer Multiple Comparison Tests as 
detailed in the Methods. By conventional criteria the data is considered to 
be not statistically significant (NS), statistically significant (*), very 
statistically significant (**), or extremely statistically significant (***). 
Abbreviations: [Tris, Trisulfide]; [Cotr, Cotrim]; [Alb, Albumin]; [LE 
%CD, Lethal effect in % cell death]; [Ref. Fig , Reference Figure]. 
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Figure 43 The effect of doxycycline and a combination of selenite and 
selenomethionine on the death of JU77 cells, MCF-7 cells and Caco-2 cells 
in the presence of human serum albumin.  
JU77 cells (     ), MCF-7 cells (     ) and Caco-2 cells (     ) in their 
exponential growth phase were treated with 20µM/20µM 
selenite/selenomethionine and 1mM doxycycline in 40g/L albumin or 1mM 
doxycycline in 40g/L albumin. Data points are the mean + SD of three 
determinations.  
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Table 41 A statistical analysis of the lethal effects of selenite and 
selenomethionine in the presence of human serum albumin including 
doxycycline or a combination of trisulfide and doxycycline in JU77, MCF-
7 and Caco-2 cells.  
 
Description LE 
%CD 
SEM 
 
Ref. 
Fig  
Level of Significance  
Comparison to [Fig x] 
Tris Doxy Alb 
(JU77) 
 
34 4.93 40g [40a] P < 0.001*** 
[40d] P < 0.001*** 
[40h] P < 0.001*** 
[40i]  P < 0.001*** 
 
Tris Doxy Alb 
(MCF-7) 
 
100 0 40h [40b] P < 0.001*** 
[40e] P < 0.001*** 
[40i]  P < 0.001*** 
 
Tris Doxy Alb 
(Caco-2) 
74 4.04 40i [40c] P < 0.001*** 
[40f]  P < 0.001*** 
 
Doxy Alb (JU77) 
 
8 1.53 40d [40a] P > 0.05 (NS) 
[40e] P < 0.001*** 
[40f]  P < 0.001*** 
 
Doxy Alb (MCF-7) 56 4.73 40e [40b] P < 0.001*** 
[40f]  P > 0.05 (NS) 
 
Doxy Alb (Caco-2) 
 
46 2.52 40f [40c] P < 0.001*** 
Alb (JU77) 3 0.58 40a [40b] P > 0.05 (NS) 
[40c] P > 0.05 (NS) 
 
Alb (MCF-7) 3 1.16 40b [40c] P > 0.05 (NS) 
 
Alb (Caco-2) 3 1.16 40c   
 
Lethal effects of compounds and their combinations were compared by 
ANOVA, Benferroni and Tukey-Kramer Multiple Comparison Tests as 
detailed in the Methods. By conventional criteria the data is considered to 
be not statistically significant (NS), statistically significant (*), very 
statistically significant (**), or extremely statistically significant (***). 
Abbreviations: [Tris, Trisulfide]; [Doxy, Doxycycline]; [Alb, Albumin]; 
[LE %CD, Lethal effect in % cell death]; [Ref. Fig , Reference Figure]. 
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3.1.10 Combinations with diethylmaleate 
Diethylmaleate depletes glutathione and increases L-cysteine transport 
across the membrane (Ruiz et.al. 2003). The viability of JU77 cells and 
MCF cells exposed to diethylmaleate decreased in a linear manner in 
human serum albumin (Figure 44). A combination of 0.4mM 
diethylmaleate with selenodimethionine reduced the concentration of 
selenodimethionine in both cell lines (table 42, p > 0.05 (NS)). This 
decreased the minimal concentration needed to kill either cell population to 
estimated 29µM selenite and selenomethionine, in the presence of human 
serum albumin (Figure 45, 46 and table 43, 44).  
3.1.11 Combinations with hydrogen peroxide 
Hydrogen peroxide (H2O2) is an important mediator of cellular signalling. 
H2O2 is involved in survival signalling, angiogenesis, cell adhesion and 
other cell functions. It induces a dose-related apoptosis (Zhou et.al. 2007).  
 
Hydrogen peroxide decreased the viability of all four cell lines. However, 
the sensitivity of the four cell lines differed, decreasing in their estimated 
LD100 values in the following order: HepG2 cells, Caco-2 cells, JU77 cells 
and MCF-7 cells (Figure 47and table 45).  
 
The potency of H2O2 increased in combination with some β-adrenergic 
compounds, as illustrated in Figure 48. In JU77 cells, adrenaline effectively 
reduced the concentration of H2O2 by 50% (table 46, p<0.01). Salbutamol 
did not significantly change the concentration of H2O2 in the presence of 
human serum albumin (table 46, p>0.05 (NS)). 
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Figure 44 The effect of diethylmaleate on the death of JU77 and MCF-7 
cells in the presence of human serum albumin.  
JU77 cells (__o__) and MCF-7 cells (__x _) in their exponential growth phase 
were treated with varying concentrations of diethylmaleate in the presence 
of 40g/L albumin. Data points are the mean + SD of three determinations.  
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Table 42 A statistical analysis of the lethal dose estimates of 
diethylmaleate in the presence of human serum albumin in JU77 and MCF-
7 cells. 
 
Description LD100 
(mM) 
SEM 
(mM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
DEM Alb (JU77) 1923 94 
 
[44b] 
 
 
DEM Alb (MCF-7) 1899 
 
133 
 
 
[44a] 
 
[44b] P > 0.05 (NS) 
 
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 44 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[DEM, Diethylmaleate]; [Alb, Albumin]; [Ref.Fig , Reference Figure].   
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Figure 45 The effect of a combination of selenite and selenomethionine 
on the death of JU77 cells in the presence of human serum albumin and 
diethylmaleate.  
JU77 cells in their exponential growth phase were treated with varying 
concentrations of selenodimethionine in 40g/L albumin in the presence 
(__o_ ) or absence  (__x _) of 400µM diethylmaleate. Data points are the 
mean + SD of three determinations.  
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Table 43 A statistical analysis of the lethal dose estimates of a selenite 
and selenomethionine in the presence of human serum albumin including 
diethylmaleate in JU77 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
DEM Tris Alb 29 3 45b [45a] P < 0.001*** 
Tris Alb 48 4 45a  
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 45 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Tris, Trisulfide]; [DEM, Diethylmaleate]; [Alb, Albumin]; [Ref.Fig , 
Reference Figure].   
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Figure 46 The effect of a combination of selenite and selenomethionine 
on the death of MCF-7 cells in the presence of human serum albumin and 
diethylmaleate.  
MCF-7 cells in their exponential growth phase were treated with varying 
concentrations of selenodimethionine in 40g/L albumin in the presence  
(__x _) or absence (__o__) of 400µM diethylmaleate. Data points are the mean 
+ SD of three determinations. 
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Table 44 A statistical analysis of the lethal dose estimates of selenite 
and selenomethionine in the presence of human serum albumin including 
diethylmaleate in MCF-7 cells. 
 
Description LD100 
(µM) 
SEM 
(µM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
DEM Tris Alb 29 3 46b 
 
[46b] P < 0.001*** 
[45b] P > 0.05 (NS) 
Tris Alb 47 3 46a  
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 46 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Tris, Trisulfide]; [DEM, Diethylmaleate]; [Alb, Albumin]; [Ref.Fig , 
Reference Figure].   
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Figure 47 The effect of hydrogen peroxide on the death of JU77, MCF-7, 
Caco-2 and HepG2 cells.  
JU77 cells (….o….), MCF-7 cells (-- x --), Caco-2 cells (__ _ ) and HepG2 
cells (__ __) in their exponential growth phase were treated with varying 
concentrations of hydrogen peroxide in the presence of 40g/L albumin. Data 
points are the mean + SD of three determinations.  
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Table 45 A statistical analysis of the lethal dose estimates of hydrogen 
peroxide in the presence of human serum albumin in JU77, MCF-7, Caco-2 
and HepG2 cells. 
 
Description LD100 
(mM) 
SEM 
(mM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
H2O2 Alb (JU77) 2 0 47c 
 
[47a] P < 0.05 * 
[47b] P < 0.001*** 
[47d] P > 0.05 (NS) 
 
H2O2 Alb (MCF-7) 1 0 47d 
 
[47a] P > 0.05 (NS) 
[47b] P < 0.05 * 
 
H2O2 Alb (HepG) 4 1 47b [47a] P > 0.05 (NS) 
H2O2 Alb (Caco-2) 3 0 47a  
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 47 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[H2O2, Hydrogenperoxide]; [Alb, Albumin]; [Ref.Fig , Reference Figure].   
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Figure 48 The effect of hydrogen peroxide on the death of JU77 cells in 
the presence of human serum albumin and β-adrenergic compounds.  
 
JU77 cells in their exponential growth phase were treated with varying 
concentrations of hydrogen peroxide in the presence of 40g/L albumin  
(_  _), 40g/L albumin and 1µM salbutamol (__o__) or 40g/L albumin and 
50nM adrenaline (__x _). Data points are the mean + SD of three 
determinations.  
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Table 46 A statistical analysis of the lethal dose estimates of hydrogen 
peroxide in the presence of human serum albumin including β-adrenergic 
compounds. 
 
Description LD100 
(mM) 
SEM 
(mM) 
Ref. 
Fig  
Level of Significance  
Comparison to 
 [Fig x] 
Salb/H202/Alb 2 0.2 48a 
 
[48b] P < 0.01 **  
[48c] P > 0.05 (NS) 
 
Adren/H202/Alb 1 0.2 48c [48b] P < 0.01 ** 
H202/Alb 2 0.2 48b  
 
Lethal doses were estimated by Probit analysis of the data illustrated in 
Figure 48 as described in the Methods. Data were compared by ANOVA, 
Benferroni and Tukey-Kramer Multiple Comparison Tests as detailed in the 
Methods. By conventional criteria the data is considered to be not 
statistically significant (NS), statistically significant (*), very statistically 
significant (**), or extremely statistically significant (***). Abbreviations: 
[Salb, Salbutamol]; [Adren, Adrenaline]; [H2O2, Hydrogenperoxide]; 
[Ref.Fig , Reference Figure].   
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3.2  The effect of selenium, selenomethionine and lithium chloride on 
arachidonic acid metabolism in JU77 cells 
 
Loss of cancer cell viability is reported to be intimately linked to changes in 
metabolism of arachidonic acid. Inhibiting enzymatic breakdown of 
arachidonic acid has been reported to decrease viability of cancer cells. 
Therefore, concentration levels of arachidonic acid metabolites were 
measured in JU77 cells while treating with lithium chloride, selenite and 
selenomethionine. As arachidonic acid can be metabolised by 
cyclooxygenases or lipoxygenases, concentrations of prostaglandin E2, 
leukotriene C and leukotriene B4 were determined.  
 
Complex and variable changes in the concentration of metabolites of 
arachidonic acid were noted after six hours of treatment of the cells. Figure 
49 illustrates expression of prostaglandin E2 levels by JU77 cells in the 
presence of the compounds. Lithium chloride or lithium chloride and 
selenomethionine reduced prostaglandin E2 levels below vehicle levels. All 
other treatments including the triple compound combination increased the 
levels of prostaglandin E2. 
 
No significant reduction of leukotriene C concentration was observed when 
cells were treated with lithium chloride or lithium chloride and 
selenomethionine relative to the vehicle control (Figure 50). However, 
selenite or lithium chloride and selenite increased the concentration of 
leukotriene C. Interestingly, the triple concentration of lithium chloride, 
selenite and selenomethionine did not alter leukotriene C levels. 
 
Lithium chloride or lithium chloride and selenomethionine reduced the 
concentration of leukotriene B4 levels below vehicle treatments (Figure 
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51). All other treatments, including the triple combination increased 
leukotriene B4 levels.   
 
After treating JU77 cells for 24 hours, prostaglandin E2 levels increased in 
the presence of lithium chloride and selenite (Figure 49). In all other cases, 
prostaglandin E2 synthesis plateaued. Expression of leukotriene C was 
elevated with selenite, lithium chloride and selenite, selenite and 
selenomethionine or lithium chloride, selenite and selenomethionine 
(Figure 50). Leukotriene B4 levels increased during treatment with lithium 
chloride and selenite and also plateaued in all other cases (Figure 51).  
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Figure 49 Expression of prostaglandin E2 by JU77 cells in the presence 
of various compounds.  
JU77 cells in their exponential growth phase were treated with 0.5mM 
lithium chloride ( Li ), 0.5mM lithium chloride and 30µM selenite ( Li+Se 
), 0.5mM lithium chloride and 30µM selenomethionine ( Li+SeM ), 30µM 
selenite ( Se ), 30µM selenite and 30µM selenomethionine ( Se+SeM ), 
30µM selenomethionine ( SeM ), 0.5mM lithium chloride and 30µM 
selenite and 30µM selenomethionine 
( Se+SeM+Li ), no treatment ( No treatment ) and prostaglandin E2 levels 
were measured after 6 and 24 hours. 
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Figure 50 Expression of leukotriene C4 by JU77 cells in the presence of 
various compounds.  
JU77 cells in their exponential growth phase were treated with 0.5mM 
lithium chloride ( Li ), 0.5mM lithium chloride and 30µM selenite ( Li+Se 
), 0.5mM lithium chloride and 30µM selenomethionine ( Li+SeM ), 30µM 
selenite ( Se ), 30µM selenite and 30µM selenomethionine ( Se+SeM ), 
30µM selenomethionine ( SeM ), 0.5mM lithium chloride and 30µM 
selenite and 30µM selenomethionine (Se+SeM+Li ), no treatment ( No 
treatment ) and leukotriene C4 levels were measured after 6 and 24 hours. 
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Figure 51 Expression of leukotriene B4 by JU77 cells in the presence of 
various compounds.  
JU77 cells in their exponential growth phase were treated with 0.5mM 
lithium chloride ( Li ), 0.5mM lithium chloride and 30µM selenite ( Li+Se), 
0.5mM lithium chloride and 30µM selenomethionine ( Li+SeM ), 30µM 
selenite ( Se ), 30µM selenite and 30µM selenomethionine ( Se+SeM ), 
30µM selenomethionine ( SeM ), 0.5mM lithium chloride and 30µM 
selenite and 30µM selenomethionine( Se+SeM+Li ), no treatment ( No 
treatment ) and leukotrien B4 levels were measured after 6 and 24 hours. 
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3.3   The effect of a combinations of lithium chloride, selenite and 
selenomethionine on JU77 mesothelioma grown in a xenograft 
model in mice 
Tumour-xenografts are useful tools enabling critical comparison between 
tumourigenic and normal tissues (Double and Bibby 1989). In this study, a 
mesothelioma tumour model was developed in nude balb/c mice as detailed 
in the Methods section 3.2.6.2 and 3.2.6.3. A cell number of 107 human 
tumour cells (JU77) were injected into nude balb/c mice in phosphate 
buffered saline following a standard protocol (Xia et.al. 2000). In general, it 
is presumed that if a tumour cell line is “tumourigenic” and the animals 
accept the injected tumour cells, self-perpetuation of tumour growth will 
follow. However, the growth of the mesothelioma tumours developed in 
this study required that insulin-like growth factor-1 be co-injected daily into 
the nude balb/c mice. This enhanced tumour onset of JU77 cells and once-
daily injections of insulin-like growth factor-1 maintained tumour growth. 
This observation is consistent with a study of Haluska et.al. 2006, who 
reported that overactivation and/or overexpression of insulin-like growth 
factor-1 receptor contributes to tumourigenicity.  
3.3.1 Animal control studies 
JU77 human mesothelioma tumours were grown in nude mice for 4 days. 
On a daily basis, insulin-like growth factor-1 was injected subcutaneously 
to enable tumour growth of JU77 cells. Then, tumours were treated with 
lithium chloride, selenite and selenomethionine and combinations thereof 
while treatment with insulin-like growth factor-1 was continued (Figure 52-
54) Treatments with single compounds did not change the rate of tumour 
growth relative to the treatment with vehicle alone (Figure 52-53 & Table 
47). Similarly, dual treatments using lithium chloride and selenite or 
lithium chloride and selenomethionine did not change the rate of tumour 
growth relative to the treatment with vehicle alone (Figure 52-53 & Table 
47).  
 170 
 
 
  
  
 
 
 
Figure 52  The effect of various treatments on JU77 tumour size in 
individual nude mice 
JU77 human mesothelioma tumours were grown in nude mice as described 
in the Methods. Treatments began on day 4 of tumour growth: A vehicle 
only (n=4); B, selenite (n=4); C, selenomethionine (n=4); D, tithium (n=4); 
E, selenium and lithium (n=3); F selenomethionine and lithium (n=3); (G), 
selenium and selenomethionine (n=3); (H) selenium, selenomethionine and 
lithium (n=4). Data for individual mice are shown.  
A B 
C D 
E F 
G H 
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Figure 53 The effect of various treatments on JU77 tumour size in nude 
mice (mean +/- SE) with trend line following onset of treatment shown 
JU77 human mesothelioma tumours were grown in nude mice as described 
in the Methods. Treatments began on day 4 of tumour growth: A vehicle 
only (n=4); B, selenite (n=4); C, selenomethionine (n=4); D, tithium (n=4); 
E, selenium and lithium (n=3); F selenomethionine and lithium (n=3); (G), 
selenium and selenomethionine (n=3); (H) selenium, selenomethionine and 
lithium (n=4). Data is illustrated as the mean plus or minus the standard 
error. Slopes were fitted to the data from day 4 with statistical comparisons 
of the trends provided in Table 47. 
A B 
C D 
E F 
G H 
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Table 47 A statistical analysis of the effect of various treatments on 
JU77 tumour size in nude mice 
 
Treatment Calculated 
Slope 
Probability that slope fitting 
treatment is different to vehicle 
 
A) Vehicle alone 
 
 
3.4 +/-  0.9 
 
 
 
B) Selenite 
 
 
2.5 +/- 1.4 
 
P = 0.576 (Not Significant)  
 
 
C) Semethionine 
 
 
2.6 +/- 0.3 
 
P = 0.431 (Not Significant)  
 
 
D) Lithium chloride 
 
 
2.8 +/- 0.8 
 
P = 0.626 (Not Significant)  
 
 
E) Selenite & Lithium 
chloride 
 
2.1 +/- 1.2 
 
P = 0.396 (Not Significant)  
 
 
F) Selenomethionine & 
Lithium choride 
 
1.5 +/- 0.9 
 
P = 0.168 (Not Significant)  
 
 
G) Selenite & 
Selenomethionine 
 
-0.2 +/- 1.1 
Slope does not differ 
significantly from zero 
(P=0.86) 
 
P = 0.020 (Significant) 
H)   Selenite, 
Selenomethionine & 
Lithium chloride 
 
-5.0 +/- 0.8 
 
 
P < 0.0001(Extremely Significant) 
 
 
The slope of each data set in Figure 53 was determined as a function of 
time following the initiation of a treatment on day 4. The probability that 
slope fitting the treatment was different to vehicle or different from zero 
was determined as described in Methods section 2.2.7.4 
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However, a dual treatment using selenite and selenomethionine reduced the 
growth of the JU77 mesothelioma tumours (Figure 52G, 53G). This effect 
was statistically significant (Table 47). Finally, the triple combination of 
lithium chloride, selenite and selenomethionine dramatically regressed the 
growth of tumours (Figure 52G, 53G and Table 47). Irrespective of the 
treatments, there was no significant weight loss with any treatment (Figure 
54, Table 48). 
 
To further evaluate the effects of the triple combination of lithium chloride, 
selenite and selenomethionine, a more detailed study was conducted and 
both tissue and blood samples were collected at different stages of the 
treatment. Tumours were grown for four days with daily subcutaneous 
injections of insulin-like growth factor-1. This ensured tumour growth over 
the period of treatment (Figure 55B). From day four onwards, a 
chemotherapeutic combination of lithium chloride (75µg once daily), 
selenite and selenomethionine (each 70µg twice daily, combined 
administration) was injected into the peritoneum. This treatment again led 
to a rapid decrease in tumour size, despite the daily administration of 
insulin-like growth factor-1. Tumours were not visible after another five 
days of treatment (Figure 55A). The controls were treated with carrier and 
insulin-like growth factor-1 twice daily and tumours continued to grow 
until they finally reached a steady-state (Figure 55B). When chemotherapy 
began, the weight of tumour-bearing animals dropped about 10% on first 
day, but this weight loss was not statistically significant and the animals 
maintained their weight thereafter (Figure 55C). The weight also did not 
change significantly in carrier-treated animals over the duration of the 
experiment (Figure 55D).   
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Figure 54 The effect of various treatments on body weight of nude mice 
(mean +/- SE) with trend line following onset of treatment shown. 
JU77 human mesothelioma tumours were grown in nude mice as described 
in the Methods. Treatments began on day 4 of tumour growth: A vehicle 
only (n=4); B, selenite (n=4); C, selenomethionine (n=4); D, tithium (n=4); 
E, selenium and lithium (n=3); F selenomethionine and lithium (n=3); (G), 
selenium and selenomethionine (n=3); (H) selenium, selenomethionine and 
lithium (n=4). Data is illustrated as the mean plus or minus the standard 
error. Slopes were fitted to the data from day 4 with statistical comparisons 
of the trends provided in Table 48.  
A B 
C D 
E F 
G H 
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Table 48 A statistical analysis of the effect of various treatments on 
body weight of nude mice 
 
Treatment Calculated 
Slope 
Probability that slope fitting 
treatment is different to vehicle 
 
G) Vehicle alone 
 
 
-0.1 +/-  0.2 
 
 
 
H) Selenite 
 
 
-0.4 +/- 0.2 
 
P = 0.412 (Not Significant)  
 
 
I) Semethionine 
 
 
-0.2 +/- 0.1 
 
P = 0.769 (Not Significant)  
 
 
J) Lithium chloride 
 
 
0.0 +/- 0.2 
 
P = 0.607 (Not Significant)  
 
 
K) Selenite & Lithium 
chloride 
 
-0.3 +/- 0.1 
 
P = 0.497 (Not Significant)  
 
 
L) Selenomethionine & 
Lithium choride 
 
-0.3 +/- 0.1 
 
P = 0.497 (Not Significant)  
 
 
G) Selenite & 
Selenomethionine 
 
-0.3 +/- 0.2 
 
 
P = 0.449 (Not Significant) 
H)   Selenite, 
Selenomethionine & 
Lithium chloride 
 
-0.5 +/- 0.3 
 
 
P = 0.279 (Not Significant) 
 
 
The slope of each data set in Figure 54 was determined as a function of 
time following the initiation of a treatment on day 4. The probability that 
slope fitting the treatment was different to vehicle or different from zero 
was determined as described in Methods section 2.2.7.4 
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Figure 55 The effect of a combination of lithium chloride, selenite and 
selenomethionine on the tumour size of growth-factor maintained JU77 
tumours in nude balb/c mice. 
 JU77 cells were injected subcutaneously into the left groin of six week old 
male, nude balb/c mice. Insulin-like growth factor-1 was injected 
subcutaneously into the groin on the side opposite to the tumour on a daily 
basis throughout the entire experiment. After four days, the tumour-bearing 
nude mice were injected intraperitoneally with either phosphate-buffered 
saline (captions B & D) or a combination of selenite, selenomethionine and 
lithium chloride in phosphate-buffered saline (captions A & C). Animals 
were sacrificed after either 0, 4, 6.5 or 9 days and tissues collected for 
histopathological analysis. Tumour size (mm2) was measured daily with an 
electronic calliper (captions A & B). Animals were weighed daily (captions 
C & D). Refer to Methods section 3.7.4 and 3.7.5 for additional details of 
this experiment. 
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3.2.2 Haematology and biochemistry 
Haematological and biochemical parameters were recorded before and after 
treatment. Data collected for the nude balb/c mice were also compared with 
control values of normal inbred C57/BL6 mice published in 2007 by 
Boehm et.al. 
 
The haematology parameters are illustrated in Figure 56. A significant 
change in the red blood cell count of nude balb/c mice was observed when 
comparing the two treatments (compound/IGF-1 and IGF-1) against no 
treatment. In both treatments, insulin-like growth factor-1 increased the 
total red blood cell count. However, no significant difference in red blood 
cell count was seen between treatment with compound/IGF-1 and treatment 
with IGF-1 only. In addition, although insulin-like growth factor-1 
increased the white blood cell count, the increase in the white cell count 
was only significant between compound/IGF-1 and the non-treated group 
and not between IGF-1 and the non-treated group or between the two 
treated groups. Interestingly, the white cell counts in control nude balb/c 
mice were significantly elevated relative to reported values of C57BL/6 
mice.  
 
Figure 57 compares the biochemical parameters in serum affected by the 
treatment with insulin-like growth factor-1 or the chemotherapy relative to 
control animals. The biochemical parameters that were measured in serum 
were aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
gamma glutamyltransferase (GGT), lactate dehydrogenase (LDH), 
bilirubin, albumin, total protein, glucose, calcium, phosphate, alkaline 
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Figure 56 The effect of a combination of lithium chloride, selenite and 
selenomethionine on the haematological parameters of growth factor-
maintained, JU77 tumour-bearing nude mice.  
Six week old male nude balb/c mice were treated for nine days either with 
75ug lithium chloride once daily, 70ug selenite and 70ug selenomethionine 
twice daily and insulin-like growth factor-1 (IGF-1) once daily (     ) or only 
with insulin-like growth factor-1 (IGF-1) once daily (     ) and haematology 
parameters were determined. A non-treated control group (     ) displayed 
the normal values in the nude balb/c mouse. The shaded area illustrates the 
normal range for C57BL/6 mice (adapted from Boehm et.al. 2006). Data 
points are the mean + SD of three determinations.  
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Figure 57 The effect of a combination of lithium chloride, selenite and 
selenomethionine on the biochemical parameters of growth factor-
maintained, JU77 tumour-bearing nude mice.  
Six week old male nude balb/c mice were treated for nine days either with 
75ug lithium chloride once daily, 70ug selenite and 70ug selenomethionine 
twice daily and insulin-like growth factor-1 (IGF-1) once daily (     ) or only 
with insulin-like growth factor-1 (IGF-1) once daily (      ) and biochemistry 
parameters were determined. A non-treated control group (      ) displayed 
the normal values in the nude balb/c mouse. The shaded area illustrates the 
normal range for C57BL/6 mice (adapted from Boehm et.al. 2006). Data 
points are the mean + SD of three determinations. 
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phosphatase (ALP), creatine kinase (CK), amylase, urea, creatinine, 
sodium, potassium, bicarbonate.  
 
Relevant changes of biochemical parameters were observed with 
administration of insulin-like growth factor-1 for aspartate 
aminotransferase, alanine aminotransferase, phosphate and creatine kinase. 
These parameters did not change more than threefold above the upper limit. 
Lactate dehydrogenase, a parameter which is very sensitive to hemolysis, 
was also elevated above the limits. This parameter is not illustrated because 
it was impossible to distinguish between the effects of (irrelevant) 
hemolysis and treatment. Chemotherapeutic treatment reversed elevation of 
parameters due to insulin-like growth factor-1 into the normal range. 
However, phosphate stayed on a twofold increased level. 
3.2.3 Histopathology 
Many hundreds of histopathological slides were made from tumours and 
normal tissues according to standard pathological procedures. The slides 
were stained with hematoxylin and eosin. Tumour tissues and normal 
tissues were collected from tumour-bearing animals that had been treated as 
follows: 
 for 4 days with insulin-like growth factor-1 
 for 6.5 days with insulin-like growth factor-1 and simultaneously for  
2.5 days with lithium chloride and selenodimethionine (days 4-6.5) 
 for 9 days with insulin-like growth factor-1 and simultaneously for 
5 days with lithium chloride and selenodimethionine (days 4-9) 
The chronological sequence of the histological changes in the tumour 
tissues is illustrated in Figure 58-63.  
 
Figure 58 illustrates a JU77 tumour grown subcutaneously for four days 
with insulin-like growth factor-1 administration. The neoplasm consists of a  
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Figure 58   The histopathological structure of a mesothelioma JU77 tumour 
grown subcutaneously for four days with daily application of IGF-1:  
The neoplasm consists of a central necrotic area surrounded by a relatively 
thick peripheral layer of closely packed malignant cells. The thickness of 
the neoplastic layer is generally regular. H&E, Mag.x100. 
 
 
 
Figure 59 The composition of the peripheral layer of a mesothelioma 
JU77 tumour grown for four days with daily application of IGF-1:  
The peripheral layer of the neoplasm is composed of large polygonal cells 
which are closely opposed and possess large mildly irregular nuclei with 
much euchromatin and multiple large nucleoli. A small proportion of these 
cells are in mitosis while others show evidence of apoptosis. H&E, 
Mag.x400 
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Figure 60 The histopathological structure of a mesothelioma JU77 
tumour grown for 6.5 days with daily application of IGF-1 and treated for 
2.5 days with application of lithium chloride once daily and selenite and 
selenomethionine twice daily:  
Much of the tumour is necrotic. A thin, irregular, fragmented layer of 
neoplastic cells can be seen at the periphery. H&E, Mag.x100 
 
 
 
Figure 61 The composition of the peripheral layer of a mesothelioma 
JU77 tumour grown for 6.5 days with daily application of IGF-1 and treated 
for 2.5 days with application of lithium chloride once daily and selenite and 
selenomethionine twice daily:  
Most of the tumour is necrotic. However, a few scattered neoplastic cells 
can still be seen at the periphery. H&E, Mag.x400 
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Figure 62 The histopathological structure of a mesothelioma JU77 
tumour grown for 9 days with daily application of IGF-1 and treated for 5 
days with application of lithium chloride once daily and selenite and 
seleno-methionine twice daily  
No neoplastic cells can be seen, and the tumour consists of scattered small 
clusters of necrotic tissue. An inflammatory infiltrate surrounds the necrotic 
tissue. H&E, Mag.x100 
 
 
 
Figure 63 A magnified view of the clusters of necrotic tissue of a 
mesothelioma JU77 tumour grown for 9 days with daily application of IGF-
1 and treated for 5 days with lithium chloride once daily and selenite and 
selenomethionine twice daily  
No intact neoplastic cells can be discerned; only necrotic tissue can be seen. 
H&E, Mag.x200   
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central necrotic area surrounded by a thick peripheral layer of closely 
packed JU77 cells. The thickness of the neoplastic layer is generally 
regular. As highlighted in Figure 59, large polygonal cells form this layer. 
They contain large mildly irregular nuclei with much euchromatin and 
multiple large nucleoli. Some of them are replicating while others show 
evidence of apoptosis. 
 
Figure 60 illustrates the first structural changes of the mesothelioma JU77 
tumour after 2.5 days of treatment with lithium chloride and 
selenodimethionine and daily administration of insulin-like growth factor-1. 
Most of the tumour is now necrotic. The peripheral layer is no longer thick.  
Irregular packing and fragmentation can be observed. Magnification of the 
peripheral layer reveals a few scattered neoplastic cells at the periphery 
(Figure 61). 
 
After five days of treatment with lithium chloride, selenite and 
selenomethionine and administration of insulin-like growth factor-1, the 
tumor is totally necrotic and surrounded by an inflammatory infiltrate 
(Figure 62). Even at higher magnification, no intact neoplastic cells can be 
seen in any of the necrotic clusters (Figure 63). To identify the few 
remaining, dead tumour cells many hundred histological slides had been 
performed. 
 
Normal tissues of the tumour-bearing rodents, like liver, lung, spleen and 
gut were processed at the same time as tumour tissues. Differences between 
insulin-like growth factor-1 with or without treatment were not observed. 
However, abnormalities were found in liver and pancreas in both 
treatments. These abnormalities seemed to be due to the inherited defect of 
the nude mice and were equally exaggerated by compound treatment with 
IGF-1 and IGF-1 alone.  
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4.0    DISCUSSION 
Lodish et.al. in 2003 described common features of cancers and compared 
them to their normal counterparts: they characterised “cancer” as having 
“unlimited replicative potential, self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evasion of apoptosis, tissue invasion 
during metastasis and sustained angiogenesis”. However, despite the 
observation that all cancers present in a uniform pattern, malignancy must 
not be interpreted as a uniform default mechanism. Various cancers show 
great differences in how their malignant transformation has taken place and 
their signalling has changed. In the first place, their cellular signalling may 
be different, depending on the tissue they originated from: a mesothelial-
derived cancer may behave differently to an epithelial-derived one. 
However, due to their malignant transformation, even cancers of similar or 
identical origin display different signalling patterns. Four cancer cell lines 
have been chosen to illustrate the diversity in cancer cell signalling. The 
diversity in signalling becomes apparent when monitoring the viability of 
these cell lines exposed to different chemotherapeutic treatments. Some 
differences and similarities in signalling of two cell lines are illustrated in 
Figure 5: the signalling pathways of the mesothelioma cell line JU77 and 
the breast cancer cell line MCF-7 were targeted with various compound 
combinations, and it was observed that their sensitivity to various 
chemotherapeutic compounds was cell line-specific. Presumably, the 
signaling pathways dictating cancer cell viability is also cell line specific.  
However, one compound combination affected both cell lines, suggesting 
that some signalling pathways leading to apoptosis were common between 
these two different cell lines. These signalling patterns as typified in the 
above examples may determine the target for treatments of these cancer 
types. 
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The process of malignant transformation usually happens spontaneously, 
but it can also be artificially induced. Cells can be “transformed” by 
exposing them to chemicals, radiation, viruses and/or other procedures. 
Tumour cells usually start to proliferate as soon as the transfomation has 
taken place. Transformed cell lines are valuable to characterise the diversity 
of cancer-specific biochemical changes for unlimited growth. However, 
treatment of these transformed cell lines does not necessarily reflect how 
the corresponding primary tumours will react to the same chemotherapeutic 
treatments. The transforming process from a primary tumour in vivo to an 
unlimited-growing cell line in vitro can change the biochemical structure of 
the cancer cells significantly and it can be quite challenging to link the 
results from experiments on transformed cancer cell-lines to treatments of 
primary tumours in vivo. In contrast, patient-derived, non-transformed 
tumours are usually difficult to cultivate outside their original hosts. 
However, if they grow, these tumours are unchanged in all the settings, 
irrespective if they grow in cell culture, in animal tumours or in clinical 
settings. In the research for this thesis, the non-transformed mesothelioma 
cell line JU77 and the three transformed cell lines MCF-7 (Breast 
carcinoma), Caeco-2 (Colon carcinoma) and HepG2 (Hepatocellular 
carcinoma) were investigated and compared in cell culture. In the beginning 
it seemed as if it was far less important to find a successful treatment for 
mesothelioma tumours than for any other tumour; the prevalence of 
mesothelioma tumours in the general population is known to be rather low 
compared to the other tumour types. However, this tumour type was finally 
chosen for ongoing in vivo experiments because it offered the opportunity 
to study the effects of chemotherapeutic treatments in different settings 
using identical patient-derived cancer cells.  
 
Prior to the work done for this thesis, all these cell lines had been grown in 
various culture conditions to optimize the doubling times of each cell line. 
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However in the present study, all four cell lines were grown using the same 
medium, in which they still replicated exponentially, although not 
necessarily in their shortest doubling time. Details of the medium 
composition are specified in Methods section 2.2.1.2. Growing them in 
similar conditions in vitro allowed comparisons between cancer cell lines. 
No attempt was made to compare normal and malignant cell lines, for 
several reasons: first, additional growth factors are needed to maintain and 
grow normal cells in culture; second, the replicating of normal cells is 
limited; and finally, exponential growth is not a regular feature of normal 
cells compared to their malignant counterparts. Sometimes, single normal 
cells like PBMCs (Peripheral blood mononuclear cells) or HUVECs 
(Human umbilical vein endothelial cells) are treated with the same 
compounds as single cancer cells to get an idea of the therapeutic index, but 
these experiments do not reflect the toxicity of compounds for normal 
tissues and they may also miss significant differences in toxicity between 
various normal tissues. Therefore, a comparison between normal and 
malignant cells was made in vivo by performing histological examinations 
of tumours and several normal tissues. This is consistent with the opinion of 
Double et.al. in 1989, who reported that the critical measure between 
tumourigenic and normal tissues is provided by xenografts models. 
 
Another cornerstone in setting the experimental conditions was to 
supplement the cell culture medium with high concentrations of insulin-like 
growth factor-1. Manez and Martinez-A. in 1998, report that tumor cells in 
vivo constitutively express growth factors and growth factor receptors as a 
result of their malignant transformation, creating autocrine loops by which 
they perpetuate their own growth. This raises reasonable doubt about the 
efficacy of chemotherapeutic agents in promoting cancer cell death, 
because it has been reported that signalling of insulin-like growth factor-1 
receptor  can substantially inhibit the therapeutic effects of 
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chemotherapeutic agents under various experimental conditions (Jernberg-
Wiklund and Nilsson 2007; Conti et.al. 2007). In light of these reports, the 
in vitro experimental conditions in my studies were established to simulate 
in vivo conditions. In an environment with high concentrations of insulin-
like growth factor-1, complete cell death of cancer populations was 
observed at high concentrations of single broad-spectrum compounds. 
Some compounds were found to be more efficient than others: however, no 
single compound was found to kill the entire cancer cell population at 
levels applicable in vivo (Figure 5, 10, 18, 21, 25, 33, 39, 44, 47). As an 
alternative approach different receptor systems were targeted using 
combinations of inhibitors. This was a reasonable approach considering 
reports of Navarro and Baserga in 2001, who inhibited an increasing 
proportion of signalling pathways originating from a single receptor and 
who discovered that receptor signalling has “limited redundandancy”. The 
approach taken in this study was to inhibit a proportion of different 
constitutively activated receptor systems in the hope that the survival 
signals of receptor systems also had “limited redundancy”.   
 
However, treatment resistance of tumours against known chemo-
therapeutic agents is not only due to high concentrations of insulin-like 
growth factor-1. Treatment resistance is a much more general problem in 
oncology. It can develop quite rapidly, it is usually fatal and it has therefore 
been part of intense research. Usually, a specific treatment is chosen for a 
particular cancer type due to a different sensitivity of the various cancers to 
chemotherapeutics but even the most effective anti-cancer agent is usually 
not eradicating the tumour. While shrinking the size of the tumour, a certain 
number of cancer cells will still survive inside the tumour mass. An 
increase in chemotherapeutic concentration is limited by the maximum 
tolerated dose of the drugs. Tumours that are exposed to such chemical 
inhibitions for a certain time develop a partial necrosis and some of the 
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remaining cancer cells inside the tumour mass become resistant. These cells 
learn how to attenuate the effects of the applied chemicals. They slowly 
change their inbuilt signalling structure that consists of an enormous 
redundancy and overlap of signalling pathways and this finally attenuates 
the so-called “targeted chemical inhibitions”. As mentioned before, the 
level of redundancy and overlap in signaling structure can differ 
significantly between different cancer cells and normal cells and this seems 
to be one reason that different cancer cells develop different mechanisms of 
resistance. But irrespective that cancer cells might develop different 
mechanisms of resistance and irrespective of the biochemical mechanism 
involved therein, the focus should not be on the developing resistance but 
on the treatment in the first place. If a treatment kills 100% of the cancer 
cells in a short time after its application, there is no time left for the cancer 
cells to develop a resistance. Such effective combinations can either be 
cancer cell-type specific or they may be effective in all different kinds of 
cancers.  
 
However, the number of inhibitor combinations that could be chosen is 
virtually unlimited. Some natural compounds which are listed in the 
literature review were tested as they offered promise as “pre-made 
inhibition cocktails” targeting various key signalling pathways. Compounds 
with low toxicity and epidemiologically proven anti-cancer effects were 
preferred selections. The approach taken was to combine broad-spectrum 
chemotherapeutic agents with several narrow-spectrum inhibitors. The 
number of inhibitor combinations that could be chosen from the 99 
compounds was virtually unlimited (9.3x 10155), so combinations were 
limited to sextuple combinations with a particular focus placed on those 
compound combinations that include those highlighted in columns A and B 
of Table 2. In total, approximately 30000 combinations of compounds were 
tested. 
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Combinations with narrow-spectrum inhibitors reduced the concentration of 
the broad-inhibiting compounds needed to effectively kill cancer cell 
populations. Using the broad-spectrum inhibitors staurosporine, ascorbic 
acid and selenite, the concentration could be reduced into a therapeutic 
range (Figure 6, 8, 24, 26, 27, 28, 29, 31). However, as Figure 6 and 7 
illustrate, the effective death of cancer cell lines within a therapeutic range 
required selection of compound combinations that worked in synergy with 
each other. 
  
As illustrated in Figure 6 and 9, staurosporine concentrations declined into 
a therapeutic range when combined with narrow-spectrum inhibitors on 
mesothelioma JU77 cells, but it was impossible to achieve an equivalent 
result in breast cancer MCF-7 cells despite a wide-spread search for 
combinations. Staurosporine at a concentration of 60nM seemed to be the 
minimal critical concentration of staurosporine to promote cell death in 
MCF-7 cells, but was still too high to be applicable in vivo. Interestingly, 
60nM staurosporine is known to inhibit the insulin receptor kinase.  
 
The testing of compounds against various cancer cell lines is widely 
accepted in the literature as a general screening tool (Garrett et.al. 2003). 
Foetal calf serum is usually included as a medium supplement. Usually, the 
results from these in vitro experiments with foetal calf serum are then later 
transferred into animal studies and clinical settings. However, in animal 
studies, the compounds are exposed to adult albumin. Results of 
experiments in this thesis illustrate, that the effects of compounds can 
change dramatically when exposed to different kinds of albumin: 
compounds adhere more firmly to adult albumin, leaving only the freely 
dissociated proportion of the compound active. This is illustrated in Figure 
10. In this Figure, genistein attached to adult albumin in the presence of 
10% foetal calf serum looses 25% of its potency. This can be reversed by 
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combining genistein and albumin with warfarin, which displaces genistein 
from adult albumin and reinstitutes its potency. Thus, the potency of 
compounds can change by binding to adult albumin. It is surprising that the 
effect of adult albumin is not considered in vitro studies prior to animal 
testing of compounds. I could not find a publication describing the partial 
replacement of foetal calf albumin with adult albumin, or of the addition of 
adult albumin to cancer cell cultures.  
 
Brodersen and Honore reported in 1989 that adult albumin binds 
chemotherapeutic compounds stronger than neonatal albumin. Research 
conducted to investigate the change in the binding effects of albumin 
indicated that an increase in S-nitrosylation of albumin can cause a decrease 
in ligand-affinity (Kashiba-Iwatsuki, Miyamoto and Inoue 1997). High 
levels of S-nitrosylated albumin were discovered in fetal and neonatal sera 
(Christen et.al. 2007). In addition, the concentration of alpha 1-acid 
glycoprotein, a plasma binding protein, is much lower in fetal and neonatal 
serum than in adult serum (McNamara and Alcorn 2002). Thus, a low 
binding capacity of fetal serum can result in a high bioavailability of 
compounds in cell culture which does not reflect the situation in animal 
studies. 
      
Predicting the bioavailability of compounds is a crucial consideration in 
any drug study. If compounds have low aqueous solubility, a therapeutic 
concentration in serum may not be achieved. Lipinski et.al. in 1997 stated 
in his “Rule of Five” that the molecular properties of a compound are 
important for their absorption, distribution, metabolism and excretion 
(ADME). Changing the molecular properties of compounds to increase 
their solubility without destroying or changing their function has attracted 
wide-spread attention in biomedical and pharmaceutical research. This 
point is well illustrated in Figure 11 where the solubility of genistein is 
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considered. Hydrolyzing genistein increases its solubility several 
thousandfold but decreases its potency by half. Due to its enhanced 
solubility, its bioavailability increases: genistein chalcone is easily absorbed 
and distributed in vivo, and adherence to albumin does not limit the 
bioavailability. Other approaches can be used to increase compound 
solubility. For example, compounds may be transiently dissolved in either 
protic or aprotic substances (like ethanol, or dimethyl sulphoxide). This 
increases aqueous solubility in vitro slightly. However in vivo, these 
transiently dissolving compounds are not approved for treatment (for 
example, dimethyl sulphoxide) or have undesired side effects (for example, 
ethanol). Other pharmaceutical options to increase solubility and 
bioavailability are the inclusion of compounds into cyclodextrins (Carrier, 
Miller and Ahmed 2007), the formation of nanoparticles (Uner and Yener 
2007), the formation of micelles (Narang, Delmarre and Gao 2007) and the 
use of predrugs (Steffansen 2004).     
 
Lipinski`s “Rule of Five” characterises the criteria determining the 
bioavailability of compounds in vivo, and predicts adsorption, distribution, 
metabolism and excretion characteristics of the compounds. This affects 
their bioavailability at a tumour site. However, therapeutic effects are 
dependent not only on the bioavailability of compounds but also on the 
potency and specificity of compounds for their target structure. The 
problem can be further compounded because there may also be 
heterogeneity in a cancer cell population. This is illustrated in Figure 18 
and 19: a concentration of 30µM mifepristone alone killed only 85% MCF-
7 breast cancer cells. The remaining 15% of MCF-7 cells were unaffected 
by the mifepristone treatment even at very high concentrations. However, 
the second subpopulation was sensitive to 30µM mifepristone in 
combination with a low, non-lethal concentration of staurosporine.  
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In the search for successful chemotherapeutic combinations with 
satisfactory bioavailability, other broad-spectrum inhibitors were also 
investigated. Vitamin C is known to prevent lipid peroxidation and protein 
oxidation (Suh, Zhu and Frei 2003); selenotrisulphides changes methylation 
patterns (Vanyuschin 2006); β-lapachone activates cell cycle checkpoint 
regulation (Li et.al. 2003); glycolysis inhibitors influence the “aerobic 
glycolysis” (Pelicano et.al. 2006); antibiotics inhibit isozymes of 
glutathione S-transferase a detoxifying enzyme (Mukanganyama et.al. 
2002); diethylmaleate changes cellular replication due to a redox 
mechanism involving glutathione (Fratelli et.al. 2005); hydrogen-peroxide 
reacts as a signalling molecule (Zhung and Schnellmann 2004). Trialling 
these compounds in vitro in the presence of human albumin revealed 
several combinations that were effective in killing JU77 and MCF-7 cancer 
cells within a therapeutic range. These are illustrated in Figure 24 for 
vitamin C, in Figure 34, 35, 36, 37, 38 for selenotrisulphides, Figure 39 and 
40 for β-lapachone, Figure 41 for glycolysis inhibitors, Figure 42 and 43 for 
antibiotics and Figure 45 and 46 for diethylmaleate. However, no 
combination with hydrogen peroxide was discovered that killed a whole 
cell population within a therapeutic concentration. A combination of 
lithium chloride and selenotrisulphides was the most promising of all these 
successful in vitro combinations. This combination proved to be 
remarkably potent and highly bioavailable, and therefore was chosen as the 
preferred candidate for an in vivo animal trial. Whilst the following 
discussion focuses on these combinations with lithium chloride and 
selenotrisulphides, it will be interesting to also explore some of the 
remaining successful in vitro combinations.  
 
Selenium-containing compounds display promising in vitro and in vivo 
features for cancer treatment. They appear in either inorganic or organic 
form. Inorganic selenite dose-dependently killed mesothelioma and breast 
 194 
cancer cells. This is illustrated in Figure 25 and 30. In human serum 
albumin, the concentration of selenite needed to kill cells, increased to 
several times the maximum tolerated dose. However, when combined with 
sulphydryl group-containing compounds, its potency was restored. 
Trisulphides were formed by adding sulphydryl group-containing 
compounds. Combining selenite with different sulphydryl group-containing 
compounds did not change their efficacy in human serum albumin. As 
illustrated in Figure 32 and 33, selenite combined with cysteine, 
selenomethionine, glutathione, α-lipoic acid and dihydrolipoic acid, were 
equally potent. Controls containing single sulphydryl group-containing 
compounds had little effect on cancer cells. The trisulphide 
“selenodimethionine” formed by selenite and selenomethionine, gained 
potency in the presence of lithium chloride or geldanamycin (Figure 34 and 
35), mercaptoethanol (Figure 36) or mercaptoethanol plus gadolinium 
chloride (Figure 37). All these combinations were effective within the 
therapeutic range of selenotrisulphide. Remarkably, all four cell lines were 
similarly sensitive to trisulphide combinations, as illustrated in Figure 38. 
Other compounds like β-lapachone, glycolysis inhibitors, antibiotics and 
diethylmaleate also synergised with these trisulphides, as illustrated in 
Figure 39, 40, 41, 42, 43, 45 and 46. The compound combination 
“selenotrisulphide” was selected for animal trials in vivo.       
 
Holub in 1989 discovered that nude mice grow xenografts after injection of 
human tumor cells, as a result of the inherited deterioration of their thymus 
glands and their failure to generate mature T lymphocytes. Double and 
Bibby in 1989 identified tumor-xenografts as a useful tool that provides a 
critical measure of tumor versus normal tissue. This process is the generally 
accepted final step in preclinical drug development (Garrett et.al. 2003). 
The non-transformed human mesothelioma cell line JU77 was chosen for 
the xenograft model for this study in nude balb/c mice to test the trisulphide 
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combinations mentioned above.  
The nude mice did not grow any mesothelioma tumors in the absence of 
insulin-like growth factor-1 supplementation in the animals. The 
mesothelioma cell line JU77 did not seem to be tumorigenic. Either the 
innate immune system of the nude mice was able to reject the injected 
tumor cells, or high insulin-like growth factor-1 concentrations co-delivered 
with the cells into the mice in vitro influenced tumorigenicity in vivo. It was 
also possible that both factors were at work.  
 
In general, factors that influence tumorigenicity are considered targets for 
treatment. Haluska et.al. in 2006, stated that overactivation and/or 
overexpression of insulin-like growth factor-1 receptor and insulin receptor 
contribute to tumourigenicity, proliferation, metastasis and drug resistance. 
By enhancing the concentration of insulin-like growth factor-1 in the nude 
mouse model used in this study, the JU77 cell line switched from a non 
tumourigenic to a tumourigenic cell line. 
 
While the ratio between insulin-like growth factor-1 and insulin-like growth 
factor binding protein is usually stable, continuous supplementation of 
insulin-like growth factor-1 in the nude mouse in this study could have 
changed the ratio. This may be the reason for the switch in tumourigenicity. 
A similar imbalance is observed when serum proteases or matrix 
metalloproteinases (MMPs) cleave the insulin-like growth factor binding 
proteins. This also creates a change in the ratio between growth factor and 
binding protein, although at a lower concentration. An important example is 
provided by Miyamoto et.al. in 2004 who characterised matrix 
metalloproteinase 7 as one of the insulin-like growth factor binding protein 
3 proteinases releasing the insulin-like growth factor-1, with a resulting 
change in the ratio. 
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In the tumor model developed for this study, the concentrations of insulin-
like growth factor-1 and insulin-like growth factor binding proteins were 
not measured and this limits the conclusions that may be drawn. However, 
awareness of the axis-dependent promotion of tumour cell replication 
indicates that there is a need for a review of the “golden standard” of drug 
development. Future testing of compound combinations in syngeneic and 
xenograft models in vivo should include the simultaneous measurement of 
the ratio between insulin-like growth factor-1 and the insulin-like growth 
factor binding proteins to determine whether there is an imbalance in the 
ratio and if this is shown to be so, to correct the imbalance. It could well be 
that the potency of chemotherapeutic combinations increases when the 
freely available concentration of insulin-like growth factor-1 is limited. 
  
As soon as JU77 mesothelioma cells in vivo were supplemented with daily 
injections of insulin-like growth factor-1, tumours started to grow. As 
illustrated in Figure 52, 53 and 55, tumours grew rapidly and reached a 
steady state in size after one week. The stagnating size can be explained by 
the fact that these tumours were mainly agglomerations of single tumour 
cells depending on diffusion with very little angiogenesis. While a tumour 
grew in size, the centre of the tumour became necrotic. After a week there 
was a dynamic steady state between tumour cell replicating in the outer 
layers and cells dying off towards the centre. The histology of the tumours 
highlighted thick neoplastic layers surrounding a central necrosis (Figure 
58). With the onset of the lithium chloride and selenotrisulphide treatment, 
a critical lymph concentration was rapidly achieved, and the tumours` size 
decreased quickly, with the thick cover of neoplastic cells changing into a 
thin, fragmented and irregular layer (Figure 60). Finally, the tumours 
disappeared, leaving behind a few clusters of necrotic cells with an 
inflammatory infiltration (Figure 62).  
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The combination of lithium chloride and selenotrisulphide was clearly 
bioavailable and potent, as subcutaneous lymph-concentrations were 
achieved that are lethal for JU77 mesothelioma cells. Treating the JU77 
cells with single compounds, with dual combinations or with the triple 
combination indicated that using all three compounds was a mandatory 
requirement and this was confirmed in vivo for shrinking the tumours 
(Figure 52H, 53H). A dual combination of selenite and selenomethionine 
delayed tumour growth but did not destroy the tumour (Figure 52G, 53G). 
All other single and dual treatments were statistically indistinguishable 
from the vehicle (Table 47). The triple combination was highly selective to 
cancer cells because normal tissues like liver, lung, gut spleen or skin that 
were exposed to the same lymph-concencentration of lithium chloride and 
selenotrisulphides were not destroyed. In addition, no significant loss in 
weight of animals was observed with any of the individual or combinations 
of treatments (Table 48).  The red and white cell count increased 
substantially, due to daily injections of insulin-like growth factor-1, but did 
not change further with compound treatment (Figure 56). The white cell 
count of a nude mouse is extremely high (80000/mm3) in any case; perhaps 
this compensates for the missing adaptive immune system. Finally, some 
biochemical parameters changed about threefold above normal limit. Again 
this was due to insulin-like growth factor-1, and was not further changed 
with compound treatment (Figure 57A, B and C). 
 
In an attempt to explore the biochemical mechanism of JU77 cell death, 
measuring the enzyme activity of arachidonic acid metabolism seemed to 
be an attractive avenue to gain further insight as it has been reported by    
(Schroeder et al.2007) that simultaneous inhibition of cyclooxygenases 
(COX) and lipoxygenases (LOX), both pathways of arachidonic 
metabolism, can lead to death of cancer cells. Depending on the cell line 
and the experimental conditions in the literature, COX-activity and -
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expression were altered by lithium chloride (Bosetti et al. 2002) and 
selenomethionine (Cherukuri et al, 2005) while LOX-activity was blocked 
by selenite (Bjoernstedt et al. 1996).  However, whilst various individual 
treatments with selenium, selenomethionine and lithium chlordie or 
combinations thereof induced a number of changes and trends in the 
expressions of prostaglandin E2 and leukotrienes C and B in JU77 cells in 
this study (Figures 49-51), it was difficult to detect any obvious and logic 
pattern of changes.  Interestingly, and somewhat surprisingly, the patterns 
of expression of prostaglandin E2 and leukotrience B4 mirrored each other 
closely.  It is apparent that the effect of the compounds on arachidonic acid 
metabolism, whilst of interest, is highly complex. It is clearly beyond the 
scope of this study to untangle the specific biochemical pathway(s) leading 
to the observed changes in arachidonic acid metabolism.  Given the 
overlapping nature of most of the biochemical pathways involved in 
metabolism, and the highly diverse array of biochemical actions of each of 
the individual compounds, it will be an extraordinarily difficult task to 
define the primary pathways involved in the mechanism of action of the 
compound combinations used in this study. 
 
Nevertheless, it is apparent that the combination of lithium chloride and 
selenotrisulphides is a new, potent treatment with very few side effects.      
However, the success of this treatment is conditional: tumourigenicity was 
achieved by supplementing insulin-like growth factor-1. If tumourigenicity 
is determined by the balance between growth factor and binding proteins it 
could also be accomplished by cleaving the binding proteins. Twelve 
species of these cleaving enzymes exist and each species contains many 
members. They are involved in cell adhesion, cell fusion, membrane 
shedding and proteolysis (Mitsui et.al. 2006) and called “A disintegrin and 
metalloproteinases (ADAMs)”. As an example, insulin-like growth factor 
binding protein 3 (IGFBP-3) is the main binding protein of insulin-like 
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growth factor-1 and can be cleaved by the membrane-anchored matrix 
metalloproteinase MMP-1 (Rajah et.al. 1996), MMP-2, MMP-3 (Fowlkes 
et.al. 1994), MMP-7 (Miyamoto et.al. 2004), the serum protease calpain 
(Berg, Bang and Carlsson-Skwirut 2007) and growth hormone dependent 
serum protease (Rutishauser et.al. 1993). This list may not be complete. 
 
The regulation of expression and activity of enzymes which cleave insulin-
like growth factor binding protein 3 has been further investigated: 
expression of MMP-7 is dependent on the formation of advanced glycated 
endproducts (McLennan et.al. 2007) and polyamines (Matters, Manni and 
Bond 2005). Expression of MMP-1 is under the influence of leukotriene D4 
(Rajah et.al. 1996). Finally, the activity of matrix metalloproteinases and 
serum proteases is regulated by an orchestra of tissue inhibitors (Fowlkes 
et.al. 1995). The clinical relevance of expression, activity and cleavage of 
insulin-like growth factor binding proteins is still under investigation. 
 
Further research could investigate compound combinations in a non-growth 
factor supplemented tumour model. In such a scenario, chemotherapy 
would have to correct the growth factor/binding protein ratio as well as 
targeting oncogenic cellular structures. Most of the chemotherapeutic 
compounds that reduce insulin-like growth factor-1 or enhance insulin-like 
growth factor binding protein-3 are available and of low toxicity.  
  
Another strategy might be to divert attention to the host response. In vivo, 
an excess of insulin-like growth factor-1 down-regulates apoptosis of 
granulocytes and maintains ongoing inflammation. This disables responses 
of the innate immune system (Rossi et.al. 2007). Surprisingly, exposing the 
innate immune system to certain microbial components like mycoplasma or 
chlamydia or streptococci or heliobacter has a similar effect as an excess of 
insulin-like growth factor-1. These infections are known to be highly 
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correlated to different cancers (Huang, et.al. 2001). The connection 
between exposure to microbial components and increased signalling of the 
insulin-like growth factor-1 receptor was independently investigated by 
Francois and Into in 2005. They observed that certain microbial 
components activate Toll receptor pathways which merge with insulin-like 
growth factor-1 receptor phosphorylation cascades: Francois et.al. 
illustrated in 2005 that Toll receptors activate phosphatidyl inositol 3-
kinase/AKT and NF-kappa B. Into and Shibata noted in 2005 that 
mycoplasmal lipoproteins and staphylococcal peptidoglycans induce 
apoptosis signal-regulating kinase 1 (ASK1), which mediates sustained 
activation of the p38 mitogen-activated protein kinase. Constitutively 
activated Toll receptor signalling and continuous insulin-like growth factor-
1 supplementation seem to exert similar immune response changes. 
Therefore, it might be of interest to investigate the combined inhibition of 
Toll receptor activation and binding protein cleavage with trisulphides on 
cancer cells.    
 
Now the circle seems to close. In this thesis combinations of 
chemotherapeutic compounds were studied that target constitutively active 
signalling pathways in cancer cells. A mixture of selenite and 
selenomethionine was discovered to be effective against four different 
cancer cell lines. While trialling this compound combination in vivo, it 
became apparent that tumour onset and growth switches with 
supplementation of insulin-like growth factor-1 which may disable the 
hosts` immune response against cancerous signalling. Future research could 
investigate if the compound combination containing lithium chloride, 
selenite and selenomethionine is able to destroy in vivo mesothelioma 
tumours that are grown without injection of growth factors. If not, it will be 
of great interest to establish whether a combined inhibition of insulin-like 
growth factor-1 and the aberrant signaling pathways will have the desired 
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impact on these tumours. The reduction of insulin-like growth factor-1 
concentrations could be realised by several means: growth hormone 
releasing hormone inhibitors reduce growth hormone and insulin-like-
growth factor-1 release. They are known to induce apoptosis in many 
cancers (Rekasi et.al. 2005, Szepeshazi et.al. 2000). A monoclonal 
antibody against insulin-like growth factor-1 receptor is available and could 
inhibit the binding of insulin-like growth factor-1 to the receptor (Scotlandi 
et.al.1998). Applying insulin-like growth factor binding protein 3 could 
reduce the freely available amount of insulin-like growth factor-1 in serum 
and is known to induce apoptosis in many cancers (Kim et.al. 2004). The 
options to inhibit simultaneously tumourigenicity and aberrant signalling in 
vivo are manyfold. Further observations from this kind of research may 
indicate how the default mechanism in cancer may best be targeted in a 
combined fashion. It seems to me as if this combined approach of 
controlling endocrine “loops” and/or feedback to the 
pituitary/hypothalamus together with aberrant cancerous signaling is the 
roadmap for further research into how it may be possible to achieve the 
goal of a cancer cure.  
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Appendix 1 
 
 
Compounds    Supplier    
         
         
17-Aageldanamycin    Sigma Australia   
Adrenaline    Point Walter Pharmacy  
8Cl-cAMP     Merck Colchester UK  
Ascorbate     Dr.W.Barnes   
Aspirin     Point Walter Pharmacy  
ATP     Sigma Australia   
Avandia     Dr.W.Barnes   
Bromelin     Sigma Australia   
Bromocriptin    Point Walter Pharmacy  
tert-Butylbenzoicacid    Sigma Australia   
Caesium chloride    Sigma Australia   
Chloramphenicol    Biochemistry Curtin   
Ciprobay     Point Walter Pharmacy  
Citrate     Pharmacy Curtin   
Clindamycin    Point Walter Pharmacy  
Curcumin     Sigma Australia   
Cyproterone acetate    Sigma Australia   
2-Deoxyglucose    Biomed.Curtin   
Dexamethasone    Biomed Curtin   
DHEA     Dr.W.Barnes   
DHLA(Trisulphide)    Dr.W.Barnes   
Dichloroacetate    Sigma Australia   
Dicumarol     Sigma Australia   
Diphenyleneiodonium    Sigma Australia   
Diethylmaleate    Sigma Australia   
Digoxin     Point Walter Pharmacy  
Doxycyclin    Point Walter Pharmacy  
DMSO     Biomed.Curtin   
EGCG     Dr.W.Barnes   
Emodin     Dr.W.Barnes   
Epichlorohydrin    Sigma Australia   
Equol     Sigma Australia   
Estradiol     Biomed.Curtin   
p-Ethylphenol    Sigma Australia   
Forskolin     Merck Colchester UK  
Gadolinium chloride    Sigma Australia   
Geftinib     Biaffin Kassel Germany  
Geldanamycin    Sigma Australia   
Genistein     Sigma Australia   
Glibenclamid    Point Walter Pharmacy  
Glutathione red.    Sigma Australia   
Glycerol     Biochemistry Curtin   
Glyceryltrinitrate    Point Walter Pharmacy  
Haloperidol    Point Walter Pharmacy  
Hesperidin    Dr.W.Barnes   
Hesperitin     Dr.W.Barnes   
1,6-Hexabromocriptin    Sigma Australia   
     Sigma Australia   
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IBMX     Sigma Australia   
Ibuprufen     Point Walter Pharmacy  
Iodoacetate    Sigma Australia   
β-Lapachone    Sigma Australia   
Letrozole     Point Walter Pharmacy  
Lithium chloride    Biochemistry Curtin   
α-Lipoic acid    Dr.W.Barnes   
LY294002     Biaffin Kassel Germany  
Magnesium chloride    Biomed.Curtin   
Menadione    Sigma Australia   
Mercaptoethanol    Pharmacy Curtin   
Metformin     Biomed.Curtin   
Methylene blue    Pharmacy Curtin   
Metoprolol    Point Walter Pharmacy  
Mifepristone    Sigma Australia   
NADH     Sigma Australia   
NADPH     Sigma Australia   
Naphtalene    Sigma Australia   
Oxamate     Sigma Australia   
Oxythiamine    Sigma Australia   
Oxytocin     Point Walter Pharmacy  
Parthenolide    Dr.W.Barnes   
PD153035    Biaffin Kassel Germany  
PD98058     Biaffin Kassel Germany  
Penicillin/Streptomyc    Invitrogen Australi   
Picropodophyllin    Biaffin Kassel Germany  
PP2     Biaffin Kassel Germany  
Progesteron    Biomed.Curtin   
Quercetin     Dr.W.Barnes   
Rapamycin    Biaffin Kassel Germany  
Red Clover    Dr.W.Barnes   
Salbutamol    Point Walter Pharmacy  
Salicylic acid    Biochemistry Curtin   
Selenate     Biochemistry Curtin   
Selenite     Sigma Australia   
Selenomethionine    Sigma Australia   
Se-piccolinate    Dr.W.Barnes   
Sulphamethoxazole    Point Walter Pharmacy  
Sulphosalazine    Point Walter Pharmacy  
Suramin     Pharmacy Curtin   
Staurosporine    Biaffin Kassel Germany  
Tamoxifen     Point Walter Pharmacy  
Tautomycin    Biaffin Kassel Germany  
Tetrathiomolybdate    Dr.W.Barnes   
Theophylline    Point Walter Pharmacy  
Thiosulphate    Biochemistry Curtin   
Trimethoprime    Point Walter Pharmacy  
Trypsin     Biomed.Curtin   
Verapamil     Point Walter Pharmacy  
Warfarin     Point Walter Pharmacy  
Wortmannin    Biaffin Kassel Germany  
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                                             Table of Compounds  
 
Compounds  
       
MW  Solubility aqueousConc.range 
     aequous  upper/lower limit 
         
17-Aageldanamycin  585.1  slightly  200nM 20nM 
Adrenaline  183.1  100mg/L  1µM 10nM 
8Cl-cAMP   363.7  soluble  200µM 2µM 
Ascorbate   176.1  620g/L  50mM 500µM 
Aspirin   180.2  10g/L  50µM 1µM 
ATP   573.1  soluble  1mM 100µM 
Avandia   473.5  soluble  10µM 1µM 
Bromelin   33000.1  soluble  10µM 10nM 
Bromocriptin  654.6  2.4mg/L  1nM 100pM 
tert-Butylbenzoicacid  178.1  70mg/L  30µM 3µM 
Caesium chloride  168.7  300g/L  1mM 100µM 
Chloramphenicol  323.1  slightly  10µM 1µM 
Ciprobay   331.4  16.5mg/L  50µM 5µM 
Citrate   294.1  6g/L  50mM 1mM 
Clindamycin  551.4  30mg/L  50µM 5µm 
Curcumin   368.3  30ng/L  200µM 20µM 
2-Deoxyglucose  164.2  131g/L  1mM 100µM 
Dexamethasone  516.4  insoluble  10µM 1µM 
DHEA   288.1  30mg/L  1µM 100nM 
DHLA(Trisulphide)  228.3  slightly  1mM 10µM 
Dichloroacetate  150.9  slightly  2mM 200µM 
Dicumarol   336.3  128mg/L  25µM 5µM 
Diphenyleneiodonium  314.6  slightly  10µM 1µM 
Diethylmaleate  172.1  slightly  200µM 20µM 
Digoxin   780.9  slightly  20nM 2nM 
Doxycyclin  444.4  1.8mg/L  4µM 1µM 
DMSO   78.1  soluble  250mM 1mM 
EGCG   458.2  5g/L  100µM 1µM 
Emodin   270.2  slightly  200µM 20µM 
Epichlorohydrin  92.1  65g/L  500µM 5µM 
Equol   242.2  slightly  400µM 10µm 
Estradiol   272.4  slightly  10nM 1pM 
p-Ethylphenol  122.2  slightly  100µM 1µM 
Forskolin   410.5  10mg/L  500µM 10µM 
Gadolinium chloride  263.2  soluble  500µM 50µM 
Geftinib   446.9  slightly  2µM 0.5µM 
Geldanamycin  560.6  slightly  20nM 2nM 
Genistein   270.2  miscible  500µM 50µM 
Glibenclamid  494.1  4mg/L  50µM 1µM 
Glutathione red.  307.3  soluble  5mM 50µM 
Glycerol   92.1  soluble  1mM 10µM 
Glyceryltrinitrate  227.1  1g/L  100µM 10µM 
Haloperidol  530.1  Soluble  10µM 100nM 
Hesperidin  610.1  Slightly  1mM 100µM 
Hesperitin   302.3  Slightly  1mM 100µM 
1,6-Hexabromocriptin      734.8  Slightly  100µM 10µM 
H2O2   38.1  Soluble  10mM 100µM 
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Compounds  
       
MW  Solubility aqueousConc.range 
     Aqueous  upper/lower limit 
         
         
IBMX   222.2  Slightly  1mM 500µM 
Ibuprufen   206.3  Slightly  1µM 200nM 
Iodoacetate  207.1  103g/L  100µM 10µM 
β-Lapachone  242.1  Slightly  100µM 1µM 
Letrozole   285.3  41mg/L  10µM 100nM 
Lithium chloride  42  630.7g/L  10mM 100µM 
α-Lipoic acid  228.3  Slightly  10mM 100µM 
LY294002   343.8  Slightly  40µM 10µM 
Magnesium chloride  203.3  542g/L  40mM 4mM 
Menadione  276.2  Slightly  50µM 0.5µM 
Mercaptoethanol  78.1  Miscible  100µM 10µM 
Metformin   129.2  Soluble  100µM 10µM 
Methylene blue  373.1  35.5g/L  100µM 10µM 
Metoprolol  684.1  soluble  100µM 10µM 
Mifepristone  429.6  slightly  100µM 1µM 
NADH   709.4  soluble  1mM 10µM 
NADPH   833.4  soluble  1mM 10µM 
Naphtalene  128.1  30mg/L  100µM 10µM 
Oxamate   111.2  50g/L  10mM 100µM 
Oxythiamine  338.3  soluble  1µM 100nM 
Oxytocin   1007.19  soluble  500nM 10nM 
Parthenolide  248.3  slightly  2µM 20nM 
PD153035  396.7  slightly  10µM 100nM 
PD98058   267.3  slightly  40µM 10µM 
Picropodophyllin  414.4  slightly  10µM 1µM 
PP2   553.6  slightly  10µM 100nM 
Progesteron  314.5  6mg/L  10nM 1pM 
Quercetin   302.2  slightly  500µM 50µM 
Rapamycin  914.2  6mg/L  200nM 20nM 
Red Clover         N/A  slightly  N/A N/A 
Salbutamol  576.7  slightly  100µM 1µM 
Salicylic acid  138.1  2g/L  100µM 10µM 
Selenate   184.1  soluble  100µM 1µM 
Selenite   172.9  85g/L  100µM 1µM 
Selenomethionine  196.1  soluble  100µM 1µM 
Se-piccolinate         N/A  slightly  N/A N/A 
Sulphamethoxazole  253.3  13.4g/L  200µM 5µM 
Sulphosalazine  398.4  slightly  50µM 5µM 
Suramin   1297.1  soluble  300µM 3µM 
Staurosporine  466.5  slightly  10µM 10nM 
Tamoxifen   371.5  500mg/L  10µM 1µM 
Tautomycin  767.1  slightly  10µM 100nM 
Tetrathiomolybdate  260.9  slightly  100µM 10µM 
Theophylline  180.2  moderate  100µM 10µM 
Thiosulphate  158.3  soluble  10mM 100µM 
Trimethoprime  290.3  400mg/L  50µM 5µM 
Trypsin   23800.1  soluble  10µM 10nM 
Verapamil   496.2  soluble  50µM 2.5µM 
Warfarin   308.1  1.7g/L  300µM 100µM 
Wortmannin  428.4  miscible  100µM 1µM 
 
